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ABSTRACT
Background: Paracetamol overdose (POD) remains a pressing clinical problem as
despite the availability of a safe and effective antidote, patients continue to die or require
a liver transplant. Recent evidence suggests that toxicity after POD may be more than a
simple direct toxic effect as has previously been accepted and that Kupffer cells and
cytokine4s such as TNF-a are involved in the pathogenesis of liver injury.
Paracetamol and Hepatocyte Apoptosis Examination of liver in patients after POD
revealed hepatocyte apoptosis occurring alongside striking regenerative activity.
Apoptosis is important for several reasons. First, at this time paracetamol is undetectable
in serum and paracetamol metabolites should be cleared from the liver, so apoptosis is
not directly induced by paracetamol. Second, the rate of apoptosis represents a
significant rate of cell loss from the liver. Third, the apoptosis occurs despite the
background of regeneration.
Paracetamol and TNF-a: Some, but not all, studies support a role for TNF-a in
inducing liver injury after paracetamol overdose. In a murine model, TNF-a was
elevated in serum after POD but inhibition ofTNF-a action did not alter survival or liver
injury. However, TNF-a augmented paracetamol toxicity in vitro by increasing rates of
both apoptosis and necrosis; TNF-a also lowered the threshold for toxicity.
Paradoxically, while TNF-a had no apparent effect on hepatocytes in the absence of
paracetamol, pretreatment with TNF-a protected against subsequent paracetamol
toxicity.
Paracetamol and Kupffer Cells: Kupffer cells modulate toxic hepatic injury induced by
several agents including paracetamol. Co-culture experiments comparing hepatocytes
alone or in culture with Kupffer cells showed no differences in toxicity. However,
production of TNF-a by macrophages was augmented by paracetamol and was further
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significantly elevated in co-culture with hepatocytes. The levels of TNF-a in these
experiments was similar to the concentration of recombinant TNF-a which augmented
paracetamol toxicity in hepatocytes alone in previous studies but in this model no
difference in toxicity was noted. This finding suggests that Kupffer cells produce TNF-a
in response to high doses of paracetamol, that hepatocytes behave differently in co-
culture than when grown alone and that the differences in response may relate to soluble
factors produced by Kupffer cells.
Conclusions: These studies offer new insights into mechanisms of hepatocyte death by
apoptosis and regeneration in the context of drug-induced liver injury. A model is
presented whereby toxin-induced activation of Kupffer cells with resulting production of
cytokines modulates hepatocyte responses and alters the course of disease.
iii
ACKNOWLEDGEMENTS
I would like to thank many people for assistance in carrying out the research work and
completing this thesis.
I am indebted to Professor David Harrison for help and advice from the beginning in
setting up the project, for invaluable discussions when things went wrong and in support
for travelling to various meetings to present the data. He also afforded me the
opportunity to learn some liver pathology in parallel with this work, for which I am very
grateful.
I would like to thank Dr Ken Simpson for support and encouragement, and for access to
some of his previous data and expertise.
I am grateful to Nicola Martin, a good friend and co-worker in the laboratory, for her
cheerful assistance on many occasions.
I would like to thank Mrs Frances Rae who provided a great deal of advice, support and
help throughout. I would also like to thank Dr Sarah Howie for her invaluable
experience and advice in many areas but particularly flow cytometry.
I thank Sharon White and Linda More, who worked closely with me in the laboratory
with unfailing enthusiasm whether things went right or wrong and made the group a
happy one to be in. I am also very grateful to Tim Andrews, who was an enthusiastic and
hardworking member of the team during his BSc year.
I would like to thank all other staff from the 3 rd floor laboratory, but in particular
Matthias Dollinger, for advice and support on murine culture and co-culture; Alexey
Glazyrin, the mad Russian, for teaching me how to perfuse liver with a method that only
he has perfected; and Amanda Forsyth, research technician, an enthusiastic and hard-
iv
working member of the team. I would also like to thank the other members of the liver
research group.
I am grateful to Paul Fineron and Tim Squires for advice and support in working with the
coproxamol overdose cases.
I thank John Verth and all the other staff in the old animal house for unfailing help and
support in mouse perfusions.
I thank Dr Marilyn Moore for providing huffy coats and plasma for isolation of
macrophages.
I am greatly indebted to PPP Healthcare / Royal College of Pathologists for providing the
research fellowship that allowed me to carry out this work. I would also like to thank
SHERT for financial support of the project.
I would like to dedicate this thesis to Rachel and Emma who will see a bit more of
me from now on.
v
DECLARATION OF ORIGINALITY
I declare that the contents of this thesis have been composed exclusively by me, and that
with the exceptions noted below, the work conducted and described herein is entirely my
own.
For the data described in chapter 2 most of the immunohistochemistry was carried out by
research technicians in the Department of Pathology, University of Edinburgh. All
histological analysis was carried out by myself.
The cases of coproxamol and methadone overdose used in chapter 3 were identified by
Tim Squires, who provided clinical and toxicological data.
The laboratory work for chapters 4-7 was carried out as part of a research group, with
some work carried out by myself and some carried out by research technicians. This
included cell culture work, ELISA assays, immunohistochemistry and molecular biology.
The animal experiments in chapter 5 were carried out in the University of Michigan, Ann
Arbor, USA by Dr Ken Simpson, an MRC (UK) Travelling Fellow, supported by NIH
Grants HL02401, HL31693, HL35276, HL50057. My contribution to this work was in
analysis of the data and writing the paper that has subsequently been published (J Pathol;
190: 489-494, 2000).





Chapter 1 Introduction 1
Chapter 2 Paracetamol toxicity in human liver 15
Chapter 3 Early events in paracetamol toxicity 31
Chapter 4 Characterisation of paracetamol toxicity in vitro 39
Chapter 5 The role of TNF-a in paracetamol toxicity 64
Chapter 6 The role of Kupffer cells in paracetamol toxicity 88
Chapter 7 Genetic polymorphisms in tumour necrosis factor 103











INTRODUCTION: THE PARACETAMOL PARADIGM
Background: The problem of paracetamol overdose
Paracetamol (acetaminophen, N-acetyl-para-aminophenol, 4 acetamidophenol) is a
mild analgesic with virtually no side effects at the recommended dosage (The Lancet,
1981). Toxicity after overdose was first described in the 1960's in animals (Eder,
1964; Boyd and Bereczky, 1966) and then in humans (Davidson and Eastham, 1966;
Thomson and Prescott, 1966). Paracetamol overdosage (POD) has become
increasingly popular as a method of self-harm and has increased strikingly in
incidence from the 1960's to the 1990's, with approximately 70,000 cases of
paracetamol overdose occurring in the UK each year (Meredith et al, 1986; Litovitz
et al, 1988; Fagan and Wannan, 1996). An increased understanding of the
mechanisms of toxicity associated with depletion of glutathione led to the
development of a safe, cheap and effective antidote (N-acetylcysteine: Prescott,
1981; Smilkstein et al, 1988; Jones, 1998). Hepatotoxicity can therefore be prevented
in the vast majority of cases with a significant reduction in severe liver injury and
huge improvement in survival after POD (Prescott, 1981; Prescott, 1983). However,
despite this POD has become the commonest cause of fulminant liver failure and the
commonest reason for emergency liver transplantation in the UK and the US (Makin
et al, 1995; Schiodt et al, 1997; Bissell et al, 2001). Most patients who develop liver
injury present late (after the period in which NAC has proven efficacy: [Meredith et
al, 1986]) or have an unusual presentation (e.g. staggered overdose or therapeutic
misadventure [Read et al, 1986; Fry and Seeff, 1995; Bridger et al, 1998]). Once
liver failure has developed, current therapeutic options are limited as deterioration is
relatively rapid and there is a narrow "window of opportunity" (O'Grady, 1991). In
one series, only 35% of patients who fulfilled transplant criteria after POD actually
underwent liver transplantation (Bemal et al, 1998b). Evidence has emerged over
the last decade that additional mechanisms may be involved in paracetamol toxicity
(e.g. activation of Kupffer cells and production of cytokines such as TNF-a). An
understanding of these mechanisms of toxicity may lead to the development of new
therapies to address what is a major clinical challenge.
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Mechanisms of paracetamol toxicity
1. Bioactivation
Paracetamol itself is non-toxic and toxicity requires bioactivation i.e. production of
reactive metabolites during liver metabolism: this area has been extensively studied
(reviewed in Nelson, 1990; Thomas, 1993; Nelson, 1995) and is summarised in
Figure 1.1. The major metabolic pathways for paracetamol involve glucuronidation
or sulphation (1), forming non-toxic, soluble metabolites (2) that are excreted in
urine (3). At therapeutic doses, approximately 5% of ingested paracetamol is
metabolised by the cytochrome p450 system (CYP450: 4). This second pathway
results in formation of a highly toxic electrophile (N-acetyl-p-benzoquinoneimine -
NAPQI; 5). This metabolite is rapidly conjugated to non-toxic cysteine or
mercapturate metabolites in a glutathione-dependent manner and excreted in urine
and in bile (6). After paracetamol overdose, glucuronide and sulphate become
depleted, with a concomitant increase in CYP450-dependent metabolism leading to
increased production of NAPQI. As glutathione is depleted to 20-30% of normal or
less (Mitchell et al, 1973: 7), intracellular accumulation of NAPQI occurs and is a
critical event in paracetamol toxicity (Holme et al, 1984; Albano et al, 1985)
resulting in cellular injury by a variety ofmechanisms (8).
2. Metabolic factors influencing hepatic injury
Paracetamol toxicity is enhanced by factors that deplete glutathione (e.g. low protein
diet) or increase formation ofNAPQI (e.g. induction ofCYP450 enzymes) within the
liver (Thomas, 1993). The opposite also holds true where repletion of glutathione
(e.g. administration of cysteine or methionine) or reduction in NAPQI formation (e.g.
inhibition of CYP450 enzymes) and can reduce paracetamol toxicity (Thomas,
1993). CYP1A2 and CYP2E1 are the most important cytochrome isoforms in
paracetamol metabolism in humans with CYP2E1 the major form (Raucy et al, 1989;
Anundi et al, 1993). The importance of these enzymes is supported by the fact that
CYP1A2 and CYP2E1 double knockout mice are protected from paracetamol
toxicity (Zaher et al, 1998). CYP450 expression may vary up to tenfold between
individuals, which may influence toxicity (Seddon et al, 1987); CYP2E1 is inducible
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Figure 1.1 Paracetamol metabolism
Numbers refer to the description in the text. NAPQI = N-acetyl-p-
aminobenzoquinone imine. Adapted from Thomas, 1993.
by ethanol and isoniazid and therefore users of either of these drugs may be at higher
risk of toxicity (Ryan et al, 1986; Hall et al, 1986). The situation in alcoholics is
more complex, however, as glutathione levels are usually also low and acute
administration of alcohol appears to protect from paracetamol toxicity (reviewed in
Nelson, 1990). Several other factors influence paracetamol toxicity including
species, age and pregnancy (Nelson, 1990) but these largely relate to differences in
metabolic pathways (Green et al, 1984; Holme and Soderlund, 1986; Smolarek et al,
1990; Nelson, 1990).
As therapeutic administration ofN-acetylcysteine can completely prevent liver injury
in clinical practice, glutathione depletion is an important factor in the development of
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liver injury. However, glutathione depletion alone can injure hepatocytes (Anundi et
al, 1979) and glutathione depletion is not the only determinant of liver injury in
paracetamol toxicity (Larrauri et al, 1987). Evidence exists that more than one
pathway to hepatic injury exists (Dai and Cederbaum, 1995) and that different
pathways maybe important at different drug concentrations (Farber et al, 1988).
3. Mechanisms of cellular injury and death
Sufficient evidence exists that metabolites of paracetamol (NAPQI) directly injure
hepatocytes as the major feature ofparacetamol overdose. However, conflicting data
exist as to the precise mechanisms of cell injury and death (reviewed in Nelson,
1995). A strong correlation has been shown between paracetamol toxicity and the
degree of covalent binding (and hence inactivation) of intracellular proteins (Jollow
et al, 1973; Hinson and Pumford, 1995; Pumford and Halmes, 1997; Cohen et al,
1997) as a major mechanism of cell loss. However, additional mechanisms of
cytotoxicity exist including oxidative stress with associated oxidation of thiols and
lipid peroxidation (Kyle et al, 1987; Arnaiz et al, 1995); disruption of calcium
homeostasis with associated disruption of the cytoskeleton and DNA (Nelson, 1990;
Orrenius et al, 1991); and activation of lysosomal enzymes (Khandkar et al, 1996).
The precise mechanism of direct cellular injury death is probably a complex
combination of several of these mechanisms.
Indirect mechanisms of paracetamol toxicity
Increasing evidence has emerged that in addition to direct injury by toxic
metabolites, indirect mechanisms are important in the pathogenesis of liver injury by
several xenobiotics including paracetamol. Several lines of evidence support this
concept:
1. interaction of various toxic agents with Kupffer cells can reduce or augment
liver injury
2. cytokines such as TNF-a are produced during toxic liver injury and may alter the
outcome
3. apoptosis has been observed as a mechanism of cell loss during toxic liver injury
in addition to necrosis
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1. Kupffer cells and toxic liver injury
Kupffer cells are resident liver macrophages, making up approximately 15% of cells
within the liver (Kuiper et al, 1994). Kupffer cells have a variety of functions
including phagocytosis, immune regulation, production of bioactive
(proinflammatory) substances and cytotoxicity: Kupffer cells also have a role in
hepatic regeneration (reviewed in Winwood and Arthur, 1998). Compelling evidence
now exists from observation of macrophage accumulation and activation and
experimental modulation ofmacrophage function that Kupffer cells are an important
element in the pathogenesis of hepatic injury by various toxic agents (reviewed in
Laskin and Pendino, 1995; Laskin, 1996; Tsukamoto and Lin, 1997; Bissell et al,
2001).
a. Kupffer cell accumulation and activation: A typical response to many
xenobiotics is accumulation of activated macrophages. Macrophage recruitment has
been shown following liver injury by various toxic agents including endotoxin
(Pilaro and Laskin, 1986), carbon tetrachloride (Johnson et al, 1992), phenobarbital
(Laskin et al, 1988), allyl alcohol (Przybocki et al, 1992), galactosamine (MacDonald
et al, 1987) and paracetamol (Laskin and Pilaro, 1986). Macrophages accumulate in
areas of tissue injury, the pattern of macrophage infiltration varying with different
agents e.g. zone 3 for paracetamol and carbon tetrachloride, zone 1 for allyl alcohol,
scattered for other toxicants such as galactosamine (Laskin, 1996). The
accumulation of macrophages is explained by a combination of proliferation of
Kupffer cells and recruitment from circulating monocytes (Johnson et al, 1992;
Geerts et al, 1988; Jonker et al, 1990). Macrophages that accumulate exhibit an
"activated" phenotype with enhanced phagocytic, cytotoxic and metabolic activity
and enhanced production of inflammatory mediators (reviewed in Laskin and
Pendino, 1995). However, the situation is more complex than simple activation, as
Kupffer cell accumulation and activation induced by C. parvum protects against
carbon tetrachloride and paracetamol injury by reducing expression of cytochrome
P450 enzymes (Raiford and Thigpen, 1994). In some models of hepatotoxicity
endotoxin elevation in portal blood is associated with Kupffer cell activation and
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may also alter ICAM-1 expression on endothelium, facilitating accumulation of
inflammatory cells (Nolan, 1989; Ahmad et al, 1999)
b. Kupffer cell modification: The most convincing evidence that Kupffer cells have
an important role in toxic liver injury comes from studies where modification of
Kupffer cells function results in a reduction in liver injury. Administration of anti¬
inflammatory agents such as hydrocortisone reduces hepatic injury secondary to
carbon tetrachloride (Sudhir and Budhiraja, 1992). More specifically, administration
of macrophage-depleting agents such as gadolinium chloride, dextran sulphate or
diphosphonate has resulted in protection against ischaemia / reperfusion injury
(Shiratori et al, 1994) and liver injury caused by several toxins including carbon
tetrachloride (Chamulitrat et al, 1995), ethanol (Iimuro et al, 1997), galactosamine
(Stachlewitz et al, 1999) and paracetamol (Laskin et al, 1995; Goldin et al, 1996;
Michael et al, 1999). Conversely, studies that have experimentally induced
activation of macrophages (e.g. administration of LPS or poly I:C) have shown
augmentation of hepatotoxicity secondary to carbon tetrachloride, galactosamine, C.
parvum and paracetamol (Laskin and Pendino, 1995). The mechanism whereby
Kupffer cells act is thought mainly to relate to production of bioactive inflammatory
mediators.
c. Other cell types in paracetamol toxicity: Other cell types may also have a role in
paracetamol toxicity. Conflicting evidence exists regarding the role of polymorphs
in paracetamol toxicity (Jaeschke and Mitchell, 1989; Welty et al, 1993; Smith et al,
1998) and endothelial cell injury may contribute to necrosis in paracetamol-induced
injury (DeLeve et al, 1997).
2. Production of bioactive substances in toxic injury
The production of various biologically active substances including reactive oxygen
and nitrogen intermediates, lipid mediators and cytokines and chemokines has been
reported following hepatic injury by many toxins; the major source ofmost of these
agents is presumed to be Kupffer cells,
a. Reactive oxygen and nitrogen intermediates
Reactive oxygen species (ROS) are produced in many settings of cellular stress and
injury and are produced both intracellularly (within hepatocytes) and extracellularly
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(from Kupffer cells and neutrophils). ROS have been shown to contribute to
ischaemia/reperfusion injury, endotoxaemia and toxin-induced injury in the liver
where activated Kupffer cells predominantly release them as a critical element
mediating hepatocyte injury (DelMaestro et al, 1980; Shiratori et al, 1990; Wang et
al, 1992). ROS, including superoxide, hydrogen peroxide and hydroxyl, injure cells
by a variety of mechanisms including lipid peroxidation, inactivation of anti-
proteases, induction of apoptosis and modulation of gene transcription (Jaeschke et
al, 1999; Jaeschke, 1999). Administration of antioxidants may be protective against
ROS (Thomas, 1993; Gunawardhana et al, 1993; Laskin and Pendino, 1995) and in
the setting of paracetamol poisoning, hepatocyte injury has been reduced by
administration of superoxide dismutase (Nakae et al, 1990) and toxicity is reduced in
metallothionein-null mice (Rofe et al, 1998).
Nitric oxide (NO) is produced by activated macrophages and has been implicated in
various models of liver injury although its role in paracetamol toxicity is not clear.
Paracetamol toxicity causes oxidative stress resulting in production of NO, which
protects against injury (Kuo et al, 1997). However, conflicting studies have shown
that paracetamol toxicity is reduced when NO formation is inhibited (Gardner et al,
1998). One mechanism whereby NO may be toxic is that superoxide can react with
NO to form peroxynitrite, a highly reactive cytotoxic species that may contribute to
hepatocyte death after paracetamol poisoning (Michael et al, 1999).
b. Cytokines
Good evidence exists that production of TNF-a is a common pathway to hepatic
injury by various toxins (reviewed in Schumann and Tiegs, 1999) including
galactosamine (Stachlewitz et al, 1999), ethanol (Iimuro et al, 1997), carbon tetra¬
chloride (Czaja et al, 1995), actinomycin D (Leist et al, 1997) and a-amanitin (Leist
et al, 1997). TNF-a is a pleiotropic cytokine with important roles in hepatocyte
death by necrosis and apoptosis (Hill et al, 1992), hepatic regeneration
(Michalopoulos and DeFrances, 1997) and protecting against subsequent hepatic
injury (Takehara et al, 1998). TNF-a is not directly toxic to hepatocyte, the
cytotoxic effect requiring sensitisation by inhibition of RNA or protein synthesis
(Hill et al, 1992). The role of TNF-a in paracetamol toxicity remains controversial
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as a range of conflicting reports exist (DeVictor et al, 1992; Blazka et al, 1995;
Blazka et al, 1996; Boess et al, 1998).
Production of IL-la has also been described in paracetamol toxicity (Blazka et al,
1995) and IL-la protected against paracetamol toxicity in mice (Renic et al, 1993).
Chemokines such as CINC/gro (rat) and MIP-2 (mouse) are also produced in
paracetamol toxicity (Takada et al, 1995; Horbach et al, 1997). Chemokines are best
characterised as chemotactic mediators of polymorph infiltration and mediate liver
injury during ischaemia/reperfusion (Lentsch et al, 1998). However, administration
of CXC chemokines including MIP-2 has resulted in protection against paracetamol
toxicity, by facilitating hepatic regeneration (Hogaboam et al, 1999). The role of
different cytokines and chemokines and how they interact in paracetamol toxicity is
not known.
c. Other mediators
Lipid mediators (prostaglandins and leukotrienes) are produced by activated
macrophages and in models of lung injury may modulate expression of cytokines
(e.g. TNF-a [Christman et al, 1991]). Activated macrophages also release hydrolytic
enzymes that may contribute to liver injury or alter hepatocyte functioning (Tanner et
al, 1980; Decker, 1980).
3. Apoptosis and toxic liver injury
Several good reviews of apoptosis in the liver exist (Alison and Sarraf, 1994; Galle,
1997; Feldman, 1997; Patel et al, 1998). Apoptosis is an important mechanism to
eliminate senescent, injured or deleterious cells, is the major mechanism of cell loss
in liver atrophy and is an important contributor to liver homeostasis (Galle, 1997).
Recent evidence has suggested that apoptosis is also an important mechanism of cell
loss during a range of disparate liver diseases including viral hepatitis, cholestatic
and biliary disease, hepatocarcinogenesis, allograft rejection, metabolic disease and
toxin or drug-induced disease both in human liver disease and in animal models (see




Table 1.1: Apoptosis and Liver Disease (Human and Experimental)
Liver Disease Reference
Viral Hepatitis Yellow fever Feldman, 1997 [rev]
Hepatitis B,C,D Fang et al, 1994
Kondo et al, 1997
Lau et al, 1998 [rev]
Immune Injury Allograft Rejection Afford et al, 1995
Krams and Martinez, 1998
Hepatocarcinogenesis Schulte-Hermann et al, 1997 [rev]
Pitot, 1998 [rev]
Thorgeirsson et al, 1998 [rev]
Cholestatic Disease Cholestasis Patel et al, 1994
PBC Patel and Gores, 1995 [rev]
Kuroki et al, 1996
Ischaemia Ischaemia/reperfusion
injury
Cursio et al, 1999
Metabolic Disease Wilson's disease Strand et al, 1998
Iron overload Kato et al, 1996
Drugs Ethanol Nanji, 1998 [rev]
Cocaine Cascales et al, 1994
Cytostatic drugs Muller et al, 1997
Jiang et al, 1999
Galactosamine Medline etal, 1970*
Carbon tetrachloride Shi et al, 1998
Dimethylnitrosamine Pritchard and Butler, 1989
Thioacetamide Ledda-Columbano et al, 1991
Paracetamol Ray et al, 1996
Table 1.1
rev = review article. *published before first description of apoptosis but probably
represents apoptosis.
i. Detection of apoptosis
Many methods have been used to measure apoptosis. There is currently no
consensus as to the most appropriate method and it is accepted that different methods
are better in different experimental models (reviewed in Goldsworthy et al, 1996;
Patel et al, 1998). Further problems in measuring apoptosis in that apoptotic bodies
are small and may be relatively infrequent and that the duration of apoptosis is short
(Grassl-Kraupp et al, 1995; Galle and Krammer, 1998). Choosing an appropriate
method to detect and quantify apoptosis is important.
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ii. Apoptosis and necrosis
Many toxic agents produce hepatic necrosis as the major form of cell loss but the
liver also shows evidence of apoptosis, the significance of which is unknown (e.g.
thioacetamide [Ledda-Columbano et al, 1991], galactosamine [Medline et al, 1970]
carbon tetrachloride [Shi et al, 1998], dimethylnitrosamine [Pritchard and Butler,
1989] and paracetamol [Ray et al, 1996]). In many of these models apoptosis
precedes necrosis (Pritchard and Butler, 1989; Shi et al, 1998) but the contribution of
apoptosis to total liver injury is not known. Several problems are noted in
distinguishing apoptosis and necrosis (Columbano, 1995). Problems exist in
identification and measurement of apoptosis and necrosis as some markers may be
found during both processes (e.g TUNEL staining [Grasl-Kraupp et al, 1995] and
DNA laddering [Bohlinger et al, 1996]). The end-stage of apoptosis may also be
indistinguishable from necrosis (especially in tissue culture) and if insufficient tissue
phagocytic capacity is present in vivo apoptosis may result in secondary necrosis
with little inflammation (Oberhammer et al, 1996). As some features of apoptosis
and necrosis overlap, the concept of "necrapoptosis" has been suggested (LeMasters,
1999). This concept was proposed to avoid confusion and to explain some of the
common pathways to apoptosis and necrosis, the type of death depending on
mitochondrial permeability and cellular ATP stores (Leist et al, 1997; LeMasters,
1999). Conceptual difficulties remain, however, as the presence of shared pathways
does not necessarily merit separation of a third mechanism of cell death and there is
no reason why different mechanisms of cell death should not co-exist.
iii. Apoptosis and inflammation
Apoptosis does not induce an inflammatory reaction and therefore is thought to be
biologically beneficial compared with necrosis in which secondary inflammation is a
sine quo non (Allison and Sarraf, 1994; Columbano 1995). However, recent
evidence suggests that in certain situations apoptosis may also cause inflammation
(Miwa et al, 1998; Lawson et al, 1998).
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iv. Different pathways to signal apoptosis
Apoptosis is a genetically regulated, tightly controlled process of cell elimination,
often signalled by specific receptor pathways; the occurrence of apoptosis raises
important questions as to pathogenic pathways of disease. However, in several
models of liver injury, induction of apoptosis by specific signal-receptor pathways
has been confirmed. The CD95 (Fas) / CD95 ligand (FasL) pathway is well-
characterised and, as hepatocytes express Fas, has a role in liver homeostasis
(reviewed in Krammer, 1998; Feldmann et al, 1998). FasL is expressed mainly on T
cells, mediating T cell-induced apoptosis is various physiological and pathological
states (Vignaux and Golstein, 1994), but may also be expressed on hepatocytes and
therefore may mediate both immune and nonimmune hepatocyte apoptosis (Galle et
al, 1995). Fas / FasL signalling has been implicated in the pathogenesis of many
important liver diseases (reviewed in Galle and Krammer, 1998), including viral
hepatitis (Galle et al, 1995; Kondo et al, 1997), chronic CMV infection (Fleck et al,
1998), adenovirus infection (with consequences for gene therapy studies: Liu et al,
2000), alcoholic hepatitis (Galle and Krammer, 1998), primary biliary cirrhosis
(Kuroki et al, 1996), Wilson's disease (Strand et al, 1998) and allograft rejection
(Krams et al, 1998). The TNF-a / TNFR pathway is also well-defined and
contributes to liver injury and apoptosis in many models including viral hepatitis
(Bradham et al, 1998), adenovirus infection (Liu et al, 2000), fulminant liver failure
(Muto et al, 1988), endotoxin administration (Beutler et al, 1985) and liver injury
induced by several drugs and toxins including alcohol (reviewed in McLain et al,
1999), galactosamine (Stachlewitz et al, 1999), carbon tetrachloride (Czaja et al,
1995) and after paracetamol overdose (reviewed in Schumann and Tiegs, 1999).
Other apoptosis-signalling pathways of less importance include TGF-(3 / TGF
receptor, as is involved in regression after mitogenesis (Oberhammer et al, 1992;
Grasl-Kraupp et al, 1998), perforin / granzyme in T cell-mediated liver injury (Galle
and Krammer, 1998) and ceramide (Hoekstra, 1999). In some systems apoptosis
may be signalled by more than one pathway (Jiang et al, 1999; Liu et al, 2000).
While some preliminary studies suggested that the Fas / FasL pathway may be
involved in paracetamol toxicity (Braithwaite et al, 1998), this data has not proved
reproducible (personal observation). However, a role for cytokine-induced
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apoptosis, with TNF-a the main candidate (Leist et al, 1998) remains feasible in
paracetamol toxicity. A mechanistic understanding of apoptosis may help elucidate
appropriate pathways to allow intervention to increase or reduce apoptosis as
appropriate (see below; Corcoran et al, 1994).
v. Inhibition of apoptosis
In certain situations apoptosis can be specifically inhibited, offering a novel approach
to reducing hepatic injury (reviewed in Patel et al, 1998). Blocking apoptosis in
hepatocytes in inflammatory / toxic diseases may improve outcome by reducing
hepatocyte loss. For example, reperfusion injury can be blocked by a caspase
inhibitor (Cursio et al, 1999) and Fas-induced apoptosis can be inhibited by
clenbuterol (Andre et al, 1999). This represents the opposite approach to that
espoused in hepatocarcinogenesis, where apoptosis may be reduced and
augmentation of apoptosis may be beneficial (Grassl-Kraupp et al, 1998).
vi. Apoptosis and non-parenchymal cells
Apoptosis in hepatocytes has been extensively studied but non-parenchymal cells has
have received little attention. However, non-parenchymal cells are important in
causing and perhaps also in treating liver disease. Stellate cells have an important
role in causing liver fibrosis and inducing apoptosis in stellate cells may be a useful
therapeutic option (Cales, 1998). Kupffer cells may promote liver injury induced by
various toxins (Laskin, 1996) and induction of apoptosis in Kupffer cells may reduce
injury.
4. Summary
Good evidence now exists that indirect mechanisms contribute to the toxicity of
many xenobiotic drugs. Accumulation and activation of Kupffer cells is associated
with increased production of various bioactive substances including cytokines such
as TNF-a and chemokines such as MIP-2. These agents may have a central role in
hepatocyte death by apoptosis and necrosis and may also be involved in regeneration
after toxic injury. Paracetamol overdose is an important clinical problem to which




The purpose of this study is to investigate hepatic injury and regeneration after
paracetamol overdose by studying the role of Kupffer cells, cytokines such as TNF-a
and apoptosis in the pathogenesis of paracetamol toxicity. Several questions will be
specifically addressed:
1. Does apoptosis occur in human liver after paracetamol overdose?
2. Do Kupffer cells have a role in toxicity after paracetamol overdose?
3. Does TNF-a have a role in paracetamol toxicity?
4. Are other cytokines or chemokines involved in paracetamol toxicity?
5. Can any mechanisms be identified which may lead to the development of new
approaches to therapy after paracetamol poisoning?
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CHAPTER TWO
PARACETAMOL TOXICITY IN HUMAN LIVER
SUMMARY
This study of paracetamol toxicity in human liver after POD revealed hepatocyte
apoptosis at time of liver transplantation or death associated with striking regenerative
activity. The biological significance and control of this is not known, but Kupffer cell
activation with cytokine production is highlighted as a potential mechanism to link
hepatocyte apoptosis and proliferation.
INTRODUCTION
Although apoptosis has been recognised to occur in the liver for many years, only
recently has evidence begun to accumulate that hepatocyte apoptosis is important in the
pathogenesis of many liver diseases including viral, cholestatic and toxin-induced
hepatic injury (Patel et al, 1998). This is particularly interesting for toxic injury (e.g.
following paracetamol overdose), where necrosis is the major mechanism of hepatocyte
loss and induction of apoptosis not only offers new insights into the pathogenesis of
liver injury but also offers new therapeutic opportunities (Thompson, 1995; Patel et al,
1999).
Paracetamol overdose is a major clinical problem as it represents the commonest cause
of fulminant hepatic failure in the UK and the USA and is subsequently one of the
commonest reasons for emergency liver transplantation (Makin et al, 1995; Fagan and
Wannan, 1996; Schiodt et al, 1997). The availability of an effective antidote (N-
acetylcysteine) has meant that the majority of patients do not develop severe hepatic
injury. However, severe liver injury remains a major clinical challenge, as management
options are limited for those patients who develop hepatic failure (reviewed in O'Grady,
1997). While the development of reliable prognostic criteria has allowed identification
of a group with a poor predicted prognosis who will benefit from liver transplantation
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(O'Grady et al, 1989; Donaldson et al, 1993; Bernal et al, 1998b) the overall death rate
for this group is significant at 25-40% (Schiodt et al, 1999; Ostapowicz and Lee, 2000).
Patients who die or undergo liver transplantation following paracetamol overdose (POD)
invariably show severe zonal liver necrosis (Portmann et al, 1975; Lesna et al, 1996) as
the result of direct hepatic injury from toxic paracetamol metabolites (Jollow et al,
1973); recovery is associated with rapid and efficient regeneration (Lesna et al, 1976).
However, good evidence exists that paracetamol toxicity is more complex than simple
direct injury from the toxic metabolites and that additional mechanisms may modulate
liver injury following POD such as Kupffer cell activation (reviewed in Laskin and
Pendino, 1995) or production of TNF-a (Blazka et al, 1995). Hepatocyte apoptosis has
been reported in paracetamol toxicity in murine liver (Ray et al, 1996) but has not been
identified in human liver (Afford et al, 1995); the significance of apoptosis in
paracetamol toxicity is not known.
The aims of this study were to investigate hepatocyte apoptosis and regeneration and
Kupffer cell populations in human liver after POD.
MATERIALS AND METHODS
Patient Characteristics and Tissue Studied
This study was carried out with the approval of the local ethical committee. All patients
presenting to the Scottish Liver Transplant Unit (SLTU) with fulminant hepatic failure
(FHF) from 1992 - 1997 were identified (Table 2.1). Patients were included in the study
when formalin-fixed, paraffin-embedded tissue blocks were available for study i.e.
patients who had either received a liver transplant, or had died and an autopsy had been
carried out. At least 6 blocks of liver were available for transplant cases; 1 to 5 blocks
were available in autopsy cases. A proportion of the autopsy cases were excluded where
significant autolysis precluded accurate histological analysis (POD 20 and non-POD 5
autopsy cases). The remaining cases were then separated into two groups into those
secondary to POD and those of any other aetiology (non-POD: Table 2.1) for
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comparison. Four-micron sections were stained with haematoxylin and eosin.
Table 2.1
FHF Total Survived OLT Died No Path Autolysis Study
cases
All Cases 295 191 35 71* 13 25 66
POD 241 167 20 56* 10 20 44
Non-POD 54 24 15 15 3 5 22
Table 2.1 FHF = Fulminant Flepatic Failure; Total = total number of cases presenting to
SLTU in FHF from 1992-1997; Survived = patients who survived without liver
transplant; OLT = Liver transplant carried out (*2 patients died after OLT); Died =
patients who died (* 2 patients died after OLT); No Path = patients for whom
pathological material was unavailable (POD: 5 patients had an autopsy elsewhere and
blocks were not available, 3 cases had an autopsy limited to the brain, 2 patients did not
have an autopsy: non-POD 1 patient had limited autopsy, 2 patients did not have an
autopsy); POD - Paracetamol Overdose; non-POD = FHF of any other aetiology (see
Table 2.2 for list of aetiologies).
Immunohistochemistry
Immunohistochemistry was carried out using the EnvisionTM+ system (Dako)
following the standard manufacturers protocol after antigen retrieval by microwaving for
15 minutes in EDTA (lmM:pH8). Antibodies used were Ki-67 (clone MIB-1:
Immunotech) to detect proliferating cells and CD68 (clone PGM-1: Dako) to detect
Kupffer cells.
Quantitative Analysis
Necrosis was assessed on H&E stained sections, dividing cases into two groups: those
showing either massive or sub-massive necrosis. Massive necrosis was defined as when
no surviving hepatocytes were present on light microscopy. All remaining cases showed
extensive (sub-massive) necrosis but with surviving hepatocytes in zone 1; in these cases
hepatocyte injury was scored as present or absent, based on the presence of nuclear
enlargement and cytoplasmic vacuolation. One representative section from the cases
with submassive necrosis was then subsequently assessed to determine the rate of
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hepatocyte apoptosis and proliferation in the areas of surviving parenchyma. Apoptosis
was quantitated on H&E-stained sections using morphological criteria as previously
used in our laboratory (Howie et al, 1994) counting only hepatocytes showing
unequivocal apoptotic morphology in areas of non-necrotic hepatic parenchyma.
Mitotic figures were counted in a similar manner. Proliferation was further quantitated
by calculating the proportion of hepatocytes that expressed Ki-67, an antigen expressed
in all phases of the cell cycle except GO (Key et al, 1993). Kupffer cells were
quantitated by counting the number of cells expressing CD68 present in areas of
surviving hepatic parenchyma. For all quantitative counts, multiple fields were assessed
and at least 1000 cells were counted in each case.
Statistical analysis
Comparison between the POD and non-POD groups was carried out for the quantitative
data by simple graph plotting (MedCalc™, Belgium). Using this method, when the
shoulders in the box-plots do not overlap then the difference is likely to be significant
(p<0.05).
RESULTS
Apoptosis and proliferation after paracetamol overdose
As expected all POD cases showed significant hepatic necrosis with 13 cases (30%)
showing massive necrosis and the other 31 cases (70%) showing sub-massive necrosis
(Figure 2.1). In some of the cases with submassive necrosis the necrosis was variable
and in areas was "massive"; this group basically represented patients with sufficient
parenchyma on which to score apoptosis and proliferation. Most of these cases showed
evidence of hepatocyte injury (29/32 cases: Figure 2.2). Hepatocyte apoptosis was then
counted in all livers with sub-massive necrosis. Hepatocyte apoptosis was identified in
all 32 scoreable cases (with submassive, not massive necrosis) at the time of
transplantation or post mortem (Figure 2.3) with a median apoptotic index of 0.6%.
Striking proliferative activity was also identified in resected livers after POD (Figure
2.4) with a median mitotic index of 0.35% and Ki-67 positivity index of 4.2%.
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Figure 2.1
Figure 2.1
Photomicrographs showing (i) severe hepatic necrosis after POD [^indicates rim of
surviving parenchyma in zone 1] and (ii) panacinar hepatic necrosis.
Figure 2.2
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Photomicrograph showing hepatocyte injury in a case of POD. The most notable feature
of injuiy was striking cytoplasmic clearing and vacuolation. There was also a degree of
variability in nuclear size.
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Figure 2.3
Photomicrographs showing hepatocyte apoptosis. Apoptotic hepatocytes were only
counted when cells showed apoptotic morphology (cell shrinkage, chromatin
condensation and nuclear separation into haematoxyphilic balls) and were considered to














Photomicrographs showing typical mitotic and Ki-67 positive hepatocytes after POD.
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Comparison of POD and non-POD cases
In the non-POD group massive necrosis was identified in 9 cases (41%) with sub-
massive necrosis in 15 cases (69%). Hepatocyte injury was noted in the minority of
these cases (5/15). In contrast to POD hepatocyte apoptosis was only seen in 9/15 of
non-POD cases and apoptotic indices were much higher in POD (median 0.6, range 0.2-
2.4) than non-POD cases (median 0.1, range 0-0.7: Figure 2.5). Much lower rates of
mitosis and Ki-67 positivity were also seen in the non-POD group than had been noted
after POD (Mitotic rate: POD [median 0.35 range 0-3.5] and non-POD [median 0.1,
range 0-1.2]: Figure 2.6. Ki-67 positivity: POD [median 4.2, range 0.8-15.5] and non-
POD [median 0.2, range 0-2.5]: Figure 2.7). No association between rates of apoptosis









Apoptotic Index (%apoptotic hepatocytes) for POD and non-POD groups. Apoptotic
index. Box-and-whisker plot (box represents 25 to 75 percentile with median: whiskers
represent 95% CI of median). Shoulders on box-plot do not overlap indicating that the
two groups are different with a 95% CI.
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Mitotic Index (% mitotic hepatocytes) for POD and non-POD groups
Box-and-whisker plots (box represents 25 to 75 percentile with median: whiskers












Proliferative Index (% K.i-67 positive hepatocytes) for POD and non-POD groups
Box-and-whisker plots (box represents 25 to 75 percentile with median: whiskers
represent 95% CI of median). Shoulders on box-plot do not overlap indicating that the
two groups are different with a 95% CI.
Kupffer Cell Number
Zones of necrosis showed striking, confluent infiltration by CD-68-positive cells that
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within viable hepatic parenchyma the proportion ofCD-68 positive cells was the same in
POD (median 13.8%, range 8-20.7) and non-POD cases (median 12.6%, range 7.2-22.6)
and was similar to that seen in normal liver (median 15.6%, range 13.2-18.2%; Kuiper et
al, 1994). Double-staining was not carried out Ki-67 positivity was noted in a small
proportion of the apparent CD-68 positive cells.
Figure 2.8
Photomicrograph showing accumulation of CD-68 positive cells in areas of zone 2-3
necrosis and few CD-68 positive cells present in surviving zone 1 parenchyma (asterix).
Clinical parameters of liver failure
The POD and non-POD groups represent patients with liver disease of similar clinical
severity as measured by the King's College prognostic criteria (O'Grady et al, 1989:
poor criteria met in 39/44 POD and 21/22 non-POD cases; Table 2.2) and also had a
similar age and sex distribution. There were no differences between the groups in
biochemical parameters of liver injury (maximum bilirubin, ALT, AST), maximum
creatinine, mode of death or severity of encephalopathy. A prolonged prothrombin time
(PT) was noted in POD compared with non-POD patients (maximum PT 95 s for POD
Figure 2.8
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and 59s for non-POD), an expected feature of paracetamol overdose. The major
difference between the two groups was in the duration of illness with a mean disease
length of 89.8 hours for POD (time from overdose to liver transplantation) and 20.9 days
for non-POD (time from jaundice to encephalopathy).
Separating POD cases into those with massive versus sub-massive necrosis revealed no
difference between these groups in terms of paracetamol level (maximum or at
presentation), time to presentation at the SLTU, biochemical parameters of liver injury,




Age Sex PT Score Duration
POD 44 36.5
(16-63)
13:31 97 39 89.8 hours*
Non-POD 22 42
(15-62)
7:15 56 21 20.9 days**
Table 2.2 Total cases - cases included in study; Age - median, range; Sex (m:f); PT -
Maximum prothrombin time in seconds; Score = number of patients who reached poor
prognostic criteria (O'Grady et al, 1989). Duration - measured from overdose to
transplant in POD cases* and from onset of jaundice to development of encephalopathy
for non-POD cases**. Aetiology of non-POD Cases: Unknown (nonAnonBnonC)
hepatitis - 14; Drug-Induced (not paracetamol) - 3; Budd-Chiari - 3; Alcohol - 2;
Wilson's - 1; Autoimmune Hepatitis - 1; Hepatitis A - 1; Ischaemia - 1.
DISCUSSION
Hepatocyte necrosis and apoptosis after paracetamol overdose
Extensive and severe hepatic necrosis is well-recognised as a characteristic finding in
liver failure after paracetamol overdose (Lesna et al, 1976; Portmann et al, 1975).
Although the maximum extent of necrosis after which recovery is not possible is not
clear, greater than 60% hepatic necrosis in human liver is associated with a poor
outcome (Portmann et al, 1975; Gazzard et al, 1975). While formal quantification of the
extent of necrosis was not carried out, all cases in this study probably had greater than
60% necrosis. In addition, this is the first definite description of hepatocyte apoptosis
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after POD.
Apoptosis has been increasingly recognised to be an important mechanism of cell loss in
toxic injury caused by a variety of drugs and toxins including alcohol, carbon tetra¬
chloride, galactosamine, amanitin and bile salts (Leist et al, 1997; Patel et al, 1998).
From this study, apoptosis has been identified after paracetamol overdose in human
liver. Apoptosis has previously been described paracetamol-induced liver injury in
murine liver (Ray et al, 1996) and although both early studies identified acidophil bodies
in some cases (Portmann et al, 1975; Lesna et al, 1976), it has been suggested that
apoptosis does not occur after paracetamol overdose in human liver (Afford et al, 1995).
The latter study used an in situ end-labelling method to detect apoptosis and concluded
that significant hepatocyte apoptosis does not occur after paracetamol overdose in a
limited series of 4 cases (Afford et al, 1995). However, the rate of 1-2% apoptosis
suggested (Afford et al, 1995) is in keeping with the rates of apoptosis in this study
made by morphological assessment, which is generally considered to be a better method
for quantitatation of apoptosis (Goldsworthy et al, 1996; Galle, 1997). Given the known
difficulties of quantifying apoptosis in vivo and short duration of visible changes
(Grassl-Kraupp et al, 1995; Galle and Krammer, 1998), low rates of apoptosis are not
surprising. In the rat, a rate of 0.5% hepatocyte apoptosis has been estimated to result in
25% reduction in liver mass in a few days (Bursch et al, 1990), suggesting the rates of
apoptosis noted in this study would account for a rapid loss of a significant proportion of
cells and may contribute to the liver failure in these patients.
Liver regeneration after paracetamol overdose
The regenerative response after paracetamol-induced liver injury has been studied
previously, using different methodology but with broadly comparable data to this study
(Koukoulis et al, 1992; Donaldson et al, 1993). The first study used PCNA staining to
assess proliferation and identified rates of hepatocyte proliferation of 50-60% in cases at
a comparable time to this study. While these rates are higher than the levels of Ki-67
positivity in this study (up to 15%), PCNA has a long half-life and may be induced in
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quiescent cells (Hall et al, 1990; Ottavio et al, 1990). Furthermore while Ki-67 is cell
cycle-specific PCNA is not as it also stains cells that have suffered DNA damage, which
may occur after paracetamol poisoning (Holme and Soderlund, 1986). The second study
found mitotic figures in hepatocytes in a greater proportion of cases of POD than cases
of other aetiology, similar to this study, although mitotic counts were not carried out.
The lower level ofmitosis than Ki-67 positivity noted in this study can be explained by
the short duration ofmitosis and staining of cells in all phases of the cell cycle by Ki-67.
Furthermore, this is the first study to identify hepatocyte apoptosis in the context of
regeneration after toxic injury (see below).
Liver pathology in the absence of paracetamol
This study investigates "late" changes after paracetamol overdose i.e. those occurring at
time of liver transplantation or death. At this time paracetamol is absent from serum
(Thomas, 1993), raising interesting questions about the pathogenesis of the pathological
changes. There are several possibilities:
1. Elevated rates ofapoptosis andproliferation are directly attributable to paracetamol,
despite its absence from serum. Paracetamol-protein adducts can be identified
immunohistochemically and by Western blot and have been identified in regenerating
hepatocytes in mouse-liver 72 hours after overdose (Roberts et al, 1991). However,
paracetamol adducts can also be identified with non-toxic doses of paracetamol and are a
good marker of covalent binding (Bartolone et al, 1987; Hinson et al, 1998) but may be
long-lived and therefore may not represent an accurate indicator of ongoing injury.
2. Elevated rates of apoptosis and proliferation are a generic feature of regeneration
after any acute, massive liver injuiy. The comparison between POD and non-POD
patients noted striking differences in rates of apoptosis, mitosis and Ki-67 positivity.
The non-POD patients are recognised to be an imperfect control group for several
reasons: (i) they represent a heterogeneous group of patients with different liver
diseases; (ii) different prognostic criteria are used for POD and non-POD patients
although both sets of criteria accurately predict outcome (O'Grady, 1989); and (iii) the
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non-POD cases have a much longer clinical duration than POD. However, biopsies are
not available from "survivors" of POD, which would be ideal controls, and the non-POD
group has been used as the best available group for comparison. Patients with non-
paracetamol-drug-induced liver failure may represent a much better control group but
the 3 patients in the non-POD group with drug-induced liver failure unfortunately all
showed massive hepatic necrosis. The reason for the striking differences in apoptosis
and proliferation between POD and non-POD cases is not known. While it may be due
to paracetamol itself (see above), it seems likely that in paracetamol overdose there is a
single massive insult and stimulus to regenerate and a short clinical duration, whereas in
other cases of liver failure the duration is longer with ongoing injury. The close
association of apoptosis and regeneration is recognised (Fan et al, 1998; Paulovich et al,
1997) and apoptosis has been suggested to be a mechanism of "fine-tuning" liver mass
during regeneration (Sakamoto et al, 1999; Hasegawa et al, 1999). After partial
hepatectomy in mice and rats apoptosis occurs up to 96 hours after hepatectomy and
follows a peak of BrdU/thymidine positivity (Sakamoto et al, 1999; Sigal et al, 1999).
IL-6, a critical part of the regenerative response may also be an important regulator of
apoptosis during proliferation; after partial hepatectomy IL-6 knockout mice restore
liver mass more slowly than wild type mice but have a lower net rate of proliferation and
a lower rate of hepatocyte apoptosis (Sakamoto et al, 1999). The intriguing possibility is
raised that an efficient regenerative process may contribute to liver injury by inducing
concurrent cell loss by apoptosis, and suggests that intervening to alter the balance of
cytokines may alter regeneration and improve the outcome.
3. Elevated rates of apoptosis and proliferation are induced by cytokines produced by
activated macrophages. Extensive experimental evidence suggests that modulation of
Kupffer cells can alter hepatotoxicity (Laskin et al, 1995; Goldin et al, 1996) associated
with production of bioactive substances including reactive oxygen and nitrogen species
(Michael et al, 1999) and cytokines such as TNF-a (Blazka et al, 1995). TNF-a in
particular is implicated in toxic liver injury induced by various chemicals and can cause
hepatocyte death by apoptosis and also signal hepatocyte proliferation (Bradham et al,
1998; Taub, 1998). This study of Kupffer cells confirm previously published
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observations in human liver, namely that there is striking accumulation of Kupffer cells
within areas of necrosis but there is no increase in Kupffer cells in surviving
parenchyma (Mathew et al, 1994) and that Kupffer cells are proliferating (Koukoulis et
al, 1990). While the production of cytokines is a feasible explanation for the elevated
rates of apoptosis and regeneration, this observational study offers little in resolving the
role ofKupffer cells and cytokines.
4. Elevated rates of apoptosis and proliferation occur as the result of secondary
ischaemic damage adjacent to necrotic liver. The suggestion that ischaemia may occur
adjacent to necrosis has been previously proposed to explain the hepatocyte injury noted
in surviving parenchyma (Portmann et al, 1975). The injury noted in that study was
characterised by nuclear pleomorphism, cell swelling and cytoplasmic vacuolation and
seen mainly in patients who survived without liver transplantation (Portmann et al,
1975). This study confirmed hepatocyte injury in patients who died or underwent liver
transplantation and was seen in most POD cases and few non-POD cases.
Microvascular changes in zone 3 and polymorph plugging of sinusoids may contribute
to early liver injury but conflicting evidence exists (Jaeschke and Mitchell, 1989; Welty
et al, 1993; Lim et al, 1995). The situation after paracetamol overdose may be
analogous to that occurring after myocardial infarction or cerebrovascular accident,
where additional cell loss by apoptosis occurs outwith an area of ischaemic necrosis
(Cohen, 1993; Gottlieb et al, 1994; Uyama et al, 1994). Of particular interest is the
observation that inhibition of apoptosis in these situations can improve the outcome,
raising the possibility of specifically inhibiting apoptosis after paracetamol overdose to
improve the outcome.
5. Elevated rates of apoptosis and proliferation occur by a combination ofsome or all
the above mechanisms. Evidence exists to support all of the above mechanisms to
explain elevated rates of hepatocyte apoptosis and proliferation after paracetamol
overdose. Kupffer cells and cytokines such as TNF-a remain promising candidates for a
major role in paracetamol toxicity as they are involved in liver regeneration, toxic injury
and also ischaemic injury. Further mechanistic studies of Kupffer cells and their
secreted products are required to unravel the mechanisms of liver injury and
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regeneration.
Liver death and regeneration in paracetamol toxicity
The major concern in paracetamol toxicity is the considerable clinical challenge of
improving the outcome for patients who develop severe liver injury where mortality is
high and therapeutic options are limited (Peleman et al, 1988; O'Grady et al, 1989).
This observational study raises many important issues regarding paracetamol toxicity in
human liver. Apoptosis is confirmed to occur during paracetamol toxicity in human
liver at a late time and is associated with brisk hepatocyte regeneration. While the
precise pathogenesis is not known and further research is required to understand the
mechanisms of injury and regeneration in the liver, certain targets for potential
therapeutic intervention have been identified. In particular specific inhibition of
apoptosis and cytokines modulation of regeneration are appealing new approaches to
improve outcome after paracetamol overdose in the future.
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CHAPTER THREE
EARLY EVENTS IN PARACETAMOL TOXICITY
SUMMARY
Patients dying after coproxamol (combination of dextropropoxyphene and
paracetamol) overdose represents a novel approach to investigate liver pathology
caused by paracetamol. In this study, pathological changes in the liver attributable to
paracetamol including necrosis, apoptosis, lipofuscin accumulation and hepatocyte
injury were identified after coproxamol overdose. These features should be borne in
mind as possible markers of paracetamol toxicity when a good history or toxicology
is not available.
INTRODUCTION
Good evidence now exists that hepatocyte apoptosis occurs in addition to necrosis in
murine and human liver but further studies are required to elucidate the role of
apoptosis in paracetamol toxicity (Ray et al, 1996; chapter 2). The pathogenesis of
paracetamol toxicity is complex. In addition to direct hepatocyte injury from toxic
paracetamol metabolites, evidence has emerged from several experimental models
that indirect factors such as Kupffer cell activation and cytokine production may be
involved in paracetamol hepatotoxicity (Laskin 1996). However, species variation in
paracetamol toxicity is well-described (Green et al, 1984; Holme and Soderlund,
1986; Smolarek et al, 1990) and the relevance of this new data in human liver is not
clear. A major problem in studying paracetamol toxicity in humans is the lack of
human liver tissue available in the early stages of paracetamol toxicity: there is no
indication for biopsy after paracetamol overdose as clotting is invariably deranged
and the risk of serious haemorrhage is significant. Some early studies of paracetamol
toxicity in human liver identified early changes of toxicity including lipofuscin
accumulation (Portmann et al, 1975; Lesna et al, 1976).
An alternative approach to study paracetamol toxicity in human liver is patients who
die after overdosage of coproxamol. Coproxamol is a proprietary combination of
dextropropoxyphene and paracetamol which when taken in overdose results in rapid
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death due to dcxtropropoxypheiie (opiate overdosage) with no derangement in liver
function (Young and Lawson, 1980; Lawson and Northridge, 1987; Spooner and
Harvey, 1993). A minority of patients (5/27) develop liver failure secondary to the
paracetamol component (Read et al, 1986) although the liver pathology after
coproxamol overdose has not been studied.
The aims of this study were to investigate the pathological changes in human liver
following coproxamol overdose, to address whether or not features of paracetamol
toxicity including hepatocyte apoptosis were evident.
MATERIALS AND METHODS
Patient characteristics and tissue studied
A consecutive series of patients dying of coproxamol overdosage were identified
from the files of the Forensic Medicine Unit, University of Edinburgh over a three-
year period from 1996 to 1999 as part of an ethically approved study of drug-related
death (Prof A Busuttil, Dr P Fineron, Prof DJ Harrison). A similar series of age and
sex-matched patients dying secondary to methadone overdose with no history of
ingestion of paracetamol were identified for the same period (see Table 3.3). For
each case 1-5 blocks of liver were available for study from which H&E sections were
available.
Morphological Analysis
Several pathological features that have been previously described in paracetamol
toxicity were studied (Table 3.1).
H&E-stained sections were examined to assess these features: lipofuscin deposition,
hepatocyte injury and hepatic necrosis were scored as present or absent and
hepatocyte apoptosis was scored by counting the number of apoptotic hepatocytes
identified in 10 high power fields (x400). Autolysis was present in 5/23 cases after
coproxamol overdose and 3/18 cases after methadone overdose; owing to the poor
preservation these cases were excluded from the assessment of apoptosis.
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Table 3.1
Pathological features of paracetamol toxicity Reference
Lipofuscin deposition in hepatocytes Portmann et al, 1975;
Lesna et al, 1976
Hepatocyte injury* Portmann et al, 1975;
Chapter 2
Hepatocyte necrosis Portmann et al, 1975;
Lesna et al, 1976
Hepatic apoptosis Afford et al, 1995;
Chapter 2
Table 3.1 Morphological assessment of liver pathology after paracetamol overdose.
*hepatocyte injury is characterised by nuclear enlargement and cytoplasmic
vacuolation
RESULTS
Liver pathology after coproxamol overdose
After coproxamol overdose there was accumulation of lipofuscin in zone 3
hepatocytes (13% of cases), hepatocyte injury (61%), hepatic necrosis (9%) and
hepatocyte apoptosis (26% of cases; Figure 3.1 and Table 3.2). In cases where
apoptosis was identified a formal count was made and a mean of 1.8 ± 1.4 apoptotic
bodies was identified per 10 high power fields. All of these pathological features
were present only in zone 3 of the liver in coproxamol overdose cases and were not
noted in any case of methadone overdose, suggesting that they are attributable to the
paracetamol component of coproxamol. Notable hepatic congestion (expansion of
sinusoids that were filled with blood) was present in 43% of case of coproxamol
overdose and 77% of cases of methadone overdose. Three methadone cases also
showed features suggestive of hepatitis C virus infection (lymphocytic infiltrate in
portal tracts with lymphoid aggregates, mild increase of lymphocytes in the hepatic
parenchyma) although no information was available regarding hepatitis virus
serology.
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Figure 3.1
Histopathological changes in zone 3 of the liver after coproxamol overdose.






(23 cases) (18 cases)
Lipofuscin accumulation 3 0
(13%)





Hepatocyte apoptosis 6* 0
(26%)
Pathological Changes in Liver after Coproxamol orMethadone Overdose
Aetiology: Coproxamol = death after coproxamol overdose; Methadone = death after
methadone overdose. * = assessed in 18 cases only - see methods.
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Clinical Parameters
The patient groups in this study all died acutely of opiate poisoning, and none had
any clinical evidence of liver disease. The cases were age and sex matched and had a
similar time to death (Median age 34 years; female:male ratio 1.3:1.
DISCUSSION
Paracetamol toxicity after coproxamol overdose
This study of patients dying after coproxamol overdose represents a novel approach
to investigate paracetamol toxicity in human liver. The dextropropoxyphene
component of coproxamol is associated with a risk of rapid death due to opiate
toxicity (Whittington and Barclay, 1981). Patients dying after methadone overdose
represent a very useful comparison group as although methadone and
dextroproxyphene are different agents, both have similar pharmacological action,
have a similar risk of rapid death due to respiratory depression and there is no
evidence that either drug causes liver injury. Several potential problems exist as
several patients may have consumed alcohol or other drugs as well as coproxamol (8
cases alcohol, 3 cases benzodiazepine, 2 cases amitryptriline, 2 cases morphine).
Occasional cases showed mild macrovesicular steatosis but features suggestive of
alcoholic hepatitis were not noted in any case. A further potential problem was that
an accurate time from overdose to death was not available in all cases and in some
was estimated.
Less than 20% of patients who take an overdose of coproxamol develop liver failure
at some time (Read et al, 1986) and in this study group none of the patients had any
clinical evidence of liver disease. Despite this, over 60% of the patients had
pathological changes in the liver attributable to paracetamol. This figure may be
artefactually high as the group under study is biased towards those who may have
developed liver injury, as opiate-induced death, followed by autopsy, was the major
selection criterion, and any patients who survived with or without treatment were not
included.
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This study provides further evidence that apoptosis occurs as a feature of
paracetamol toxicity in human liver, occurring at an early time before necrosis may
develop. The two early studies of paracetamol toxicity both identified acidophil
bodies in some cases after paracetamol overdose (Portmann et al, 1975; Lesna et al,
1976) and probably represent the first description of paracetamol-induced hepatocyte
apoptosis but would require further verification. The rates of apoptosis are extremely
low, but are comparable with those described in the previous chapter after
paracetamol overdose (there are approximately 1000 - 1500 hepatocytes in 10 high
power fields). As previously discussed low rates of apoptosis may nevertheless
result in significant cell loss from the liver.
Several studies have addressed the pathological changes in human liver following
paracetamol overdose (summarised in Table 3.4). All previous studies have been of
patients who have taken an overdose of paracetamol. However, this observational
study has identified several pathological changes in the liver after coproxamol
overdose, which are attributable as early effects in paracetamol toxicity as they are
not present in a similar group of patients dying after methadone overdose. There is
evidence of hepatocyte death by necrosis in a minority of cases, an interesting
finding as most patients who overdose on coproxamol do not develop "toxic" levels
of paracetamol as the paracetamol dose is relatively low (Young and Lawson, 1980).
These patients often die early, frequently prior to admission to hospital, and precise
details of dose and time since overdose are often not available (Young, 1983;
Whittington, 1984). Cautionary literature suggests that paracetamol toxicity may be
overdiagnosed as a cause of death (Spooner and Harvey, 1993), however, this study
suggests that the opposite should also be borne in mind and that paracetamol toxicity
should not be forgotten where death occurs because of toxic effects of another drug.
While zone 3 hepatic necrosis is the main feature of established paracetamol toxicity,
early features of toxicity including lipofuscin accumulation (Portmann et al, 1975;
Lesna et al, 1976) related to the effects of lipid peroxidation, and hepatocyte injury
as indicated by cytoplasmic vacuolation and swelling (Portmann et al, 1975; chapter
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Table 3.4
Reference Histopathology after POD
Portmann et al, 1975 Grading of injury and zone 3 necrosis
Hepatocyte injury adjacent to necrosis
Lipofuscin deposition in hepatocytes
Evidence of regeneration
Quantitation of necrosis





Koukoulis et al, 1992 Zone 3 necrosis
Regeneration (PCNA positivity)
Mathew et al, 1994 Grading of hepatic injury and necrosis
Quantitation ofKupffer cells and stellate cells
Table 3.4 Histopathology of the liver after POD (paracetamol overdose)
2) have been previously described and are confirmed in this study. While intuitively
one might expect zone 3 congestion as an early feature of paracetamol toxicity, this
was noted in more cases where paracetamol was absent than present. Lipofuscin
accumulation was present only after coproxamol overdose but was only present in
13% of cases. Hepatocyte injury characterised by vacuolation and swelling was
present in over 60% of cases of coproxamol overdose and was not present where
paracetamol was absent. This may be a useful marker to suggest the possibility of
paracetamol toxicity in cases where a good history or toxicology is not available.
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CHAPTER FOUR
CHARACTERISATION OF PARACETAMOL TOXICITY IN VITRO
SUMMARY
The aims of this study were to develop and characterise a model of paracetamol
hepatotoxicity in vitro. Primary murine hepatocytes and two human hepatocyte cell
lines were used. Paracetamol caused dose-dependent hepatotoxicity above a
threshold level, with the human cell lines more sensitive to the effects of paracetamol
and showing a more predictable pattern of toxicity than primary murine hepatocytes.
Paracetamol caused significant rates of hepatocyte apoptosis by morphological
assessment and annexin V staining, confirmed by electron microscopy. Necrosis was
measured by propidium iodide uptake and flow cytometric detection. Paracetamol
also blocked cell cycle activity by reducing rates ofmitosis and BrdU incorporation.
The study describes a well-characterised model of paracetamol toxicity, confirming
that apoptosis occurs as a significant mechanism of cell loss.
INTRODUCTION
The major mechanism of cell death in paracetamol toxicity is necrosis, however,
increasing evidence has suggested that apoptosis may also occur. Apoptosis
represents a novel pathway during paracetamol toxicity and sufficient evidence exists
from other models of liver injury to suggest that apoptosis may be an important
mechanism of cell loss (Patel et al, 1998). Moreover, apoptosis is a tightly regulated
process and specific inhibitors of apoptosis exist, raising the possibility of
therapeutic intervention to reduce liver injury (Patel et al, 1999). Several groups
have studied the occurrence of apoptosis in paracetamol toxicity using a wide range
of doses and methods to study apoptosis (summarised in table 4.1). Apoptosis has
been convincingly demonstrated in murine liver in vivo (Ray et al, 1996) and in
various non-hepatic cell lines (Holownia et al, 1997; Wiger et al, 1999) and now in
human liver (personal observations, chapters 2 and 3). However, the role of
apoptosis in contributing to loss of liver mass in paracetamol toxicity is not known.
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Table 4.1 Studies of Paracetamol-induced apoptosis
Apoptosis - method(s) used to study apoptosis. * PC 12 cells are a rat adrenal phaeo-
chromocytoma cell line. # HL60 cells are a promyelocyte leukaemia cell line
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Ilepatocytes in culture are a useful model of liver injury. Most specific liver
functions are retained by hepatocytes in culture (Ichiara et al, 1982; Castell et al,
1985; Guillouzo et al, 1986; Gomez-Lechon et al, 1990); in addition most drugs and
toxins injure cultured hepatocytes in a similar manner to that seen in hepatocytes in
vivo (Ekwall and Acosta, 1982; Jover et al, 1992). The main benefit of an in vitro
approach is simplicity, removing many of the complexities that occur in vivo.
Paracetamol poisoning is suited to an in vitro approach because paracetamol toxicity
occurs by similar mechanisms in vivo and in vitro i.e. hepatotoxicity is dose-
dependent above a threshold (Shear et al, 1995); toxicity results in glutathione
depletion (Larrauri et al, 1987; Adamson and Harman, 1993); and rescue by
administration ofN-acetyl cysteine prevents injury (Massey and Racz, 1981). Many
different in vitro models of paracetamol toxicity have been described using human or
murine hepatocytes.
The aim of this study was to develop and characterise paracetamol hepatotoxicity in
murine and human hepatocytes in vitro.
MATERIALS AND METHODS
Isolation ofmurine hepatocytes
Hepatocytes were isolated using a modified two-step collagenase perfusion method
developed in this laboratory. The composition of the media is given in the appendix.
10-12 week old male C3H mice were killed by cervical dislocation and the inferior
vena cava was cannulated via the right heart using 1mm plastic tubing attached to a
peristaltic pump (Watson Marlow). Infusion of perfusion medium was commenced
at a flow rate of 1Oml/minute for a few seconds until the liver blanched and expanded
slightly at which point the portal vein was incised. Perfusion medium was infused
for 5 minutes. Digestion medium was then infused for a further 6-10 minutes at the
same flow rate. The liver was carefully removed, placed in a sterile petri dish in 2-
3ml digestion medium and carefully broken into small pieces using two pairs of
sterile forceps. Plating medium was added and the resulting fragments and cell
suspension were passed through a lOOnm sterile filter (Nunc). The resulting cell
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suspension was cenlrifuged at 300g for 10 minutes. The cell pellet was resuspended
in 8ml plating medium and 5.25ml Percoll/Hanks buffered saline (Sigma Aldrich,
Poole) and centrifuged at 300g for a further 10 minutes. The top layer of dead cells
was discarded and the cell pellet resuspended in 5ml plating medium. Cells were
counted and viability was assessed using trypan blue exclusion: cells were only used
if viability was greater than 85%. Cells were plated on cultureware (Gibco-BRL,
Paisley) previously coated with 1% fibronectin (Sigma; Appendix 1) in sterile PBS at
4°C overnight and placed in a 37°C incubator for 2 hours to allow the hepatocytes to
adhere. The medium was changed to culture medium and the cells were incubated
overnight prior to commencing each experiment. Several pilot experiments were
carried out to establish optimal culture media and appropriate culture supplements,
detailed in Appendix 2.
Human hepatocyte cell lines
Two human hepatocyte cell lines (HepG2 and WRL 68) were chosen for study.
HepG2 cells, a human hepatoma cell line (Knowles et al, 1980; Darlington et al,
1987), were maintained in DMEM (Gibco) supplemented with 200mM L-glutamine
and antibiotics (penicillin/streptomycin). WRL 68 cells, a normal human embryonal
hepatocyte cell line (ECACC, Cambridge), were maintained in MEM (Sigma)
supplemented with L-glutamine and antibiotics. Both cell lines express phenotypic
characteristics of hepatocytes and have been used previously in drug toxicology
studies (Darlington et al, 1987; Roe et al, 1993; Gutierrez-Ruiz et al, 1994). Serum-
free culture conditions were developed to allow characterisation of cytokine
production in subsequent experiments at a cell density that allowed logarithmic
growth of untreated cells and therefore eliminate effects relating to cell confluence.
All experiments were carried out on cultureware (Gibco) previously coated with 1%
fibronectin (Sigma) in sterile PBS at 4°C overnight. Cells were plated at 2x104 cells
per well in 24 well plates or at lxl04 cells per well in eight well glass chamber
slides. Cells were allowed to settle for two hours (WRL 68) or overnight (HepG2) at
which time non-adherent cells were washed off, the media was changed and
experiments were begun. Several pilot experiments were carried out to determine
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optimal culture conditions in terms of a serum-free system with hepatocyte growth
supplements added (Appendix 3).
Measuring paracetamol hepatotoxicity
Paracetamol (Sigma) was dissolved directly in the appropriate culture media. BrdU
(proliferation labelling agent, Boehringer: 1:100) was added three hours before
ending each experiment. Cytotoxicity was assessed using the MTT assay as a
measure of cell number. The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] assay (Mosmann, 1983; Denizot and Lang, 1986;
Carmichael et al, 1987) is a simple and reliable colorimetric method to assess cell
number in drug toxicology studies (Carmichael et al, 1987). The culture supernatant
was removed and the cells were washed gently with sterile PBS. MTT working
solution (MTT stock lOmg/ml in PBS: working solution 1.6ml stock added to 5.4ml
culture media) was added and the cells incubated at 37°C for four hours. The MTT
working solution was carefully removed and the cells washed gently with PBS.
Dimethyl sulphoxide (DMSO) was added to dissolve the formazan salt and the plates
were read on an ELISA plate reader (Dynatech) within 15 minutes. Pilot studies were
carried out to validate the use ofMTT as a measure of cell number in the cell lines
(Appendix 4).
Morphological assessment of injury and apoptosis
For morphological assessment, culture slides were fixed in 85% methanol / 10%
formaldehyde [40%] / 5% glacial acetic acid at 4°C overnight and stored for up to
one week. Slides were stained with Feulgen's method (Appendix 5) and
counterstained with light green. The slides were examined to identify any
morphological evidence of cytotoxicity as previously described (Hayes and
Pickering, 1985). Counting of apoptotic and mitotic cells was carried out based on
morphological criteria. In pilot studies running means were carried out to determine
the minimum number of cells required to detect a significant difference between
samples (Appendix 6). Subsequently, at least 1000 cells were counted in each case.
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Immunohistochemistry
For immunohistochemistry, culture slides were fixed in acetone/methanol (1:1) at
4°C for 10 minutes and then stored in TBS at 4°C for up to 2 weeks prior to staining.
Immunohistochemistry was carried out using the Envision™+ system (Dako) using
the standard manufacturers protocol. For human cells, immunohistochemistry was
carried out for BrdU and Ki-67. For murine cells, immunohistochemistry was
carried out for BrdU only because antibodies against Ki-67 do not work in murine
tissue (data not shown). For BrdU immunohistochemistry slides were pre-treated
with 2N hydrochloric acid for 10 minutes and the anti-BrdU antibody (clone M0744,
Dako; 1:500 dilution) was incubated for 1 hour at room temperature. No
pretreatment was required for Ki-67 immunohistochemistry; the antibody (clone
MIB-1, Dako; 1:100) was incubated for 1 hour at room temperature. Slides were
assessed calculating the proportion of positive and negative cells after calculation of
a running mean to determine how many cells had to be counted (Appendix 6).
Annexin V Staining
Cells were grown on fibronectin-coated petri dishes and supernatants were retained
and mixed with adherent cells harvested using 0.02mM EDTA. Samples were
centrifiiged at 300g for 10 minutes, washed in cold PBS and resuspended in binding
buffer (lOmM HEPES/NaOH [pH7.4], 140mM NaCl, 2.5mM CaCl2) at a
concentration of 106 cells per ml. 10)0.1 of FITC-labelled Annexin V (R&D Systems)
was added to 100|il of the sample (105 cells) and after gentle mixing it was incubated
at room temperature for 15 minutes in the dark. 10|ll of propidium iodide solution
(50|J.g/ml in PBS) and 400|il of binding buffer were added and samples were
assessed by flow cytometry (Coulter EPICS™) within 1 hour.
Electron Microscopy
Samples of control and paracetamol-treated cells (72 hours) were harvested using
0.02mM EDTA / lxtrypsin and fixed in glutaraldehyde. Grids for electron
microscopy were prepared using standard techniques.
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Statistical Analysis
Differences were assessed using a one-way analysis of variance (MedCalc ,
Belgium), with a value ofp<0.05 chosen as significant.
RESULTS
Paracetamol toxicity in murine and human hepatocytes
Administration of paracetamol to primary murine hepatocytes resulted in a reduction
in cell number with 20mM paracetamol at 24, 48 and 72 hours and lOmM
paracetamol at 48 and 72 hours (p<0.05; Figure 4.1). Lower doses of paracetamol
did not significantly alter cell number at any time. As a general comment, the cell
number data showed marked variability in the murine model, with wide variability in
most experiments.








Cell number measured by MTT assay for primary murine hepatocytes. The control
represents cells with media only: other groups have the dose of paracetamol noted.
* reduction in cell number compared with untreated controls (p<0.05). Results are
the mean of four repeat experiments.
In human hepatocytes, paracetamol caused a dose-dependent reduction in cell
number in both cell lines after 48 and 72 hours, however, HepG2 cells were less
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sensitive to paracetamol than WRL 68 cells (Figure 4.2 and 4.3). The threshold for
toxicity was at 2.5mM paracetamol for both cell lines. At this dose there was a
significant reduction in cell number compared with untreated controls but the cell
number still increased with time. At higher doses of paracetamol (>10mM for WRL
68 cells, >20mM for HepG2 cells) there was a significant reduction in cell number
compared with controls and also compared with the starting number of cells at all
time points (p<0.05). A "balance point" was noted for both cell lines, where there
was significant toxicity compared with controls but the actual cell number did not
change over the 72 hour period (5mM for WRL 68, lOmM for HepG2). These doses
were utilised for further studies on apoptosis and proliferation as there was
significant toxicity, but the cell number remained high enough to allow study of
surviving cells.







0 24 48 72
Figure 4.2.
Cell number, measured by MTT assay, for HepG2 cells up to 72 hours.
Control represents cells with media only, the other groups have the dose
of paracetamol noted. See text for significant differences (p<0.05).
HepG2
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Figure 4.3.
Cell number, measured by MTT assay, for WRL 68 cells up to 72 hours.
Control represents cells with media only; the other groups have the dose of
paracetamol noted. See text for significant differences (p<0.05).
Paracetamol causes hepatocyte apoptosis and necrosis
Electron microscopy confirmed the presence of many cells with classic morphology
of apoptosis (Figure 4.4), namely cell shrinkage, condensation of chromatin into
compact masses, nuclear fragmentation, cytoplasmic vacuolation and membrane
blebbing (Wyllie et al, 1980). Feulgen-stained culture slides similarly showed many
cells with classical apoptotic morphology (Figure 4.5) and allowed quantitation of
apoptotic and viable cells. Rates of apoptosis were significantly greater in
paracetamol-treated than control groups at 24, 48 and 72 hours and also increased
significantly with time (p<0.05; Table 4.2).
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Figure 4.4 Paracetamol induces hepatocyte apoptosis
Figure 4.4 Electron micrograph showing typical apoptotic morphology in a
hepatocyte (WRL 68) incubated with lOmM paracetamol for 48 hours.
Figure 4.5 Paracetamol induces hepatocyte apoptosis
Figure 4.5 Photomicrographs of hepatocytes (WRL 68) showing apoptotic
morphology. The apoptotic cells are shrunken, with condensation of the nucleus
into tight balls of condensed chromatin and formation ofmultiple small apoptotic
bodies.
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Table 4.2 Paracetamol-induced hepatocyte apoptosis
Cells 24 48 72
WRL 68 control 0 + 0.11 0.8 ± 1.18 0.6 ±0.51
paracetamol 1.1 ± 1.71* 5.8 ± 1.13* 14.6 ±4.36*
HepG2 control 1.4 + 0.89 0.4 ± 0.37 0.4 ±0.52
paracetamol 3.7 ± 1.38* 8.9 ±2.55* 11.0 ±3.38*
Table 4.2 Percentage of apoptotic hepatocytes on Feulgen-stained culture slides at 24,
48 and 72 hours. Data are mean ± standard deviation. Control = cells in serum-free
culture media. Paracetamol = 5mM paracetamol for WRL 68, lOmM for HepG2. * =
greater than control (p<0.05).
Annexin V staining showed increased annexin positivity, indicating early apoptosis,
in hepatocytes treated with paracetamol (Figure 4.6). Quantitation of apoptosis was
possible comparing the proportion of annexin positive, PI negative cells (apoptosis)
with cells which were PI positive (necrosis); the necrotic population by definition
included cells undergoing secondary necrosis as the end-stage of apoptosis.
Paracetamol caused striking necrosis, associated with an increase in the rate of
apoptosis (Figure 4.7). Comparison of rates of apoptosis derived from culture slides
and annexin showed a good correlation (r = 0.9 [0.36-0.99; p=0.013]; Table 4.3).
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Figure 4.6 Paracetamol increases annexin V staining
Figure 4.6
Flow histogram showing an increase in annexin V staining in WRL 68 cells
treated with paracetamol (P) versus control (C).
Figure 4.7
Flow histograms comparing WRL 68 cells with paracetamol and without
(control) after 72 hours. The graphs are scattergrams showing the number of
events (cells) that are positive for PI (FL3 log) and for annexin V (FL1 log).
The bottom right quadrant represents apoptosis (annexin positive, PI
negative). The two top boxes represent necrosis (PI positive).
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Table 4.3 Rates of apoptosis and necrosis by flow cytometry
WRL 68 cells 24 48 72
Apoptosis control 2.68 1.93 2.3
paracetamol 6.43 9.3 11.28
Necrosis control 7.9 8.58 12.4
paracetamol 20.07 33.90 53.00
Table 4.3
Flow cytometric analysis of annexin V staining and PI incorporation (total of 3x105
cells per count. Apoptosis = percentage of annexin V positive cells; Necrosis =
percentage of PI positive cells, control = untreated, paracetamol = 5mM paracetamol.
Paracetamol induces hepatocyte injury
Examination of human livers after paracetamol overdose has identified evidence of
injury in non-necrotic hepatocytes characterised by swelling and vacuolation
(Portmann et al, 1975). Hepatocytes exposed to paracetamol in vitro likewise
showed morphological differences from untreated cells. The cells appeared smaller
and showed marked cytoplasmic vacuolation with striking formation of cytoplasmic
processes (Figure 4.8). This morphological change was first noted after six hours
incubation with toxic doses of paracetamol and was then present at all subsequent
time points studied. Notably, the appearance was seen human cells treated with
doses of paracetamol at which cell death did not occur (1.25mM paracetamol for
both cell lines). In pilot experiments, WRL 68 cells were incubated with paracetamol
doses of low toxicity (2.5-5mM) for 6-12 hours and the media was then changed
after which time the morphological changes regressed, supporting the concept that
they represent reversible (sub-lethal) hepatocyte injury.
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Figure 4.8. Paracetamol induces hcpatocyte injury
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Figure 4.8 Photomicrographs of control hepatocytes (WRL 68: a and c)
and hepatocytes incubated with 5mM paracetamol, showing morphological
evidence of injury (b and d). The injured cells are smaller than control cells
with striking formation of fine cytoplasmic processes.
Paracetamol blocks hepatocyte proliferation
The reduction in hepatocyte numbers noted with paracetamol could be explained
simply by an induction of cell death (apoptosis and/or necrosis). However, when
proliferation was measured, paracetamol also caused a dose-dependent reduction in
mitosis at 24, 48 and 72 hours (p<0.05; Table 4.4). Paracetamol also caused a
significant increase in BrdU positivity at 24 hours followed by a reduction to low
levels at 48 and 72 hours (p<0.05; Figure 4.9, Table 4.4). One problem in the
interpretation ofBrdU staining was that the intensity of staining was relatively low in
many cells; any definite nuclear staining was scored as positive.
Immunohistochemistry for Ki-67, an antigen expressed in all phases of the cell cycle
(Key et al, 1993), revealed strong expression in 99 ± 1.5% of cells at all times, with
and without paracetamol (Figure 4.9). These findings suggest that paracetamol
inhibits proliferation and that the reduction in hepatocyte numbers occurs caused by
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paracetamol occurs by a combination of cell death and reduction in proliferative
activity.
Table 4.4
MITOSIS 24 48 72
WRL 68 control 6.1 ±3.96 4.6 ±2.84 5.8 ± 1.33
paracetamol 0.3 ±0.72* 0* 0.2 ±0.49*
HepG2 control 4.6 ±4.08 7.7 ±4.41 5.3 ±3.35
paracetamol 0.6 ±0.62* 0* 0 ± 0.15*
BrdU POSITIVITY
WRL 68 control 32.88 ±3.83 36.22 ±5.5 32.29 ±2.08
paracetamol 68.03 ± 14.25** 18.6 ± 16.95* 1.2 ± 1.8*
HepG2 control 33.3 ±7.77 29.85 ±5.02 34.4 ±3.08
paracetamol 56.15 ± 18.9** 33.08 ±9.85 9.9 ±3.56*
Table 4.4 Hepatocyte mitosisand BrdU -positivity in paracetamol toxicity
MITOSIS = Percentage ofmitotic hepatocytes on Feulgen-stained culture slides at
24, 48 and 72 hours. BrdU = Percentage ofmitotic hepatocytes on Feulgen-stained
culture slides at 24, 48 and 72 hours. Data are mean ± standard deviation. Control =
cells in serum-free culture media. Paracetamol = 5mM paracetamol forWRL 68,
lOmM for HepG2. * = less than control (p<0.05): ** = greater than controls
(p<0.05).
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Figure 4.9 BrdU incorporation and Ki-67 expression
Figure 4.9 Photomicrograph of hepatocytes showing BrdU positivity (left)
and Ki-67 expression (right). Almost all cells showed strong nuclear
positivity for Ki-67. In contrast BrdU staining is of still strong but stain
many fewer cells.
DISCUSSION
Although necrosis is recognised to be the major mechanism of cell loss after
paracetamol overdose, recent evidence has indicated that apoptosis may also occur in
murine liver (Ray et al, 1996) and various non-liver cell lines (Holownia et al, 1997;
Wiger et al, 1999) but the evidence in human liver is not clear (Afford et al, 1995;
personal observations in chapters 2 and 3). This study describes an in vitro model of
paracetamol toxicity, using primary murine hepatocytes or human hepatocyte cell
lines, in which apoptosis occurred in addition to necrosis and proliferation was
inhibited.
Paracetamol toxicity and apoptosis
There are considerable problems in the study of apoptosis in the liver as the process
of apoptosis is rapid and characteristic changes have a short duration (Collucci, 1996;
Patel et al, 1998). The number of apoptotic cell may therefore be low, however,
apparently low rates of apoptosis may nevertheless cause significant loss of liver
mass (Bursch et al, 1990).
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Confirmation of hepatocyte apoptosis in paracetamol toxicity: Early studies in mice
found a strong association between nuclear accumulation of calcium with cell death,
and while DNA ladders were shown differentiation between necrosis and apoptosis
was not made (Ray et al, 1991; Shen et al, 1991; Shen et al, 1992; Ray et al, 1993).
The same group provided the first convincing evidence that apoptosis occurs in
addition to and preceding necrosis (Ray et al, 1996) by showing DNA laddering and
morphological changes of apoptosis although the validity of using morphology to
separate apoptotic and necrotic cells in areas of injury is questionable. Paracetamol
also causes apoptosis in non-hepatic cell lines (Holownia et al, 1997; Wiger et al,
1999). However, species differences in toxicity may exist as DNA fragmentation
does not occur in trout hepatocytes although a non-toxic dose of paracetamol inhibits
protein synthesis (Miller et al, 1993; Miller et al, 1999). This study confirms that
paracetamol-induced apoptosis occurs in murine and human hepatocytes in vitro,
using electron microscopy as the gold standard method to confirm apoptosis based
on well-documented and characteristic morphological appearances (Wyllie et al,
1980; Goldsworthy et al, 1996).
The mechanisms whereby paracetamol causes apoptosis require further study as
conflicting data exists: paracetamol toxicity is associated with a reduction in bcl-XL
expression (an anti-apoptotic protein; Ray et al, 1999) but other groups have shown
that paracetamol does not activate classical caspase pathways and in certain
situations may actually inhibit apoptosis (Lawson et al, 1999).
Quantitation of Hepatocyte Apoptosis: Morphological assessment of apoptosis by
light microscopy was chosen for this study as a reliable and accurate method to
confirm and quantitate apoptosis (Howie et al, 1994; Arends et al, 1994; Galle, 1997;
Sloop et al, 1999). Problems with this method include that it is cumbersome and
time-consuming to count numerous samples, possible errors may occur in
identification of apoptotic cells and the number of cells to be counted is usually high
as the duration of apoptosis is short and hence apoptotic rates may be low. These
problems were addressed by using a running mean to determine the minimum
number of cells that had to be counted to identify a 2% difference in apoptotic rate,
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with sessions at a multiheader microscope with an experienced observer in the early
stages of analysis to clearly denote morphological parameters considered to be
apoptosis.
Detection of annexin V staining was chosen as a second method to study apoptosis.
Annexin V has a high affinity for phosphatidylserine, normally found on the inner
surface of the plasma membrane but externalised as an early event in apoptosis
(Vermes et al, 1995; Lowin et al, 1996). Annexin V has been used to detect
apoptosis in several cell types (Martin et al, 1995), correlating well with other
methods of cell loss (Goldberg et al, 1999) and detectable by either fluorescence
microscopy or by flow cytometry, with no definite benefit gained by either method
(Plasier et al, 1999). Flow cytometry was chosen because the addition of PI allowed
simultaneous evaluation of necrosis (Vermes et al, 1995). Both adherent and
detached cells were studied to improve accuracy as increased floating cells (possibly
early apoptosis) have been noted in paracetamol toxicity in vitro (Dai and
Cederbaum, 1995) and cells may detach early in the apoptotic process (Arends et al,
1993). The main weakness of the annexin method is that it uses unfixed cells and
requires immediate analysis, limiting the number of simultaneous experiments. A
further weakness is that cross-reaction with necrotic cells may occur where
membrane damage has occurred and phosphatidylserine becomes accessible (Plasier
et al, 1999). However, an excellent correlation was noted comparing morphological
scoring and measurement of annexin V staining by flow cytometry in quantitation of
apoptosis (r = 0.9, p=0.013). This suggests that these techniques are both useful and
reliable methods to quantify apoptosis.
Other methods have been developed which can identify characteristic (but not
necessarily specific) features of apoptosis such as DNA fragmentation, caspase
activation, PARP cleavage, detection of TGF-p, formation of neocytokeratin 18
(Leers et al, 1999) or eosin autofluorescence (Goldsworthy et al, 1996; Patel, 1998).
In situ detection of DNA fragmentation (e.g. in situ end-labelling [ISEL] or TDT
uridine triphosphate nick end-labelling [TUNEL]) has been used to detect apoptosis
in many studies and has been proposed to be more sensitive than conventional
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morphological examination (Wheeldon et al, 1995). However, problems exist, most
notably that the method is not specific for apoptosis as necrotic and autolytic cells or
cells undergoing DNA repair may also be positive (Grassl-Kraup et al, 1995; Mangili
et al, 1999; Orita et al, 1999; Kanoh, et al, 1999; Lawson et al, 1999). Marked
variation in staining may also be seen depending on length and type of fixation
(Tateyama et al, 1998; Kiyozuka et al, 1999), tissue sectioning (Sloop et al, 1999)
and proteinase K digestion (Mangili et al, 1999). Furthermore, while apparently
normal cells may be positive, clearly apoptotic cells on morphological grounds may
be negative in the same sample (Cuello-Carrion and Ciocca, 1999; personal
observation). It has been suggested that the main use of this method probably
requires simultaneous simple morphological analysis (Mangili et al, 1999) and
several pilot experiments during this study found TUNEL to be unreliable.
Apoptosis and necrosis in paracetamol toxicity
The extent of necrosis in vivo is not the only factor determining the outcome in
paracetamol toxicity. However, separating apoptosis and necrosis as mechanisms of
cell loss is problematic. From the in vivo studies in human liver described
previously rates of apoptosis are very low (chapter 2), but this does not exclude a
significant reduction in cell number attributable to apoptosis (Bursch et al, 1990). In
this in vitro model, apoptosis occurs at a much higher rate than in vivo (up to 12%),
suggesting that apoptosis contributes significantly to hepatocyte loss during
paracetamol poisoning. The data for primary murine hepatocytes is less clear as
apoptotic rates are lower.
In the flow cytometry studies, control cells had a low level of necrosis (PI positivity:
11.8%) although it seems likely that the PI positivity relates to membrane damage
induced when the cells were detached from the culture dish, with 7-12% of cells
positive in control samples. Administration of paracetamol caused a significant
increase in PI positivity, presumably related to induction of necrosis, with values of
positivity up to 53% after 72 hours.
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Hepatocyte injury: a measure of reversible hepatotoxicity?
Morphological changes induced by high doses of paracetamol have been previously
noted, including plasma membrane damage and blebbing, probably the same as the
elongated cytoplasmic processes noted in this study (George et al, 1981; Koo et al,
1987). Furthermore, it has been suggested that morphological assessment (cellular
granularity, rounding up and detachment) may be a sensitive measurement of
paracetamol toxicity, especially after chronic exposure (Hall et al, 1993). However,
others did not identify significant morphological changes of injury (Hayes and
Pickering, 1985; Hayes et al, 1986). The injury noted in this study clearly appeared
to be a reversible phenomenon as it was seen not only at toxic but also at sub-toxic
doses of paracetamol, that is where cell loss did not occur (e.g. 1.25 and 2.5mM
paracetamol in human hepatocyte cell lines). This injury is presumably the in vitro
equivalent of the hepatocyte injury noted after paracetamol overdose in vivo
(chapters 2 and 3).
Paracetamol inhibits proliferation
Paracetamol toxicity has been shown to cause hepatocyte death by both necrosis and
apoptosis. However, paracetamol also inhibits hepatocyte proliferation, a factor that
may contribute to the toxicity noted. The first report of antiproliferative effects of
paracetamol was noted in lymphocytes (Timson, 1968). In this study paracetamol
caused a significant inhibition of proliferation with a reduction in mitotic rate at all
time-points, even before significant cell loss occurred, and a reduction in BrdU
positivity at 48 and 72 hours. An unexpected finding was the increase in BrdU
positivity at 24 hours, a consistent feature of paracetamol toxicity (see below). One
problem in interpreting this data is the very high intrinsic rate of proliferation in the
human cell lines, and direct comparison with primary hepatocytes, or the liver in
vivo, requires some caution. Nevertheless, if paracetamol inhibits hepatocyte
proliferation this may have a profound effect as enhanced proliferation may protect
against injury (Calabrese et al, 1993; Chanda and Mehendale, 1996).
The mechanism whereby paracetamol inhibits proliferation is not known although it
may block DNA replication and impair DNA repair by inhibiting dNTP synthesis
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(Brunborg et al, 1995). Paracetamol has been shown to inhibit DNA synthesis in
several tissues in the rat but paradoxically not the liver (Lister and McLean, 1997). It
has been suggested that the antiproliferative effect of paracetamol occurs via a
different pathway to that causing cell death (Wiger et al, 1999). In the early stages of
toxicity in this study paracetamol is associated with increased BrdU positivity, the
BrdU positivity then dropping to low levels. This supports the concept suggested by
Wiger et al (1999) that paracetamol induces a cell cycle arrest, with the arrested cells
subsequently dying. After paracetamol poisoning there is a transient reduction in
NF-kB activity with inhibition of G0/G1 cell cycle transition and activation of c-myc
and Raf-1 kinase (Blazka et al, 1995/1996; Boulares et al, 1999). Further studies are
required to elucidate the intracellular pathways by which paracetamol causes these
effects.
The usefulness of in vitro models of paracetamol toxicity
In vitro models of paracetamol toxicity are extremely useful because of similarities
to toxicity in vivo: metabolism of paracetamol is similar (Kane et al, 1980),
hepatotoxicity is dose-dependent (Shear et al, 1995), glutathione depletion occurs
(Flarman and Fischer 1983; Larrauri et al, 1987; Adamson and Flarman, 1993) and
administration of N-acetyl cysteine prevents injury (Massey and Racz, 1981).
Flowever, potential differences have been noted between toxicity in vitro and in vivo.
First, a significant consideration is the pharmacokinetics of paracetamol, where the
concentration in vitro remains the same throughout but in vivo it is rapidly
eliminated from the liver (Fischer et al, 1981). Second, paracetamol is bioactivated
to NAPQI, the toxic metabolite in vivo, but administration of NAPQI directly has a
different effect than paracetamol (Flarman et al, 1991). Third, the association of
glutathione depletion with toxicity is not as strong as in vivo and protection with N-
acetyl cysteine is not as effective in vitro (Larrauri et al, 1987). Fourth, several
authors have proposed that the various toxic effects of paracetamol may be caused by
different pathways (Wiger et al, 1999) where in vivo depletion of glutathione and
rescue by N-acetyl cysteine probably prevents most toxicity. Nevertheless, despite
these problems, in vitro studies have an important role in addressing specific
questions regarding drug toxicity.
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Paracetamol toxicity has been studied in many species, revealing striking inter¬
species differences (Green et al, 1984; Holme and Soderlund, 1986; Smolarek et al,
1990). Murine hepatocytes appear to be most similar to human hepatocytes and may
offer useful models of paracetamol toxicity although conflicting evidence exists as
paracetamol bioactivation in humans may be closer to rat than mouse liver (Seddon
et al, 1987): a summary of studies of paracetamol in human and murine cells is given
in Table 4.6. In general, the data for HepG2 cells show similar toxicity in the 4
studies including this one, the differences possibly relating to the different
methodologies used to quantitate cell death (see below and Table 4.6). Furthermore,
primary human hepatocytes show comparable levels of toxicity to cell lines.
However, for murine hepatocytes the situation is less clear. The data from this study
showed lower levels of toxicity than that previously published, with a wide range of
toxicity. However, many differences exist between the different studies including
strain, dose, culture-method and method used to measure toxicity. The primary
murine cells also showed notably wider variation in toxicity than human cell lines.
This variability is likely to be real, as the primary mouse cells represent a
heterogeneous population of hepatocytes derived from all zones of the hepatic
acinus, which may have differing sensitivity to paracetamol. In contrast the cell lines
are likely to be very homogeneous with regard to drug sensitivity. The balance of
evidence suggests that murine hepatocytes show more variation in toxicity than
human hepatocytes and suggest that where possible human cells should be used to
study paracetamol toxicity.
HepG2 cells have been used in several studies of paracetamol toxicity (Table 4.6)
with similar toxicity found in this study. HepG2 cells are a well defined and widely
used hepatic cell line known to express many functions of differentiated hepatocytes
(Morris et al, 1982; Darlington et al, 1987) and proposed to represent a suitable in
vitro model for assessment of both acute and chronic exposure to toxins (Hall et al,
1993; Nicolini et al, 1995). Furthermore HepG2 cells express CYP450 enzymes
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Table 4.6 a) % Cytotoxicity data presented as a reduction compared with untreated controls,
b) Total protein: total protein content of attached cells compared with untreated controls, c)
MTT assay, d) SRB (sulphorhodamine B): binds to fixed cellular protein and is measured
colorimetrically after solubilisation. e) Morphology: Several authors have used morph¬
ological changes as a measure of cytotoxicity (see discussion, chapter 5). f) NR = neutral
red, a vital dye. Cytotoxicity measured by NR uptake gives results consistently lower than
measured by MTT. g) LDH = lactate dehydrogenase. LDH is released after membrane
damage, h) Trypan blue is excluded by viable cells, i) Mouse strain not identified (paper in
Chinese), j) GPT / GOT are liver enzymes released when cells are injured.
Data in bold are studies of paracetamol toxicity in HepG2 cells.
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albeit at a lower level than is seen in vivo (Gugen-Guillouzo et al, 1988).
Importantly, HepG2 cells express CYPIIE1 and CYP1A2, two enzymes known to be
involved in paracetamol metabolism and activation (Roe et al, 1993). However, they
only contain 50% of the glutathione of primary hepatocytes (Grant et al, 1987).
HepG2 cells also express many cytokine genes (Stonans et al, 1999). While these
cells have been extensively used as models of liver function, the line is derived from
a hepatoma rather than normal liver and may not represent the best model of toxicity
in normal liver.
WRL-68 cells are an embryonal cell line, derived from non-neoplastic liver, which
express many functions of normal liver and have been used previously in
toxicological studies (Gutierrez-Ruiz et al, 1994; Bucio et al, 1995). These cells
were chosen for study because they were derived from normal liver and may
represent a better model to study toxicity than HepG2 cells. It has been reported that
WRL 68 cells do not express CYP450 enzymes (Olivares et al, 1997). If that were
the case then it would be likely that these cells would be relatively resistant to
paracetamol toxicity. However, the findings of this study suggest that the two cell
lines show very similar paracetamol toxicity, both qualitatively and quantitatively,
with similar threshold and dose-dependent toxicity with inhibition of proliferation.
Two possible explanations are that WRL 68 cells do in fact express CYP450
enzymes or that paracetamol toxicity in vitro is not dependent on CYP450 activity.
The latter possibility is intriguing given suggestions that some manifestations of
paracetamol toxicity occur independently of CYP450 enzymes and may explain
some of the differences between toxicity in vivo and in vitro.
Conclusions
This study describes a model of paracetamol toxicity that has been well characterised
in terms of hepatocyte loss, apoptosis and proliferation. Comparison of primary
murine hepatocytes with human hepatocyte cell lines and a review of the literature
suggest that human cells offer a better and more reproducible model of paracetamol
toxicity than murine hepatocytes.
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CHAPTER FIVE
THE ROLE OF TNF-a IN PARACETAMOL TOXICITY
SUMMARY
The role of TNF-a in paracetamol overdose is controversial. The balance of
evidence from in vivo studies is that TNF-a is produced during paracetamol toxicity
but that inhibition of it does not affect the outcome. Conversely, in vitro studies show
that TNF-a synergises with paracetamol when added simultaneously to augment
hepatocyte death by apoptosis but when TNF-a is administered before paracetamol,
it protects against toxicity. TNF-a has diverse effects on paracetamol toxicity. Its
role is not clear but it may represent a signal for hepatic regeneration.
INTRODUCTION
TNF-a and the Liver
Tumour necrosis factor-alpha (TNF-a) is a member of a superfamily of pleiotropic
cytokines that is a paracrine and endocrine mediator of inflammation and immunity
and also regulates growth and differentiation in many tissue types. Monocytes and
macrophages are the major producers of TNF-a, but most cell types in the liver
including hepatocytes, biliary epithelial cells and sinusoidal endothelial cells can
produce TNF-a (Nagano et al, 1992; Gonzalez-Amaro et al, 1994; Hoffmann et al,
1994). TNF-a interacts with two receptors, TNFR1 (p55) and TNFR2 (p75), which
may be functionally associated. TNFR1 is expressed ubiquitously and is important
in cytotoxic TNF signalling (Tartaglia et al, 1991). TNFR2 is involved in signalling
via membrane-bound TNF-a and may cooperate with TNFR1 in signalling effects of
soluble TNF-a (Tartaglia et al, 1993a; Tartaglia et al, 1993b; Grell et al, 1996). TNF
receptors lack catalytic kinase domains and rely on associated proteins to function as
signal transducers to determine which intracellular signalling pathway is activated.
Death signalling occurs via the death domain, a conserved motif found in a number
of death-signalling proteins (reviewed in Faubion and Gores, 1999). One such
receptor, FADD, interacts with TNFR1 via TRADD and also links directly with the
apoptotic cascade via caspase 8/FLICE/MACH (Boldin, et al, 1996; Hsu et al, 1996;
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Pan et al, 1997; Bradham, 1998). However, TNF receptors can also activate survival
factors such as NF-kB and jun kinase (JNK) and signal proliferation rather than
death (Rothe et al, 1995; Reinhard et al, 1997).
TNF-a is implicated in many important pathological and physiological processes in
the liver and can contribute to liver injury and regeneration. TNF-a mediates
hepatocyte death, signalling both necrosis and apoptosis in toxic liver injury (Laster
et al, 1988; Bradham et al, 1998). However, triggering cell death requires prior
inhibition ofmRNA or protein synthesis (Larrick and Wright, 1990; Hill et al, 1995).
TNF-a is also an important element in hepatic regeneration, being up-regulated after
partial hepatectomy (PH) and inducing a variety of other genes involved in
proliferation and cellular survival (Bruccoleri et al, 1997). Furthermore, regeneration
is defective in the absence ofTNF-a or TNF R1 or following inhibition ofTNF-a by
neutralising antibodies (Akerman et al, 1992). In regeneration after PH, TNF-a
signals via TNFR1 (Yamada et al, 1998), activating downstream proteins including
NF-kB in a well characterised pathway also involving IL-6 (Fitzgerald et al, 1995;
Cressman et al, 1996; Yamada et al, 1998). NF-kB activation probably represents a
critical element in determining whether survival or proliferation occurs rather than
apoptosis (Bellas et al, 1997).
TNF-a and other Cytokines in Paracetamol Toxicity
TNF-a is implicated in several experimental and important human liver diseases
including viral hepatitis (Daniels et al, 1990; Bradham et al, 1998), fulminant liver
failure (Muto et al, 1988), endotoxin administration (Beutler et al, 1985) and liver
injury induced by several drugs and toxins including alcohol (reviewed in McLain et
al, 1999), galactosamine (Gantner et al, 1995; Pfeffer et al, 1993; Stachlewitz et al,
1999), carbon tetrachloride (Czaja et al, 1995; Bruccoleri et al, 1997) and after
paracetamol overdose (reviewed in Schumann and Tiegs, 1999). Paracetamol-
induced liver injury occurs as a direct consequence of formation of a toxic metabolite
(NAPQI) that injures cells as an essential event in hepatotoxicity (Nelson, 1995;
Zaher et al, 1998). However, there is good evidence that liver injury may be
modulated by factors such as activation of Kupffer cells (Laskin et al, 1995; Goldin
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et al, 1996) associated with production of reactive oxygen and nitrogen intermediates
(Michael et al, 1999), cytokines including TNF-a and IL-la (Blazka et al, 1995) and
chemokines including CINC/gro and MIP-2 (Takada et al, 1995; Horbach et al,
1997; Hogaboam et al, 1999). The role of TNF-a in paracetamol toxicity is
controversial (DeVictor et al, 1982; Blazka et al, 1995; Blazka et al, 1996; Boess et
al, 1998).
IL-la is a cytokine that mediates the acute phase response (Dinarello, 1989; Blazka
et al, 1995) and is involved in liver growth and regeneration (Ramadori and
Armbrust, 1998). IL-la is produced after partial hepatectomy and may stimulate
proliferation in vivo, although it has an anti-proliferative effect in vitro (Koga and
Ogasawara, 1991; Higashitsuji et al, 1995; Nakamura et al, 1988). The major source
of IL-la in the liver is Kupffer cells (Higashitsuji et al, 1995) although endothelial
cells may also produce it (Feder et al, 1993). IL-la has been shown to protect
against paracetamol toxicity in rats (Renic et al, 1997).
MIP-2 is a CXC chemokine that is chemotactic for neutrophils. Recent evidence
suggests that TNF-a and IL-6 induce production of the CXC chemokines ENA-78
and MIP-2 (Colletti et al, 1996; Colletti et al, 1998). These chemokines can
contribute to the inflammatory process in acute liver injury (Lentsch et al, 1998;
Sprenger et al, 1997) but may also play a role in liver regeneration (Hogaboam et al,
1999). Administration of CXC chemokines MIP-2, IL-9 and ENA-78 protected
against liver injury after paracetamol overdose in mice (Hogaboam et al, 1999). IL-
la and MIP-2 represent good candidates, along with TNF-a, to be involved in
paracetamol toxicity.
The aims of this study were to investigate the role ofTNF-a in paracetamol toxicity:
1. using an in vitro model using human hepatocyte cell lines to investigate the
role ofTNF-a and other cytokines in hepatocyte death and regeneration.
2. using an in vivo murine model to investigate the production of TNF-a and
effects of inhibition ofTNF-a.
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MATERIALS AND METHODS
Cell lines and experimental model
The human hepatic cell lines (HepG2 and WRL 68) were used in the same in vitro
model of paracetamol toxicity as described in detail in chapter four. Briefly, cells
were seeded in fibronectin-coated culture dishes overnight in serum-free media. The
media was then replaced with fresh media or media containing paracetamol. Unless
otherwise stated, WRL 68 cells and HepG2 cells were incubated with 5mM or lOmM
paracetamol respectively for 24, 48 and 72 hours. These doses were selected as they
were toxic but cell numbers remained sufficiently high to facilitate study of apoptosis
and proliferation. Recombinant TNF-a (R&D Systems), IL-la (R&D Systems) or
GRO-(3 (Peprotech) was dissolved directly in culture media, with or without
paracetamol, as detailed below. For pretreatment experiments cells were incubated
with media containing TNF-a for 24 hours after which the media was replaced. Cell
number was assessed by MTT assay. Rates of apoptosis, mitosis and BrdU
incorporation scored on culture slides. Flow cytometry after staining with annexin V
and PI was also carried out. All methods are given in detail in chapter 4.
Murine Model of Paracetamol Overdose
Six week old female CBA/J mice were fasted with free access to water for eight
hours prior to intraperitoneal (ip) injection of paracetamol (300mg/kg) dissolved in
normal saline. Controls were sham-treated by injection of saline only. Mice were
killed by cervical dislocation at various time-points up to 24 hours and samples of
serum and liver were taken as detailed below. N-acetyl cysteine (300mg/kg by ip
injection, control injected with saline: Sigma, St Louis, Missouri, USA) was used to
prevent liver injury. Rabbit anti-murine-TNF-a antibodies were produced by
multiple site immunisation of New Zealand white rabbits with recombinant murine
TNF-a (R&D Systems) followed by purification of IgG using a protein A column.
0.5ml of immune serum was injected ip 1 hour prior to administration of
paracetamol, with non-immune serum used as a control; this immune serum has been
previously shown to inhibit the effects of TNF-a in vivo (Colletti et al, 1996;
Remick et al, 1990; Eskandari et al, 1992; Hewett et al, 1993). Other mice were
injected with IL-10 (5|ig), soluble TNF receptor-chimera (200|Lig), dexamethasone
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(4|dg) or saline as a control 1 hour before administration of paracetamol. These
treatments have also been shown to inhibit effects of TNF-a in vivo (Walley et al,
1996; Lukacs et al, 1995; Standiford et al, 1995; Chensue et al, 1991).
TNF-a Expression
Samples of liver were weighed and homogenised in 1ml of PBS containing Nonidit
P40 (0.5%) and the supernatant recovered following centrifugation. Measurement of
TNF-a from serum and liver homogenate were made using ELISA specific for
murine TNF-a as previously described (Walley et al, 1996). RNA was extracted
from liver snap-frozen in liquid nitrogen and homogenised in 1ml of 4.2M guanidine
isothiocyanate, 25mM Tris (pH 8.0), 0.5% sarkosyl and 0.1M 2-mercaptoethanol.
An equal volume of lOOmM Tris (pH8.0), lOmM EDTA and 1% SDS was added and
RNA was prepared following extraction in phenol-chloroform and chloroform-
isoamyl alcohol. The isolated RNA was quantitated by spectrophotometric analysis
at 260nm. 5pg ofRNA was reverse transcribed into cDNA using oligo (dT) primers
and AMV reverse transcriptase as previously described (Lukacs et al, 1995). The
cDNA was amplified using specific primers for TNF-a and cyclophylin as a control
(see table 5.1). The PCR amplification reaction was incubated at 94°C for 5 minutes
followed by 35 cycles at 93°C for 45 seconds, 52°C for 45 seconds and 72°C for 90
seconds. Amplification products were visualised under UV light following







Table 5.1 Primer sequences for TNF-a and cyclophylin
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Assessment of Hepatic Injury
Hepatic injury was assessed by two methods. Serum aspartate aminotransferase
(AST) activity was assessed using a standard colorimetric assay (Sigma, St Louis,
Missouri, USA) and a blinded histological assessment was made scoring hepatic
necrosis in a semi-quantitative manner (+ <30% total parenchymal necrosis, ++ 30-
60% necrosis, +++ >60% necrosis).
Statistical analysis
Differences were assessed using a one-way analysis of variance, with a value of
p<0.05 chosen as significant.
RESULTS
Paracetamol hepatotoxicity in vitro is augmented by TNF-a
The results were similar for both cell lines, hence data are presented for WRL-68
cells only for simplicity. When recombinant TNF-a was added over a wide range of
doses (0.6-100ng/ml) paracetamol toxicity in the human hepatocyte cell lines was
augmented at 24, 48 and 72 hours (p<0.05, Figure 5.1). The effect was dose-
dependent, with higher doses of TNF-a causing greater cell loss than lower doses.
The threshold for the TNF-a effect was at 0.6ng/ml. The same effects were noted
when TNF-a was added 12 hours after administration of paracetamol (data not
shown). Rates of apoptosis by morphological counting and also by annexin V
staining were higher with the combination of TNF-a and paracetamol than with
paracetamol alone (p<0.05; Table 5.2). The rate of necrosis, assessed by propidium
iodide uptake, was also higher in cells treated with TNF-a and paracetamol than with
paracetamol alone (Table 5.3).
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Figure 5.1
Effect on cell number of addition of TNF-a with paracetamol up to 72 hours. Data
are expressed as a percentage of the data for paracetamol only. Par = 5mM
paracetamol; t0.3 = 0.3ng/ml TNF-a; t0.6 = 0.6ng/ml TNF-a; 11.25 = 1.25ng/ml
TNF-a; tlO = lOng/ml TNF-a; tlOO = lOOng/nl TNF-a. * = significant reduction in
cell number compared with paracetamol only. A = significant reduction in cell




Control 0 ± 0.11 0.76 ±1.18 0.56 ± 0.51
TNF-a 0.12 ±0.27 0.62± 0.58 0.36 ±0.33
Paracetamol 1.1 ± 1.71* 5.76 ± 1.13* 14.62 ±4.36*
TNF-a / Paracetamol 4.34 ±3.88** 11.36 ±5.38** 18.6 ±5.53**
Pretreatment 0 3.88 ±1.57# 11.13 ±5.1*
NECROSIS
Control 7.90 8.58 12.40
TNF-a 4.30 7.57 12.37
Paracetamol 20.07 33.9 53.00
TNF-a / Paracetamol 19.44 39.22 41.18
Table 5.2 Rates of apoptosis and necrosis in paracetamol toxicity
Control = media only; TNF-a = 0.6ng/ml; paracetamol = 5mM; TNF-a/paracetamol
= both added simultaneously; pretreatment = 24 hour incubation with 0.6ng/ml TNF-
a then 5mM paracetamol only. Results for apoptosis are three replicate counts ±
standard deviation. * = greater than control or TNF-a alone (p<0.05). ** greater than
paracetamol, TNF-a alone and control (p<0.05). # = greater than control or TNF-a
alone but less than paracetamol-treated (p<0.05). Results for necrosis are flow
cytometric count of 30000 cells and represent the proportion ofPI positive cells.
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TNF-a reduces the threshold for paracetamol toxicity
Addition of a dose ofTNF-a known to augment toxicity (0.6ng/ml) also lowered the
threshold for hepatotoxicity: 1.25mM paracetamol toxicity was cytotoxic at 72 hours
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Figure 5.2
Administration ofTNF-a augments paracetamol toxicity at low doses: the
threshold for toxicity is reduced to 1.25mM when TNF-a is also present.
Con = control; tnf = TNF-a (0.6ng/nl; 1.25 / 2.5 = 1.25 or 2.5mM
paracetamol; tnf 1.25/2.5 = TNF-a plus 1.25 or 2.5mM paracetamol.
A = significant reduction in cell number compared with control; * =
significant reduction compared with paracetamol alone.
TNF-a has no discernible effect on cells when paracetamol is absent
When no paracetamol was present, addition of TNF-a over a range of doses (0.3-
lOng/ml) had no effect on cell number or apoptosis at 24, 48 and 72 hours.
Pretreatment with TNF-a protects against paracetamol toxicity
Pretreatment of hepatocytes with TNF-a (0.6ng/ml) for 24 hours prior to addition of
paracetamol resulted in protection against subsequent paracetamol hepatotoxicity
after 24, 48 and 72 hours exposure to paracetamol (p<0.05; Figure 5.3). At 48 hours,
the pretreated group showed no reduction in cell number compared with controls; at
72 hours the cell number was reduced but remained significantly higher than with
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paracetamol alone. The pretreated group showed a rate of apoptosis higher than
controls but lower than paracetamol-treated cells at 48 hours and the same rate of
apoptosis as paracetamol only at 72 hours (p<0.05; Table 5.2).
Figure 5.3
0.12
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Figure 5.3
Pretreatment with TNF-a (0.6ng/ml) for 24 hours prior to exposure to
paracetamol protects against toxicity, con = media only; par = 5mM
paracetamol; tnfpar = TNF-a (0.6ng/ml) and paracetamol administered
simultaneously; pre = pretreatment with TNF-a then exposure to
paracetamol only. * = significant reduction in cell number compared with
untreated controls. # significantly greater cell number than paracetamol
only; A significantly lower cell number than paracetamol only (p<0.05).
#
TNF-a alters hepatocyte proliferation
Paracetamol alone caused a significant reduction in mitosis at 24, 48 and 72 hours
and an increase and subsequent reduction in BrdU labelling index as previously
described in chapter 4. Addition of TNF-a with paracetamol resulted in a similar
reduction in mitosis but the BrdU labelling index was the same as untreated controls
i.e. it remained unchanged for the duration of the experiments with no increase and
subsequent decrease as seen with paracetamol alone (Table 5.3).
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Table 5.3
MITOSIS 24 48 72
Control 5.7613.7 4.5 ±2.08 6.82 ±2.9
TNF-a 3.1 ±1.439 3.4611.71 4.511.59
Paracetamol 0.32 ±0.72* 0* 0.22 ±0.49*
TNF-a / Paracetamol 0.34 ±0.76* 1.0611.45* 0*
Pretreatment 1.81 ±1.82* 2.1811.85** 0.1410.31*
BrdU POSITIVITY
Control 35.42 ±7.73 34.3616.93 29.32 ±4.80
TNF-a 28.7212.59 36.814.07 29.3614.84
Paracetamol 72.48113.57* 13.22115.5** 0.3 ±0.47**
TNF-a / Paracetamol 28.88 19.78 42.02126.08 31.13110.7
Pretreatment 44.4 ±8.4* 15.5 ±6.2** 11.38 16.23**
Table 5.3 Rates ofmitosis and BrdU positivity
Control = media only; TNF-a = 0.6ng/ml; paracetamol = 5mM; TNF-a/paracetamol = both
added simultaneously; pretreatment = 24 hour incubation with 0.6ng/ml TNF-a then 5mM
paracetamol only. Results are three replicate counts ± standard deviation.
MITOSIS: * = greater than control or TNF-a alone (p<0.05). ** less than control
and TNF-a alone but greater than paracetamol treated (p<0.05).
BrdU POSITIVITY: * = greater than control or TNF-a alone (p<0.05). ** less than
control and TNF-a alone (p<0.05).
Other cytokines and chemokines have no effect on paracetamol toxicity
Addition of IL-la or GRO-(3, with and without paracetamol, had no effect on cell
number or apoptosis (Figure 5.4 and 5.5).
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Figure 5.4
IL-la and paracetamol toxicity, con = control; 0.1 = Olng/ml recombinant IL-la
added; 10 = lOng/ml IL-la added; par = 5mM paracetamol. IL-la alone shows
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Figure 5.5
GRO-J3 and paracetamol toxicity, con = control; 1.25 = 1.25ng/ml recombinant
gro-p; 50 = 50ng/ml gro-(3, par = 5mM paracetamol. No differences between gro-
a only and control or gro-p plus paracetamol and paracetamol alone.
Paracetamol Toxicity In Vivo - the murine model
Administration of paracetamol resulted in liver injury after 3 hours with an increase
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the occurrence of zone 3 hepatic necrosis in all cases compared with controls, which
showed no necrosis at any time. The liver injury was completely prevented by
administration of N-acetyl cysteine (not shown), confirming that this model is
analogous to human paracetamol overdose.
TNF-a Expression after Paracetamol Overdose
Serum TNF-a was increased 3 hours after paracetamol injection (20.4±0.6pg/ml,
p<0.05: Table 5.4) and remained elevated for 24 hours compared with controls
(2.4±2.4pg/ml). Hepatic TNF-a was similar at all time-points after paracetamol
injection and did not increase compared with controls (Table 5.4). Hepatic TNF-a
RNA expression likewise showed no increase compared with controls (Figure 5.6).
Table 5.4
Serum TNF-a1 Hepatic TNF-a2
1 hour 0 1.310.5
3 hours 20 ± 7.1* 2.4510.85
6 hours 2016.8* 0.7510.05
12 hours 12.2515.5 0.810.1
24 hours 20.512* 0.8510.15
control 212 0.8 1 0.05
Table 5.4 Serum amd hepatic TNF-a after paracetamol overdose. The data
represent serum or hepatic TNF-a measured by ELISA at the given time-points
after injection of paracetamol. 1 serum TNF- in pg ml.2 hepatic TNF-a in ng/g liver
weight. * = significant increase compared with sham-treated controls (p<0.05): n=5
in each group except controls where n=7.
Inhibition of TNF-a after Paracetamol Overdose
The biological effects of TNF-a were inhibited by several different regimes
including anti-TNF-a antibodies, soluble TNF receptors, IL-10 and dexamethasone.
There were no differences in mortality, serum AST or extent of hepatic necrosis
(Table 5.5) by any of the TNF-a inhibition regimes compared with controls given
paracetamol only.
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Figure 5.6
CYCLOPHYLIN
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Figure 5.6 Hepatic TNF-a mRNA expression following paracetamol poisoning.
Total mRNA was extracted from liver tissue and cDNA synthesised to determine
mRNA expression. Cyclophylin was used as a control. The times given are hours
after paracetamol injection. C= saline-injected controls. N= negative PCR control.
No differences were noted in TNF mRNA expression.
Table 5.5
Treatment No of Mortality Serum AST Hepatic Necrosis
cases + ++ +++
control 16 0 6611 ±858 4 8 4
anti-TNF antibody 8 1 9684 ±762 0 2 5*
soluble TNFR 12 1 5770 ±772 1 3 6*
IL-10 8 1 6137 ±884 0 4 4
dexamethasone 10 0 5532 ±772 1 5 3*
Table 5.5 Mortality, serum AST and hepatic necrosis after paracetamol overdose
Control = paracetamol only; other treatments as detailed in methods. Serum AST is in
IU/1, ±SEM. * The mice that died all showed >60% hepatic necrosis. No statistically
significant differences were noted.
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DISCUSSION
In an in vitro study of paracetamol toxicity using human hepatocyte cell lines, TNF-
a was shown to have paradoxical effects. When administered with paracetamol,
TNF-a augmented paracetamol toxicity by increasing apoptosis and necrosis, and
also altered hepatocyte proliferation. However, when administered before
paracetamol, TNF-a protected against subsequent toxicity. Using an in vivo murine
model of paracetamol overdose, TNF-a was elevated in serum but not liver and
inhibition of TNF-a did not alter liver injury or survival. These experiments offer
new insights into the role ofTNF-a in liver injury after paracetamol overdose.
Paracetamol Toxicity In Vitro: (1) TNF-a augments hepatocyte death
Most studies ofTNF-a in liver injury caused by various toxins have supported a role
for TNF-a in causing hepatocyte death by apoptosis and necrosis (reviewed in
Bradham et al, 1998; Schumann and Tiegs, 1999). Consequently TNF-a has been
implicated in toxic liver injury induced by ethanol, carbon tetrachloride, endotoxin,
galactosamine and concanavalin A, where TNF-a contributes directly to liver injury
and inhibition of TNF-a reduces injury (Table 5.5) although the situation in
paracetamol toxicity is less clear. In this study, TNF-a has a synergistic effect when
administered with paracetamol, augmenting toxicity by increasing hepatocyte loss by
apoptosis. TNF-a also lowers the threshold for paracetamol toxicity, a TNF-induced
effect also noted with other toxins (Pfeffer et al, 1993; Leist et al, 1995). TNF-a can
induce cell death by both necrosis and apoptosis in a variety of settings but TNF-a
only induces hepatocyte apoptosis after protein or mRNA synthesis has been
inhibited (Hill et al, 1992; Leist et al, 1995). However, a complete block of protein
synthesis may have an opposing effect, as production of TNF-a would be inhibited
and apoptosis may be prevented (Leist et al, 1995; Leist et al, 1997). The synergism
of TNF-a and paracetamol may be explained by the ability of paracetamol to inhibit
protein synthesis (Miller et al, 1999) thereby sensitising hepatocytes to the toxic
effects of TNF-a. In this study, TNF-a had no effect on the rate of necrosis (PI
uptake) compared with samples with no TNF-a present.
78
Chapter 5: TNF-a and paracetamol toxicity
A unifying pathway has been proposed whereby different toxins may cause liver
damage both directly and synergistically with endogenous TNF-a (Figure 5.7). The
key element of this hypothesis is that several different pathways may contribute to
hepatocyte death and that exogenous toxins may interact with endogenous factors to
augment injury. A hepatotoxin may cause direct injury to hepatocytes (1) or
sensitise hepatocyte to injury by another agent or cytokine (2). Conversely a toxin
that causes hepatic necrosis may induce a brisk inflammatory reaction, with
consequent production of TNF-a by macrophages (3). Finally, a toxin may
substantially increase translocation of endotoxin from the intestine into the portal
blood (4), a strong stimulus to TNF-a production by Kupffer cells (Chensue et al,
1991). However, many of the elements in this model remain unproven as precise
mechanisms of sensitisation and the contribution of direct toxicity versus TNF-a-
dependent toxicity is not known. The role of endotoxin in hepatotoxicity is
discussed further in chapter 6.
Figure 5.7
Figure 5.7 Putative pathways of TNF-a involvement in xenobiotic-induced
hepatocyte death. (Adapted from Leist et al, 1997). LPS = lipopolysaccharide
(endotoxin).
Paracetamol Toxicity In Vitro: (2) TNF-a protects against cell death
Using the in vitro model of paracetamol toxicity, pretreatment with TNF-a had a
striking protective effect, with a reduction in cell loss and hepatocyte apoptosis up to
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72 hours. However, in the absence of paracetamol, TNF-a treatment had no
discernible effect. Pretreatment with TNF-a can protect against subsequent TNF-
induced injury and protect against fas-induced caspase activation (Jacob et al, 1990;
Hill et al, 1995; Takehara et al, 1998) but this first description of protection against
the effects of a toxic drug by TNF-a. Two alternative explanations for the protective
effect of TNF-a exist. First, TNF-a may alter CYP450 expression, reducing
paracetamol bioactivation and hence decreasing hepatotoxicity. Second, TNF-a may
signal cell survival and proliferation after injury, promoting efficient regeneration.
Conflicting data exist regarding alterations in CYP-450 activity induced by TNF-a
as a mechanism ofmodulation of hepatotoxicity after paracetamol overdose. TNF-a
may reduce CYP450 activity in mice (Ghezzi et al, 1986) although TNF-a /
lymphotoxin-a knockout mice show no difference in CYP2E1 and CYP1A2 activity
and no difference in paracetamol bioactivation compared with wild type mice (Boess
et al, 1998). Conversely, increased expression of CYP2E1 may sensitise hepatocytes
to the cytotoxic effects of TNF-a (Bissell et al, 2001). Several groups have studied
the interaction of Kupffer cells and hepatocytes in paracetamol metabolism and
toxicity. One problem is that while TNF-a is a major effector molecule, the precise
role of TNF-a in these studies is not entirely clear and other factors may also be
involved. Two groups have shown a reduction in CYP450-dependent paracetamol
metabolism using coculture of Kupffer cells and hepatocytes (Raiford and Thigpen,
1994; Milosevic et al 1999). However, two other groups have clearly demonstrated
that the Kupffer cell effect occurs with no alteration in paracetamol metabolism
(Laskin et al, 1995; Michael et al, 1999). The balance of evidence suggests that
alterations in CYP450 activity and paracetamol bioactivation is unlikely to be an
explanation for the effects of TNF-a in paracetamol toxicity but further studies
would be helpful in confirming this.
Alternatively, the mechanism whereby TNF-a induces protection may relate to the
activation of intracellular survival or proliferation pathways rather than death
pathways. TNF-a can induce both NF-kB (Rothe et al, 1995) and jun kinase (JNK;
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Reinhard et al, 1997), both pathways favouring regeneration over apoptosis (Yamada
et al, 1997; Taub, 1998) and contributing to regeneration after hepatectomy or toxic
injury (Diehl et al, 1994; Taub 1996; Bruccoleri et al, 1997). NF-kB is of particular
interest as inhibition of it converts a TNF-a-induced proliferative response to
apoptosis (Xu et al, 1998). NF-kB functions as an inhibitor of apoptosis (Bellas et
al, 1997), suppressing caspase-8 activation (Wang et al, 1998). NF-kB is normally
retained in the cytoplasm bound to its inhibitor IkB and is activated by a kinase
cascade (Israel, 1997); the activating kinase binds TRAF2 and activates IkB kinase-a
which phosphorylates IkB resulting in its ubiquitination and rapid degradation. NF-
kB then translocates to the nucleus, transcriptionally activating genes which protect
against apoptosis (including TRAF1, TRAF2, c-IAPl, c-IAP2, IEX-1L; Wang et al,
1998; Wu et al, 1998). This transcriptional activation may explain why inhibitors of
RNA or protein synthesis or dominant negative IkB (loss ofNF-kB inducibility [van
Antwerp et al, 1996]) augment killing by inhibiting the NF-kB survival signal. This
may be one specific pathway interrupted by the inhibition of RNA or protein
synthesis in TNF-a-induced cell death. In paracetamol toxicity in mice, a reduction
in NK-kB and NF-IL6 DNA binding was noted associated with an inhibition of
hepatocyte proliferation (Blazka et al, 1996; Boulares et al, 1999). Strategies to
manipulate NF-kB may be a valuable approach to therapy as augmentation ofNF-kB
may allow survival of cells that would otherwise die.
The protective effect of TNF-a in paracetamol toxicity may be similar to the well-
established effects of TNF-a in the regeneration cascade, whereby TNF-a induces
transcription of immediate early genes but is not mitogenic itself, allowing
proliferation signalled by various growth factors (reviewed in Michalopoulos, 1990;
Fausto and Webber, 1994; Fausto et al, 1995; Michalopoulos and DeFrances, 1997).
Moreover, a high proliferative capacity may be an important factor in determining
survival after liver injury and may correlate with outcome (Calabrese et al, 1993;
Mangipudy et al, 1995; Chanda and Mehendale, 1996; Horn et al, 1999). In this
model, TNF-a had no effect on mitotic rate or BrdU positivity when added to
hepatocytes alone but it altered hepatocyte proliferation when administered with
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paracetamol. BrdU positivity remained similar to untreated controls, rather than
increasing and subsequently decreasing as noted with paracetamol alone. The
mitotic rate remained very low throughout, as with paracetamol alone. Several
potential problems in interpretation include the difficulty in scoring BrdU positivity
when staining may be weak (discussed in chapter 4) and the high innate proliferative
capacity of the cell lines (approximately 98% of cells positive for Ki-67) compared
with normal liver, where Ki-67 positivity is less than 1%. The significance of the
difference in proliferation with and without TNF-a is not clear, but a tenable
suggestion is of a cell cycle arrest in or after S phase with the cycle-arrested cells
subsequently dying. The mechanism whereby co-administration of TNF-a and
paracetamol abolishes the increase and subsequent decrease of BrdU positivity seen
with paracetamol alone is not known. TNF-a may act as a signal to regenerate but
requiring other growth factors and cytokines to affect a successful regenerative
response. This may also explain some of the apparently contradictory data regarding
TNF-a as although it has a central role in liver regeneration, for example,
downstream factors such as IL-6 can replace TNF-a in the regeneration cascade after
partial hepatectomy (Cressman et al, 1996).
Paracetamol Toxicity In Vitro: (3) Other cytokines and chemokines
IL-la and GRO-p had no detectable effect on hepatocyte death or proliferation in the
in vitro model of paracetamol toxicity, despite evidence from in vivo studies that
both may act as protective factors (Renic et al, 1997; Hogaboam et al, 1999). As
with TNF-a, conflicting evidence exists regarding the role of IL-la in paracetamol
toxicity, where in some studies IL-la protected (Renic et al, 1997) and in other
studies IL-1 receptor antagonist protected against hepatic injury after POD (Blazka et
al, 1995; Blazka et al, 1996). IL-1 (3 may protect against TNF-a toxicity after
sensitisation with galactosamine, associated with production of nitric oxide
(Bohlinger et al, 1995). Conflicting evidence exists regarding the role of nitric oxide
in paracetamol toxicity, where production of nitric oxide has been shown to either
mediate or protect against hepatocyte injury (Kuo et al, 1997; Gardner et al, 1998).
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MIP-2, the mouse analogue of human GRO-J3, is an important regulator of neutrophil
infiltration and abscess formation (Ebe et al, 1999). Evidence has also emerged that
the CXC chemokines including MIP-2 may also be important regulators of liver
regeneration (Colletti et al, 1996; Colletti et al, 1998; Hogaboam et al, 1999). The
striking protective effect of protection against paracetamol toxicity by these agents
(Hogaboam et al, 1999) was not replicated using GRO-J3 in vitro.
Paracetamol toxicity in vivo: (1) the murine model
Administration of an overdose of paracetamol by intraperitoneal injection has been
used widely in studies of paracetamol toxicity in mice, as the nature and extent of
injury, high mortality and prevention of injury by N-acetyl cysteine is analogous to
paracetamol overdose in humans. Mice, hamsters and human are relatively sensitive
to paracetamol toxicity, whereas rats are relatively resistant to toxicity (Davis et al,
1974; Coldwell et al, 1976). The variation in species sensitivity to paracetamol
relates mainly to the kinetics of glutathione depletion rather than a fundamental
difference in toxicity (Davis et al, 1974). One problem with the murine model of
hepatotoxicity is the much shorter time-course in mice than in humans (24 hours
compared with 72-96 hours in humans), which gives a narrow window of
opportunity for therapeutic intervention. While animal models are extremely useful
to study drug toxicity, problems will always exist in accurately recapitulating human
disease. For example, virtually all human patients will have received N-
acetylcysteine in therapy, which has been reported to reduce production ofTNF-a by
Kupffer cells (Fox et al, 1997).
Paracetamol toxicity in vivo: (2) the role of TNF-a
TNF-a has been shown to have an important role in the pathogenesis of liver injury
caused by several toxins including carbon tetrachloride, galactosamine and ethanol
(Chamilutrat et al, 1995; Edwards et al, 1993; Mizuhara et al, 1994; Feist et al, 1995;
Iimuro et al, 1997; Table 5.6). The role of TNF-a in paracetamol overdose remains
controversial with conflicting data published in several studies. Elevation of TNF-a
in has been shown in both liver and serum after paracetamol overdose (Blazka et al,
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1995; Blazka et al, 1996). However, other groups have reported no elevation in
TNF-a in serum (DeVictor et al, 1992) or serum and liver (Boess et al, 1998) after
paracetamol poisoning in wild-type mice. The results of this study fall between these
other studies, demonstrating elevation of TNF-a in serum but not liver in
paracetamol toxicity. The reason for the disparate results is not clear but may relate
at least in part to methodological differences in the different studies.
Table 5.6
Toxic agent Inhibition of TNF Reference
a-amanitin Anti-TNF, TNFR-KO Feist et al, 1997
actinomycin D Anti-TNF, TNFR-KO Feist et al, 1997
carbon tetrachloride sTNFR Czaja et al, 1995
concanavalin-A Anti-TNF Gantner et al, 1995
Endotoxin Anti-TNF Beutler et al, 1985
Ethanol Anti-TNF Iimuro et al, 1997
galactosamine TNFR-KO Feist et al, 1995
TCDD1 Anti-TNF Fan et al, 1997
Table 5.6 Agents for which inhibition of TNF-a reduces liver injury
Inhibition of TNF-a by neutralising antibodies (Anti-TNF), TNF
receptor knockout mice (TNFR-KO) or soluble TNF receptor (sTNFR).
'2,3,7,8 - tetrachlorodibenzo-p-dioxin
Strategies to investigate the role of TNF-a have included using knockout mice or
blocking TNF-a (eg with neutralising antibodies) to study the effect of the absence
of TNF-a (Bradham et al, 1998). Blocking TNF-a expression or using anti-TNF
antibodies reduces hepatotoxicity in many experimental settings (summarised in
table 5.6) although the evidence that inhibition of TNF-a reduces liver injury in
paracetamol toxicity is controversial. The methods used in this study have all been
previously shown to effectively inhibit TNF-a. The antibody regime used to inhibit
TNF-a has been shown to effectively reduce the high levels ofTNF-a produced after
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injection of lipopolysaccharide (80000pg/ml) to undetectable levels and reduce
circulating TNF-a for 16 hours after caecal ligation and puncture (Eskandari et al,
1992). Likewise the soluble TNF receptor chimera and dexamethasone regime
inhibit TNF-a after LPS injection (Chensue et al, 1991; Lukacs et al, 1997). All
methods therefore should have been highly effective in inhibiting the low levels of
TNF-a (30pg/ml) produced in this study.
Several studies have tried to elucidate the role ofTNF-a in paracetamol toxicity with
widely conflicting results. This study identified no difference in mortality or liver
injury when TNF-a was inhibited by several different methods, supporting the
findings of Boess et al (1998) that there was no difference in liver injury comparing
TNF-a / lymphotoxin-a knockout and wild type mice (Boess et al, 1998), and
suggesting that the absence of TNF does not affect liver injury after paracetamol
overdose. However, two studies by the same group using neutralising antibodies to
inhibit TNF-a have demonstrated a significant reduction in liver injury at 4, 8 and 24
but not 12 hours, 12 hours coinciding with maximal injury (Blazka et al, 1995,
1996). The explanation for the variation in reported data relating both to production
of TNF-a and to inhibition / absence of it is not known. Comparison of the different
studies is problematic since the studies have utilised different strain, sex and age of
mice, different paracetamol administration regimes, different methods of killing of
mice, different methods to measure liver injury and different methods to detect TNF-
a (summarised in Table 5.7). These factors may explain why widely conflicting data
have been published.
All of the in vivo studies have concentrated on the first 24 hours after injury, and no
study has looked at later times for example to ascertain how the liver regenerates in
the presence or absence of TNF-a. This may be of interest because in the
regenerative response after partial hepatectomy in IL-6 knockout mice initial reports
suggested defective regeneration but later studies confirmed delayed regeneration
(Cressman et al, 1996; Sakamoto et al, 1999).
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Table 5.7 Murine In Vivo Studies of TNF-a in Paracetamol Overdose
? = sex not given in paper, w = weeks, g = grams, s = serum, 1 = liver.
The balance of evidence suggests that inhibition of TNF-a does not reduce injury or
mortality after paracetamol overdose and is therefore unlikely to be useful in therapy
to reduce injury. However, this does not exclude a role for TNF-a in paracetamol
overdose. TNF-a is not simply a pro-injurious cytokine and is an important factor in
priming for regeneration, with little known about early signalling events after severe
toxic injury. In this study TNF-a is elevated in serum but not liver, suggesting that
the source ofTNF-a is extra-hepatic (eg splenic or intestinal macrophages (Suzuki et
al, 1996; Bathe et al, 1997). However, subtle changes in TNF-a expression and
production in the liver cannot be excluded. The source of TNF-a has not been
identified in most studies of liver injury and regeneration and while it is generally
presumed that Kupffer cells are the major source of most cytokines in liver injury,
every cell-type within the liver is capable of producing TNF-a.
Given the substantial conflict in the literature regarding the role of TNF-a in
paracetamol toxicity, the possibility that TNF-a has no effect on the liver must also
be considered. Paracetamol overdose is associated with a hypothermic response
86
Chapter 5: TNF-a and paracetamol toxicity
(Walker et al, 1981) closely linked with production of cytokines such as TNF-a and
IL-la (Fey and Gauldie, 1990; Blazka et al, 1995; Blazka et al, 1996) and TNF-a
may signal a systemic response rather than a local one.
Conclusions: What is the role of TNF-a in paracetamol toxicity?
Conflicting evidence exists for the role of TNF-a in paracetamol toxicity. The in
vivo studies show that TNF-a is elevated in serum after paracetamol overdose but
that inhibition of TNF-a does not reduce liver injury. Despite this, evidence from
the in vitro studies suggests that TNF-a synergises with paracetamol to augment
hepatocyte death but protects against toxicity when given before paracetamol. The
profound effects on hepatocytes noted in vitro may be inhibited or antagonised by the
cytokine milieu in vivo; neutralising TNF-a represents a crude attempt to eliminate
TNF-a in vivo and offers little mechanistic insight into how TNF-a might contribute
to liver injury or regeneration. Nevertheless it seems unlikely that TNF-a
contributes significantly to cell loss after paracetamol overdose. However, a role for
TNF-a in hepatic regeneration after injury remains feasible. For example, after
carbon tetrachloride poisoning, TNF-a has no direct effect on injury but inhibition of
TNF-a delays the time to recovery (Bruccoleri et al, 1997), supporting the
suggestion that TNF-a may act as a stimulus to regenerate, rather than as a death-
inducing factor, after liver injury. Further evidence that the functional role ofTNF-a
may be in signalling regeneration is the ability of TNF-a to protect against
paracetamol toxicity; NF-kB is a good candidate to be the central element in this
TNF-a pathway and the possibility ofmanipulating NF-kB to promote survival over
death is intriguing (Xu et al, 1998). A better understanding of the effects of TNF-a
in the liver are extremely important in designing therapeutic interventions such as
inhibition or augmentation of cytokines and their intracellular signalling pathways.
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CHAPTER SIX
THE ROLE OF KUPFFER CELLS IN PARACETAMOL TOXICITY
SUMMARY
Compelling evidence exists for an active role for Kupffer cells in toxic liver injury,
including after paracetamol overdose. This study describes an in vitro model of co-
culture of a human hepatocyte cell line with primary human macrophages as a
surrogate for Kupffer cells. Co-culture had no apparent effect on hepatocyte number,
apoptosis or proliferation, with or without paracetamol. However, TNF-a production
by macrophages was augmented by paracetamol and was further augmented by co-
culture with hepatocytes. The concentration of TNF-a produced was comparable
with that of recombinant TNF-a known to augment paracetamol toxicity from
previous studies. This suggests that hepatocytes behave differently in co-culture than
when grown alone, and that macrophages may condition how hepatocytes respond to
exogenous stimuli by production of soluble factors. Kupffer cells are important
regulators of toxic injury to hepatocytes.
INTRODUCTION
Kupffer cells represent 80-90% of tissue macrophages in the body and make up 15%
of cells within the liver (Kuiper et al, 1994). They are situated within hepatic
sinusoids, anchored to the endothelium by cytoplasmic processes and probably have
no direct contact with hepatocytes (Bouwens et al, 1986). Kupffer cells have a
variety of functions including phagocytosis of particulate foreign material (Pilaro and
Laskin, 1986), detoxification of LPS in the portal blood (Mathison and Ulevitch,
1979), acting as antigen-presenting cells (Rogoff and Lipsky, 1980) and releasing a
large number of cytokines and inflammatory mediators (Decker, 1990; Laskin, 1990;
Laskin and Pendino, 1995). Compelling evidence exists that Kupffer cells have an
active role in toxic liver injury (Laskin and Pendino, 1995; Laskin, 1996; Tsukamoto
and Lin, 1997).
Administration of xenobiotic agents such as carbon tetrachloride, ethanol,
galactosamine and paracetamol results in accumulation of activated macrophages
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within the liver (summarised in table 6.1), the site of macrophage accumulation
depending on the toxic agent and the site of hepatic injury (Laskin and Pendino,
1995). Macrophage accumulation occurs by a combination of proliferation and
recruitment from circulating monocytes (Geerts et al, 1988; Jonker et al, 1990;
Johnson et al, 1992) and the macrophages have an activated phenotype (Laskin and
Pendino, 1995). Moreover, studies in which Kupffer cells are depleted have shown
modulation of hepatic injury: depletion of macrophages by gadolinium chloride,
dextran sulphate or diphosphonate reduces hepatic injury secondary to various agents
including carbon tetrachloride, ethanol, galactosamine and paracetamol (see table
6.1). Conversely, experimental activation of Kupffer cells has augmented injury in












allyl alcohol yes Przybocki et al, 1992
ethanol yes yes Adachi et al, 1994;
Iimuro et al, 1997
carbon
tetrachloride
yes yes yes Johnson et al, 1992;
Chamulitrat et al, 1995
dimethyl-
nitrosamine
yes yes Dobbs et al, 1997
galactosamine yes yes yes Chojkier and Fierer, 1985;
Shiratori et al, 1988;
Stachlewitz et al, 1999
lead nitrate yes Dini et al, 1997
paracetamol yes yes yes Laskin and Pilaro, 1986; Pilaro
and Laskin, 1986; Laskin,
1990; Raiford and Thigpen,
1994; Laskin et al, 1995;
Goldin et al, 1996; Michael et
al, 1999; Milosevic et al, 1999
Table 6.1 The role of Kupffer cells in toxic liver injury
Kupffer cell activation - Kupffer cells have an activated phenotype. Activation increases
toxicity - Kupffer cells activation increase toxicity caused by the named agent. Depletion
reduces toxicity - pharmacological depletion ofKupffer cells decreases toxicity of the agent.
The gaps in the table indicate that no data is available. All agents were studied in rats except
paracetamol, which has been studied in rats and mice.
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In this study an in vitro model system has been used to investigate the interactions
between Kupffer cells and hepatocytes in paracetamol toxicity. Hepatocytes in
culture offer a very useful method of hepatotoxicity as they maintain many normal
phenotypic features (Guillouzo et al, 1986). Several co-culture systems have been
described using a variety of cell types along with hepatocytes (Corlu et al, 1997;
Bhatia et al, 1999). It is evident that cellular interactions are extremely important in
maintaining hepatocyte phenotype and may also influence the way in which
hepatocytes respond to toxic stimuli (Maher and Friedman, 1993; Auth and Ichihara,
1998; Bhatia et al, 1999).
The aims of this study were to investigate the interactions between Kupffer cells and
hepatocytes in paracetamol toxicity in vitro.
MATERIALS AND METHODS
Murine Macrophages
Murine macrophages were isolated using a method established in this laboratory
using a modification of the method for primary culture of murine hepatocytes as
described in chapter 4, in which hepatic and splenic macrophages were also isolated
from the same mouse (M Dollinger, personal communication). Briefly, the discarded
supernatant was retained after the first spin from the hepatocyte perfusion and the
mouse spleen was taken, gently injected with digestion medium (appendix 1) and cut
into small pieces using sterile scissors. The spleen was then gently passed through a
cell strainer and centrifuged at 300g for 10 minutes and the pellet was resuspended in
plating medium (Appendix 1). The retained hepatic and splenic perfusion
supernatants were gently mixed and layered carefully over lymphoprep (Nycomed)
then centrifuged at 300g for 30 minutes. The interface cell population was retained
and cells were plated at 5xl05 cells per culture insert. After 2 hours the supernatant
was removed and the plates were washed three times with sterile PBS to remove all
cells that were not firmly adherent; the adherent cells represent a population
comprising mainly macrophages (M. Dollinger, personal communication). Plating
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media supplemented with 10% fetal calf serum was added and cells were washed
three times with PBS after 24 hours and cells were then ready for use in experiments.
Human Macrophages
Human macrophages were isolated from buffy coats from healthy blood donors
(courtesy ofDr M Moore). The buffy coat (100-130ml) was diluted with sterile PBS
to a final volume of 200ml, layered over lymphoprep and centrifuged at 1800rpm for
20 minutes at 4°C. The peripheral blood mononuclear cell (PBMC) layer (interface
of plasma and lymphoprep) was carefully removed by pipette, diluted with sterile
PBS and centrifuged at lOOOrpm for 15 minutes. The supernatant was discarded. The
cell pellet was resuspended in PBS, layered over lymphoprep and centrifuged at
1800rpm for 20 minutes. The PBMC were removed, resuspended in PBS and
centrifuged at 300g for 10 minutes. The pellet was resuspended in Iscove's medium
(Gibco) supplemented with 5% human serum (courtesy ofDr M Moore) and the cells
were plated in culture inserts (5x10s cells per insert). After two hours the supernatant
was removed, the cells were washed twice with PBS and the media replaced. The
cells were washed twice more, and were left in media with 5% human serum for 72-
96 hours prior to beginning each experiment.
Experimental Design
Cell culture experiments with hepatocytes were carried out as previously described,
with either primary murine hepatocytes or a hepatocyte cell line (WRL 68 cells)
grown on 12 well tissue culture plates in serum-free conditions (see chapter 4). For
co-culture, culture inserts containing macrophages were placed in wells containing
hepatocytes so that the cells shared the same culture media but had no direct contact.
Macrophage and hepatocyte numbers were estimated using the MTT assay: apoptosis
and BrdU incorporation were quantitated by direct counting. Immunohistochemistry
was carried out on culture slides or inserts fixed in acetone / methanol (1:1) for 10
minutes and stored in TBS at 4°C for up to 1 week. The antibody used against CD68
(clone PGM-1, Dako; 1:50 dilution) was incubated for 1 hour at room temperature
and no pretreatment was required. Statistical analysis was carried out using
ANOVA.
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RESULTS
Murine Co-Culture
Primary murine hepatocytes showed no change in cell number over a 72 hour culture
period both when grown alone and in co-culture with macrophages (Figure 6.1). On
the other hand, the macrophages decreased in number over the duration of the
experiments, with a significant reduction at 72 hours (p<0.05). When lOmM
paracetamol was added, there was a significant reduction in hepatocyte number at 72
hours (p<0.05) but no difference in paracetamol toxicity was noted comparing
hepatocytes alone and in co-culture with macrophages (Figure 6.2). No differences
in apoptosis, mitosis or BrdU incorporation were identified (not shown).
Figure 6.1
0.3
0 24 48 72
Figure 6.1
Cell number measured by MTT for hepatocytes alone (con), hepatocytes
in co-culture with macrophages (cocult) and macrophages alone (mo).
The data represent the mean (±standard deviation) of four repeat
experiments. * = significant reduction compared with the cell number at
time 0 (p<0.05).
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Figure 6.2
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Figure 6.2
Cell number measured by MTT for murine hepatocytes alone (con),
hepatocytes in coculture with macrophages (cocult), hepatocytes with
lOmM paracetamol (par) and hepatocytes in coculture with paracetamol
(copar). The data represent the mean of 3 repeat experiments. * =
significant reduction compared with controls (p<0.05).
Isolation of a pure population of human macrophages
The adherent cells isolated from the PBMC showed strong expression of CD68
(clone PGM-1, Dako) in all cells (Figure 6.3). This CD68 clone is specific for the
monocyte / macrophage lineage, suggesting that this is a highly efficient method to
isolate a pure population ofmacrophages.
Figure 6.3
Figure 6_3 Photomicrograph showing CD68 expression by human
macrophages grown on culture inserts. All adherent cells showed
cytoplasmic staining.
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Paracetamol Toxicity in Co-Culture
No differences were noted in cell number comparing hepatocytes alone and
hepatocytes in coculture with macrophages when paracetamol was absent or present
(Figure 6.4). Similarly, no differences were noted in the rate of apoptosis, mitosis or
BrdU positivity, comparing hepatocytes alone or in coculture (not shown). The same
results were found when HepG2 cells were substituted for WRL 68 cells, using
lOmM paracetamol (not shown). Macrophages showed no change in cell number
during the time-course of control experiments but showed a small reduction in cell
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Figure 6.4
Cell number measured by MTT for hepatocytes (WRL 68 cells) alone
(con), in co-culture with macrophages (co), hepatocytes with 5mM
paracetamol (par) and co-culture with 5mM paracetamol (copar). The
data are the mean ± standard deviation of 4 experiments. There are no
differences comparing con and co and comparing par and copar.
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Figure 6.5
Figure 6.5
Macrophage cell number alone (mo) and with 5mM paracetamol (mopar)
up to 72 hours. The data are mean ± standard deviation for 3 experiments. *
= significant reduction compared with controls (p<0.05).
TNF-a production is augmented in co-culture and with paracetamol
Secreted TNF-a was detected in culture supernatants by ELISA. Hepatocytes alone
showed no production of TNF-a with or without paracetamol (Table 6.2).
Macrophages produced low levels of TNF-a in culture (mean 47pg/ml); on addition
of paracetamol, the production of TNF-a was increased threefold by 72 hours
(154pg/ml; p<0.05). Co-culture of macrophages and hepatocytes resulted in an
increase in TNF-a production at 24, 48 and 72 hours (mean 205pg/ml). When
paracetamol was added to the co-cultures, a further substantial increase in TNF-a
was noted at 48 and 72 hours (mean 609pg/ml; p<0.05, Table 6.2).
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Table 6.2
Group Time TNF-a Range
Hepatocytes 24 0 0
48 0 0
72 0 0
Hepatocytes 24 0 0
+ 48 0 0
Paracetamol 72 0 0
Macrophages 24 38 ±24
48 64 ±22
72 38 ±33
Macrophages 24 42 ±36
+ 48 51 ±38
Paracetamol 72 154* ±59
Co-Culture 24 152** ±106
48 229** ±118
72 235** ±124
Co-Culture 24 297 ±129
+ 48 654*** ±158
Paracetamol 72 564*** ±61
Table 6.2 TNF-a concentrations in co-culture
TNF-a concentration is in pg/ml (calculated compared with recombinant TNF-a
as a standard up to lOOOpg/ml) and is based on 3 or 4 observations. The range
represents the confidence interval of the mean.
* Significant increase compared with macrophages alone at all time-points and
macrophages + paracetamol at 24 and 48 hours (p<0.05).
** Significant increase compared with macrophages alone at all time-points
(p<0.05).
*** Significant increase compared with co-culture alone at all time-points and
co-culture + paracetamol at 24 hours (p<0.05).
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DISCUSSION
TNF-a production by Kupffer cells in co-culture
Co-culture of hepatocytes with macrophages resulted in a striking up-regulation of
TNF-a production, which was further increased by addition of a toxic dose of
paracetamol. The level of TNF-a produced was comparable with a concentration of
recombinant TNF-a known to increase paracetamol hepatotoxicity (>600pg/ml; see
chapter 5) but in the co-culture model no augmentation of toxicity was seen. This
indicates that hepatocytes in co-culture behave differently to those grown alone and
supports the hypothesis that macrophages (Kupffer cells) can condition the way in
which hepatocytes respond to exogenous stimuli.
In this model, any interaction between macrophages and hepatocytes occurs by
production of soluble factors as direct cellular contact cannot occur. Detection of
TNF-a released by macrophages treated with paracetamol shows levels similar to
those reported elsewhere (Goldin et al, 1995) although another study has reported
inhibition ofTNF-a release from Kupffer cells by paracetamol (Horbach et al, 1997).
The paradoxical difference between TNF-a produced in co-culture and addition of
recombinant TNF-a is unexplained, but presumably other cytokines including one or
more survival factors are being produced in co-culture to antagonise the toxic effects
of TNF-a. This has not been further studied but it is possible that the lack ofTNF-a
effect in co-culture may relate to production of soluble TNF receptors. Proteolytic
cleavage of the external domain of TNFR1 and TNFR2 produces soluble TNFR
which increase the half-life of TNF-a but blocks interaction with membrane TNFR
and therefore act as a TNF antagonist (Van Zee et al, 1992).
The data from this study support the suggestion that macrophages produce TNF-a
during paracetamol toxicity but do not rule out the possibility that other cell types
produce TNF-a. Furthermore, the suggestion that N-acetyl cysteine suppresses
TNF-a production from Kupffer cells may be of relevance in studying the role of
TNF-a in after paracetamol overdose in humans (Fox et al, 1997). Macrophages and
monocytes are thought to be the most important producers of TNF-a but
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hepatocytes, biliary epithelial cells and sinusoidal endothelial cells can also produce
TNF-a (Gonzalez-Amaro et al, 1994; Hoffmann et al, 1994; Nagano et al, 1992).
After partial hepatectomy in rats the major sites of TNF-a production are the biliary
epithelium and endothelial cells of hepatic and portal veins and not Kupffer cells
(Lofffeda et al, 1997). However, the cellular origins of TNF-a, IL-6 and IL-1 in
regeneration and after liver injury are unknown (Taub, 1998). While this study
suggests that macrophages produce TNF-a during paracetamol toxicity, it does not
rule out the possibility that other cell types produce TNF-a. Furthermore, this data is
in direct contrast to that described in an in vivo murine model of paracetamol toxicity
(chapter 5), where TNF-a was elevated in serum but there was no elevation of TNF-
a RNA or protein in liver.
Kupffer cells and paracetamol toxicity
The findings of this study, that no difference in toxicity is noted between hepatocytes
alone or in co-culture with Kupffer cells, is an agreement with observations noted in
other studies (Raiford and Thigpen, 1994; Milosevic et al, 1999). However, both
these studies primarily addressed changes in CYP450 enzymes in paracetamol
toxicity and the data on toxicity is not presented in detail so accurate comparison of
extent of hepatocyte loss is not possible.
Three studies have identified a reduction in paracetamol toxicity after blockade of
Kupffer cells (Table 6.3). However, the available data show significant variation,
with one group showing protection up to 2 hours and no protection after that, one
group showing protection at 8 hours and the third protection at 24 hours. Several
potential problems in interpretation exist for these studies and comparability is
difficult given the disparate experimental protocols (differences in species, sex, dose
of paracetamol, method of macrophage depletion, end-points). No study has studied
injury at multiple time-points related to outcome (regeneration, maximum severity of
liver injury, survival). Gadolinium chloride is more efficient at protecting against
toxicity than dextran sulphate, correlated with a greater reduction in macrophage
number (Michael et al, 1996) but DMDP which is also efficient at reducing
macrophage number (Goldin et al, 1996) appears to offer much shorter protection.
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However, macrophage-depleting agents may affect hepatocytes and other non-
parenchymal cell types within the liver (Laskin et al, 1995) and so the differences
may not be solely dependent on Kupffer cells. Gadolinium chloride is known to
cause minor changes in hepatic function (e.g. reduction in bile flow) and may result
in activation of Kupffer cells with increased cytokine production (Ruttinger et al,
1996), the significance of which is unknown.
Table 6.3
Reference Species Paracetamol Blocking agent Time-course
dose
Laskin et al, Rat 800mg/kg GadCl 24hr*
1995 LEH (m) DexS
Goldin et al, Mouse 250gg per DMDP 2hr**
1996 C57BL/10 (f) mouse
Michael et al, Mouse 300mg/kg GadCl 8hr*
1999 B6C3F1 DexS
(m)
Table 7.4: LEH = Long Evans Hooded rat; m = male, f = female; GadCl = gadolinium
chloride; DexS = dextran sulphate; DMDP = dichloromethylene diphosphonate. * protection
form toxicity but only one time point studied. ** protection from toxicity up to 2 hours but
no protection at 4 hours.
Endotoxin and macrophage activation in hepatotoxicity
Activation of Kupffer cells, leading to increased functional capability including
increased phagocytic capacity, increased cytotoxic ability and increased production
of bioactive substances, is a fundamental component of Kupffer cell involvement in
toxic liver injury (reviewed in Decker, 1990). Several soluble substances can
activate Kupffer cells including interferon-y, endotoxin and TNF-a (Decker, 1990).
Endotoxin (lipopolysaccharide) is absorbed from the gut into the portal circulation
and is normally detoxified by Kupffer cells blood (Mathison and Ulevitch, 1979; Fox
et al, 1989). Endotoxin has an important immunomodulatory role for Kupffer cells
(reviewed in Nolan, 1989; Decker, 1990; Laskin 1996; Roth et al, 1997) as increased
endotoxin in portal blood leads to recruitment and activation of macrophages in the
liver (Pilaro and Laskin, 1986) associated with increased cytokine production
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(Chensue et al, 1991; Steinhorn and Cerra, 1997). Elevation of portal endotoxin
probably occurs because of increased intestinal permeability to it (Iimuro et al,
1997). Endotoxin is established as an important element in hepatotoxicity induced
by various agents including ethanol, carbon tetrachloride and galactosamine (Nolan
and Liebowitz, 1978; Bjarnason et al, 1984; Chojkier and Fierer, 1985; Iimuro et al,
1997). In spite of this, no study has investigated the role of endotoxin in paracetamol
toxicity.
Methodological aspects and usefulness of co-culture
This study raises intriguing questions regarding the role of Kupffer cells and TNF-a
in paracetamol toxicity. A paradox exists where TNF-a alone augments paracetamol
toxicity in vitro but in co-culture similar levels of TNF-a have no effect on toxicity.
This co-culture system may resemble more closely the situation in vivo, where the
balance of evidence suggests that TNF-a does not have a direct role in hepatotoxicity
induced by paracetamol in vivo (chapter 5).
This study represents a simple method to study toxic liver injury using a co-culture
of hepatocytes and macrophages, and is similar to the approach used to study
interactions between Kupffer cells and hepatocytes by several other groups (Goldin
et al, 1995; Steinhorn and Cerra, 1997). A critical feature of any model of hepato¬
toxicity is the ability to maintain differentiated phenotype in culture (Selden et al,
1999). A number of different studies have described to improve hepatocyte survival
and phenotype. Methodologies have included use of complex media enriched for
hepatotrophic nutrients (Block et al, 1996; Hino et al, 1999), manipulation of
extracellular matrix (Bhatia et al, 1999), admixture of different cell types with
hepatocytes (Corlu et al, 1997) and two- and three-dimensional culture systems
(Bhatia et al, 1999; Michalopoulos et al, 1999). Many issues are unresolved
regarding cellular interactions and whether direct contact or paracrine secretion of
proteins is more important in determining hepatocyte responses (Shimaoka et al,
1987).
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One problem is the difficulty in isolating and growing Kupffer cells in vitro. Kupffer
cell isolation relies on proteolytic digestion of the liver followed by centrifugal
elutriation and result in relatively low yields of cells (Knook et al, 1976; Hespeling et
al, 1995; Namieno et al, 1996). Other authors, and this study, have used
macrophages derived from peripheral blood (Goldin et al, 1995) as a surrogate for
Kupffer cells. It is not clear how well such a system compares with co-culture using
Kupffer cells and further studies are required to address this issue.
Cellular interactions in paracetamol toxicity
Other cell types have also been implicated in paracetamol toxicity, mainly relating to
microvascular changes in zone 3 in the early stages of liver injury (Lim et al, 1995).
Polymorph accumulation and microvascular plugging have been shown to precede
development of necrosis in some studies but not others (Jaeschke and Mitchell, 1989;
Welty et al, 1993), and the pathogenetic significance of this is not known. However,
other studies have shown that inhibition of neutrophils may reduce paracetamol
toxicity (Smith et al, 1998). Endothelial cells are more susceptible to paracetamol
toxicity than hepatocytes in mice; in one strain paracetamol is directly toxic to
endothelial cells, but in another strain it requires activation by hepatocytes,
presumably dependent on CYP450 isoforms (DeLeve et al, 1997). A possible role
for endothelial cells in paracetamol toxicity has therefore been proposed, where
paracetamol-induced injury to endothelial cells may contribute to zone 3 necrosis in
the early stages of injury.
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CHAPTER 7
GENETIC POLYMORPHISMS IN TUMOUR NECROSIS FACTOR
SUMMARY
Several polymorphisms have been identified in the TNF-a and lymphotoxin-a
(TNF-(3) genes, where the polymorphic alleles are associated with the level of TNF-
a production and are associated with important disease. Polymorphisms in TNF-a
and TNF-[3 characterised by Ncol restriction sites in one allele were identified by
PCR, Ncol digestion and gel electrophoresis. The TNF-a and TNF-(3 genotypes had
no association with severity of encephalopathy. However, the TNF (3 (B1B1)
phenotype showed a strong association with a high rate of hepatocyte apoptosis
(p=0.011). The B1B1 genotype is associated with lower levels of circulating TNF-a,
and also has been linked with less frequent progression to severe encephalopathy
after paracetamol overdose. TNF-a may play an important role in paracetamol
toxicity but may not simply act as a mediator of hepatocyte death.
INTRODUCTION
Evidence that TNF-a may play a role in paracetamol toxicity has been discussed in
previous chapters. In summary, TNF-a may influence hepatocyte death by apoptosis
and hepatocyte proliferation, although the precise role of TNF-a in paracetamol
toxicity is not known. However, TNF-a has a role in the pathogenesis of many
infectious and inflammatory diseases in which an association between circulating
TNF-a and disease activity has been suggested. For example TNF-a is involved in
the pathogenesis of several autoimmune diseases (reviewed in Wilson et al, 1995)
and elevated TNF-a correlates with poor outcome in sepsis of various causes (Waage
et al, 1989; Dofferhoff et al, 1992; Stuber et al, 1998). Significant inter-individual
variation exists in TNF-a levels and polymorphisms in the TNF-a and lymphotoxin-
a (TNF-P) genes may be an important factor in determining this variability (Pociot et
al, 1993; Louis et al, 1998; Stuber et al, 1998). Genetic polymorphisms in TNF
genes are associated with leishmaniasis, leprosy and a poor prognosis in cerebral
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malaria (Cabrera et al, 1995; Roy et al, 1997; McGuire et al, 1994) and have also
been associated with Crohn's disease (Louis et al, 1996).
The TNF-a and TNF-[3 genes are located on chromosome 6 in the class 3 region of
the major histocompatibility complex (MHC; Bodmer et al, 1990). Two important
features of the MHC are that several of the MHC genes are in linkage disequilibrium
and that many polymorphic sites exist Wilson et al, 1995). As a result, high levels of
TNF-a are frequently noted in individuals with HLA-DR3 or -DR4 and low levels of
TNF-a noted with HLA-DR2, suggesting polymorphism in genes regulating TNF-a
expression (Pociot et al, 1993). Several polymorphic sites have been identified on
both the TNF-a and TNF-(3 genes (reviewed in Wilson et al, 1995). Common
polymorphisms include the -308 position in the TNF-a gene, where adenosine is
substituted for guanine in the uncommon allele (TNF2; Wilson et al, 1992), and the
Ncol restriction fragment length polymorphism (RFLP) in TNF-p where the
uncommon allele has a single base substitution in intron 1 (Messer et al, 1991).
TNF2 (the uncommon allele) is a stronger transcriptional activator than TNF1 and
TNF2 is associated with an increase in serum TNF-a (Wilson et al, 1997). Likewise
the Ncol polymorphic site in the first intron of TNF-(3 (uncommon allele B2) is
associated with increased levels of TNF-a after stimulation by endotoxin (Louis et
al, 1998) although the mechanism whereby TNF-a is increased is not known. The
TNFB1B1 phenotype has been associated with elevated TNF-(3 and may have no
effect on or reduce the level of TNF-a (Messer et al, 1991; Pociot et al, 1993). In
summary, the association between TNF genotype and TNF-a level in serum complex
and has not been frilly elucidated.
The aims of this study were to investigate TNF polymorphisms after paracetamol
overdose and determine whether the TNF genotype was associated with various
pathological parameters in the liver.
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MATERIALS AND METHODS
Patients: This study was carried out with the approval of the local ethical committee
and used the same patient group as described in chapter 2. Briefly, all patients
presenting to the Scottish Liver Transplant Unit (SLTU) with fulminant hepatic
failure (FHF) from 1991 - 1997 were identified. Patients were included in the study
when tissue blocks were available. Cases secondary to paracetamol overdose (POD)
were identified as the study group. Controls were a group of healthy adult blood
donors with no history of paracetamol ingestion.
Clinical Parameters: A detailed database is maintained of all patients presenting to
the SLTU in fulminant liver failure so extensive clinical information was available
(see below). Pathological information was available as detailed in chapter 2 and
below.
DNA extraction and PCR: Briefly TNF-a has two alleles, a common allele (1; G at
position -308) and an uncommon allele (2; A at position -308). The common allele
(1) lacks a Nco\ cleavage site present in the uncommon allele (2) and the different
genotypes can be easily identified by gel electrophoresis. Likewise the
polymorphism in the first intron of TNF-J3 can be identified by the presence of an
Nco\ restriction site in the common allele (Bl) but not the uncommon allele (B2; see
Table 7.3). The PCR strategy was to amplify polymorphic regions in TNF-a
(position -308 in the promoter region) and TNF-J3 (a base-pair polymorphism in
intron 1).
DNA was extracted from 15|Lim sections using proteinase K digestion (Appendix 7).
The PCR mix comprised 1.25 units red hot DNA polymerase (AbGene) in reaction
buffer, 200pM of each dNTP, 50ng of each primer (Table 7.1) and 1.5mM MgCfr.
The PCR reaction was carried out in a Hybaid thermal cycler as detailed in Table 7.2.
10)ll of each PCR product was digested with Ncol restriction enzyme, and the
products and restriction digests were separated on a 12% polyacrylamide gel and
visualised after ethidium bromide staining to allow determination of different
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genotypes (Table 7.3; Figure 7.1). The allele nomenclature has been well-described
(Wilson et al, 1992; Louis et al, 1998; Park et al, 1998; Bernal et al, 1998).
Table 7.1
Primers Notes
TNF-a TCC TCC CTG CTC CGA TTC CG Primers supplied by Cruachem
(Bearsden) based on sequences
originally described in Wilson et al,
1992
AGG CAA TAG GTT TTG AGG GCC AT
TNF-p TGT CTC TGA CTC TCC ATC TGT C Primers supplied by Gibco-BRL
AGA AAC CCC AAG GTG AGC AGA G
Table 7.1 Primers for TNF-a and TNF-(3
Table 7.2
PCR profile
TNF-a denaturation at 94°C for 3 min
38 cycles of 60°C for 1 min, 72°C for 1 min, 94°C for 1 min
final extension at 72°C for 10 min
TNF-|3 denaturation at 94°C for 3 min
38 cycles of 63°C for 1 min, 72°C for 1 min, 94°C for 1 min
final extension at 72°C for 10 min
Table 7.2 PCR profile for TNF-a and TNF-p
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Table 7.3
TNF-a Genotype 11 12 22
PCR product (bp) 107 107 107





TNF-(3 Genotype B1B1 B1B2 B2B2
PCR product (bp) 121 121 121






Table 7.3 Nomenclature for different for TNF-a and TNF-p genotypes after Ncol
digestion
Figure 7.1
Figure 7.1 Gel photograph for TNF-a (top) and TNF-|3 (bottom) demonstrating
the typical bands identified.
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Statistical Analysis
After advice on statistical advice from Mandy Lee, Department ofMedical Statistics,
University of Edinburgh, data were analysed using Kruskal-Wallis test (MedCalc,
Belgium) with correction for multiple testing.
RESULTS
TNF Genotypes
Genotyping for TNF-a was successful in 47 cases (69%) and for TNF-(3 in 38 cases
(56%) of paracetamol overdose. All control cases were successfully genotyped. The
genotypes are given in Table 7.4.
Table 7.4
TNF-a Genotype TNF-P Genotype
11 12 22 B1B1 B1B2 B2B2
POD 55 36 9 29 32 39
control 66 29 5 10 44 46
Table 7.4 TNF-a and TNF-p genotypes
% of cases of each genotype - the nomenclature is described in the methods and is
summarised in table 7.3. TNF-a n=47; TNF-P n=38.
TNF Genotype and Paracetamol Overdose
Detailed analysis revealed no association between any of the TNF-a and TNF-p
genotypes and the various clinical parameters (Table 7.5). Analysis of the
pathological factors revealed a significant association between the TNF-P genotype
with apoptotic rate (p=0.011). Plotting the apoptotic rate for B1B1, B1B2 and B2B2
genotypes revealed a significantly higher rate of apoptosis in B1B1 than B1B2 and
B2B2 (Figure 7.2).
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ki-67 positivity4 0.432 0.745
death5 0.192 0.985
liver transplantation 0.410 0.245
Table 7.5 TNF-a and TNFP genotype and paracetamol overdose
The data presented are the p values using the Kruskal-Wallis test - significant values in bold
(p<0.05). 1 encephalopathy: grade of encephalopathy. 2 necrosis: panacinar vs. severe
necrosis (see chapter 2). 3 apoptosis: % of apoptotic hepatocytes - **association of BIB 1
genotype and a higher apoptotic rate. 4 Ki-67 positivity: % of Ki-67 positive hepatocytes. 5
death without liver transplant being carried out.







Figure 7.2 Apoptotic index plotted against TNFp genotype. The bars represent
median, upper and lower quartiles and maximum / minimum values. B1B1 n= 6 ;
B1B2 n= 5; B2B2 n= 11.
DISCUSSION
Association of TNF genotype and paracetamol overdose
The genotypes from this study show some differences from those reported elsewhere
(Table 7.6) with an increased proportion of TNF-a 22 genotype in both paracetamol
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paracetamol overdose. When looking simply at the allele frequency (Table 7.6),
there is a very slight increase in the TNF-a 2 allele in controls compared with other
studies, with a much higher frequency of the 2 allele in patients who have taken a
paracetamol overdose. For TNF-J3, the controls showed a similar allele frequency to
that described elsewhere, but the TNFB1 allele was much more commonly identified
after paracetamol overdose. The reasons for the difference in genotype distribution
and allele frequency for TNF-a 2 and TNF-(3 1 are not known. Possible explanations
include the different populations studied; this study was in a Scottish population
where other studies were carried out in London, Belgium, Germany and Korea. A
further possible explanation for the differences in the POD cases is that in this study
is the use of formalin-fixed blocks as a source of DNA for POD cases where the
controls and all the other studies have used whole blood, a more reliable source of
DNA; DNA extraction and PCR was unsuccessful in a significant proportion of POD
cases (31 % for TNF-a, 44% for TNF-p) which may have skewed the results.
Table 7.6a
Reference Patient group TNF-a genotype (%) Allele frequency
11 12 22 1 2
Bemal et al, 1998a Normal 67 32 1 0.83 0.17
paracetamol overdose 65 33 2 0.92 0.18
Park et al, 1998 Normal 77 22 1 0.88 0.12
colorectal carcinoma 82 17 1 0.91 0.09
Louis et al, 1998 Normal 72 28 0 0.86 0.14
This study Normal 66 29 5 0.80 0.20
Paracetamol 55 36 9 0.74 0.36
overdose
Reference Patient group TNF- 5 genotype (%) Allele frequency
B1B1 B1B2 B2B2 B1 B2
Stuber et al, 1996' Sepsis 10 48 42 0.35 0.65
Bemal et al. 1998a2 Normal 11 47 42 0.34 0.66
paracetamol overdose 10 46 43 0.34 0.66
Park et al, 19983 Normal 10 45 45 0.32 0.68
colorectal carcinoma* 18 52 29 0.44 0.56
This study Normal 10 44 46 0.32 0.68
Paracetamol 29 32 39 0.45 0.55
overdose
Table 7.6 Studies of genetic polymorphisms in TNF-a and TNF~p.
1 The study group was patients suffering severe sepsis of culture-proven infectious aetiology
2 The study compared normal controls with patients who had taken a paracetamol overdose
3 The study compared normal controls with patients with colorectal carcinoma.
* A significant increase in allele B1 was found in this study
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TNF genotype and hepatocyte apoptosis
While there are undoubted problems in the interpretation of studies associating
genetic polymorphisms with complex disease (see next section) this study has
identified an interesting association between the TNF B1B1 genotype and a higher
apoptotic rate after paracetamol overdose. The explanation for this association is not
known. One possibility is the known association of TNF genotype and circulating
TNF-a. The TNFB1B1 genotype may be associated with normal or low levels of
circulating TNF-a (Messer et al, 1991; Pociot et al, 1993), and may suggest that
lower levels of circulating TNF-a are associated with higher rates of apoptosis.
Conversely the higher levels of TNF-a in heterozygotes or B2B2 homozygotes may
protect against apoptosis. The role of TNF-a in paracetamol toxicity remains
controversial, as TNF-a augments or protects against hepatotoxicity in vitro
depending when it is administered and in vivo studies suggest that TNF-a is not
directly involved in hepatocyte death. This study once again suggests that TNF-a
may be protective or pro-regenerative rather than pro-injurious after paracetamol
overdose. The TNF (3 B1B1 genotype has been previously shown to be associated
with less frequent progression to severe encephalopathy although that was not
reproduced in this study.
Problems in interpreting genetic polymorphism studies
Recent conflicting studies of genetic polymorphisms and complex diseases have lead
to the criticism that this approach to study disease is flawed (Wilhelmsen, 1997;
Nature Genetics, 1999; Todd, 1999; Gambaro et al, 2000). Many of the criticism are
valid, and general principles have been proposed that such studies require large
sample sizes (>1000 cases, >1000 controls), small p values on statistical testing,
biologically sensible associations between genotype and disease and a physiological
understanding of how polymorphic alleles function. This study fulfils some, but not
all of these criteria. The genetics of the TNF loci are well-characterised, with well-
defined physiological effects on the serum concentration of TNF-a, the p values are
small, and the biological logic that TNF-a may alter hepatocyte apoptosis is
irrefutable. However, the sample size is much smaller than the suggested one, but
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the number of cases where tissue is available limits the size. Furthermore, PCR was
not successful in every case. The controls group is also imperfect, being normal
blood donors rather than a more relevant group such as patients who did not die after
paracetamol overdose. Nevertheless, despite some shortcomings this study has
identified a very interesting association between the TNFB1B1 genotype and a lower
rate of hepatocyte apoptosis after paracetamol overdose. While the significance of
this is at present unclear, this study represents a potentially important contribution to
the study ofTNF-a and liver injury and regeneration.
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CHAPTER EIGHT
SUMMARY AND CONCLUSIONS
The problems of paracetamol overdose
Paracetamol overdose remains a pressing clinical problem as the commonest cause of
fulminant liver failure in the UK. Drugs that replenish glutathione, such as N-acetyl
cysteine or methionine, are effective in preventing severe liver injury and liver
failure if given within 16 hours of overdose and have proved the value of
understanding the pathogenesis of an injury to develop and effective cure.
Necrosis, apoptosis and regeneration in paracetamol overdose
The major pathological change after paracetamol overdose is severe hepatic necrosis.
However, the extent of necrosis is not the only factor determining outcome and
increasing evidence suggests that hepatocyte apoptosis may also occur in murine
(Ray et al, 1996) and human liver (chapters 2 and 3). Two groups of patients were
studied. Patients who die following coproxamol overdose usually do so because of
opiate poisoning and do not develop features of paracetamol hepatotoxicity.
However, in this study, hepatic necrosis was seen in 9% of cases and hepatocyte
apoptosis was seen in 26% of cases of coproxamol overdose but were not seen in
patients dying because of methadone (opiate only) overdose. These findings suggest
that apoptosis may occur as an early event, possibly preceding necrosis as has been
suggested in mice (Ray et al, 1996). Further studies in patients dying after
paracetamol overdose revealed ongoing hepatocyte apoptosis at time of death or liver
transplantation, and in the presence of striking regeneration. The apoptosis in this
situation is important for three reasons. First, at this time paracetamol is undetectable
in blood, suggesting that apoptosis may occur as a direct effect of paracetamol.
Second, apoptosis occurs despite striking regenerative activity, raising the possibility
that these two conflicting processes may be associated. Third, apoptosis occurs at
low rates but may nevertheless indicate a significant attritional loss of hepatocytes at
a critical time i.e. when necrosis is maximal. The mechanistic association between
apoptosis and proliferation is not known, but the possibility that they relate to
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Kupffer cell activation and the cytokine milieu in the injured and regenerating liver
has been raised.
Models of paracetamol toxicity
An in vitro model of paracetamol hepatotoxicity was developed to further study
apoptosis and regeneration. In this model, using murine or human hepatocytes,
paracetamol caused dose-dependent hepatocyte death by necrosis and apoptosis
(chapter 4). Human cell lines represented a much more reproducible model of toxic
than primary murine cells. Apoptosis occurred at significant rates, suggesting that
apoptotic cell loss is an important contributor to hepatic injury. However, the
intrinsically high rate of proliferation in the cell lines made analysis of regeneration
problematic.
The role of TNF-a in paracetamol toxicity
TNF-a has been implicated in hepatotoxicity caused by many different toxins, in
most causes potentiating hepatocyte death by apoptosis. However, in paracetamol
toxicity, conflicting data exist regarding the role ofTNF-a. An in vivo study in mice
(chapter 4) showed that TNF-a is elevated in serum after paracetamol overdose but
that inhibition ofTNF-a does not reduce injury or improve the outcome. Using an in
vitro model with human hepatocytes (chapter 6), TNF-a augmented paracetamol
toxicity, increasing rates of both necrosis and apoptosis. However, pretreatment with
TNF-a protected against paracetamol toxicity, reducing subsequent paracetamol-
induced apoptosis. Studies genetic polymorphisms in TNF genes (chapter 8) were
problematic, given small numbers of patients but an interesting observation was an
association of the B1B1 phenotype (associated with lower levels of TNF-a) with
high rates ofhepatocytes apoptosis.
The findings regarding TNF-a are conflicting and complex. The balance of evidence
suggests that despite augmenting paracetamol toxicity in vitro, TNF-a is not a
critical mediator of toxicity in vivo. However, TNF-a may have a different role in
paracetamol toxicity, acting to signal regeneration or protect against injury. The
mechanisms by which TNF-a acts are not clearly defined, and further study is
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required. Many questions remain regarding the role of TNF-a in toxic liver injury,
and specifically after paracetamol overdose but studies to address late time-points
after overdose and hepatic regeneration and activation of hepatic survival signals
such as NF-kB activation in particular may help ascertain the role of TNF-a in toxic
liver injury. Furthermore, the source of TNF-a has not been identified in most
studies of liver injury and regeneration. While it is generally presumed that Kupffer
cells are the source ofmost cytokines in liver injury, every cell-type within the liver
is capable of producing TNF-a. Furthermore, macrophages in the spleen or intestine
may produce high levels of TNF-a (Suzuki et al, 1996; Bathe et al, 1997). The
particular difficulties of human studies must also be addressed, such as the effects of
N-acetylcysteine therapy (Fox et al, 1997). Studies in other cell types have shown
that paracetamol protects against cytotoxicity and apoptosis induced by non-steroidal
drugs (Romano et al, 1988; Schonberg and Skorpen, 1997), suggesting that the effect
of paracetamol may be cell type and context dependent.
Cellular interactions in paracetamol toxicity
Co-culture of hepatocytes with Kupffer cells allowed investigation of the cellular
interactions in paracetamol toxicity. Compelling evidence exists for an active role
for Kupffer cells in toxic liver injury, including after paracetamol overdose. In
chapter 6, an in vitro model of co-culture of a human hepatocyte cell line with
primary human macrophages revealed no apparent effect on hepatocyte number,
apoptosis or proliferation, with or without paracetamol. However, TNF-a production
by macrophages was augmented by paracetamol and was further augmented by co-
culture with hepatocytes. The concentration of TNF-a produced was comparable
with that of recombinant TNF-a known to augment paracetamol toxicity from
previous studies. This suggests that hepatocytes behave differently in co-culture than
when grown alone, and that macrophages may condition how hepatocytes respond to
exogenous stimuli by production of soluble factors and suggests that Kupffer cells
are important regulators of toxic injury to hepatocytes.
Macrophages and monocytes (but mainly Kupffer cells) are thought to be the most
important producers of TNF-a but TNF-a can also be produced by hepatocytes,
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biliary epithelial cells and sinusoidal endothelial cells (Hunt et al, 1992; Gonzalez -
Amaro et al, 1994; Hoffmann et al, 1994; Nagano et al, 1992; Loffreda et al, 1997).
However, the cellular origins of TNF-a, IL-6 and IL-1 in regeneration and after liver
injury are unknown (Taub, 1998). These studies support the suggestion that
macrophages, within or outwith the liver, produce TNF-a during paracetamol
toxicity but do not rule out the possibility that TNF-a is not produced by other cell
types. Further studies of Kupffer cell activation and patterns of cytokine and
chemokines production during liver injury and subsequent regeneration would be of
great interest to further delineate the role of Kupffer cells in these processes.
Conclusions
This work challenges the conventional approach to paracetamol toxicity as a simple
case of boring liver necrosis. Several apparent paradoxes have been identified:
1. Ongoing hepatocyte apoptosis occurs during regeneration after paracetamol
overdose
2. TNF-a has complex effects and can augment or protect against hepatocyte
apoptosis depending on the timing of administration
3. Kupffer cells produce TNF-a at levels that should cause hepatocyte apoptosis but
condition the hepatocyte response so that apoptosis is not noted.
The situation after paracetamol overdose is extremely complex and requires further
study in a variety of areas. In terms of developing new therapies to improve the
outcome, the data regarding cytokines and chemokines in controlling liver
regeneration is intriguing. Utilisation and augmentation of the liver's regenerative
capacity is an exciting prospect in therapy of acute liver failure (Kay and Fausto,
1997). The protective effects and pro-regenerative capacity in ELR-CXC
chemokines is of interest as a potential therapeutic tool in toxic liver injury although
further studies are required (Hogaboam et al, 1999).
Paracetamol toxicity - the future
While improved drug safety information and advances in packaging to limit
availability of paracetamol may help in reducing overdoses, the effects have been
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limited (Fagan and Wannan, 1996; Hawton et al, 1996) although recent data suggest
that this approach has been increasingly successful (BMJ, 2001). Combination of
methionine with paracetamol to completely prevent liver injury is possible but is
relatively expensive, requires all persons taking paracetamol to take for most an
unnecessary additional compound and may introduce side-effects where paracetamol
alone has none at recommended dosage (Bray et al, 1993). A better understanding of
paracetamol toxicity may lead to new therapies including additional methods to
replenish glutathione, and administration of other potentially protective agents such
as prostaglandin E2 or antioxidants (Farrell, 1994; Fry and Seeff, 1995). Most
studies concentrate on prevention of significant liver injury and tend to ignore the
group of patients who develop liver injury, often presenting after the time at which
current antidotes work. This important group of patients has a high mortality and
few therapeutic options apart from liver transplantation are limited (Peleman et al,
1988; O'Grady et al, 1989). Indirect approaches such as hepatocyte transplantation
after genetic manipulation of donor hepatocytes to increase hepatocyte numbers may
be useful (Kobayashi et al, 2000; Hagmann, 2000), but this does not specifically
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APPENDIX I MURINE LIVER PERFUSION AND CULTURE
Perfusion Medium (calcium-free, containing EDTA) was purchased from Gibco-BRL
(Paisley) and supplemented with gentamicin (1 pg/ml). The medium was pre-warmed to
37°C and oxygenated immediately prior to infusion.
Digestion Medium was made up fresh each fortnight.







Before perfusion 75mg collagenase (Sigma) and 5mg DNase I (Sigma) were added to
20ml of the stock and filter sterilised. The solution was made up to 100ml and pre-























Fibronectin (Sigma; lmg/ml) was diluted 1:100 in sterile PBS, added in sufficient
volume to cover the bottom of the plate / slide and left at 4°C overnight. Any excess
fibronectin solution was aspirated and the coated plates were stored at 4°C for up to one
week. Pilot experiments were carried out to assess whether fibronectin-coating made any








Comparison of cells grown on slides coated with fibronectin in
media only (con) or with 5mM paracetamol. Comparison with
same groups grown on uncoated slides (unc).
Cell numbers are lower on uncoated slides than on those coated with fibronectin. For all
subsequent experiments, all groups utilised fibronectin-coated slides.
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Appendix
APPENDIX 2A SERUM-FREE CULTURE OF MURINE HEPATOCYTES
A variety of different culture media have been used for primary rodent hepatocyte
culture. Appropriate supplements added (see appendix 1 - culture media) as previously





Primary murine hepatocytes plated and grown for 48 hours, a = modified Chee's. b = RPMI
(Gibco). c = William's E (Gibco). d = DMEM F12. e = DMEM. Each bar represents four
experiments; the error bars are 2 standard deviations.
Conclusions
After 48 hours, significantly more hepatocytes were present in Chee's media than in any
other medium (p<0.05). Chee's was therefore used for all subsequent experiments with
murine hepatocytes.
APPENDIX 2B SUPPLEMENTED CULTURE OF PRIMARY MURINE
HEPATOCYTES
Primary murine hepatocyte culture has been developed in this department over several
years (C. Bellamy, personal communication) in a wide range of studies with certain
supplements added to allow hepatocyte growth and survival in serum-free conditions.
Several experiments were carried out to assess the value of these different supplements






2A = primary hepatocytes. 2B = primary hepatocyte with lOmM paracetamol
a = media only (modified Chee's; supplemented with L-glutamine and antibiotics), b = media
plus ITS (Sigma: insulin, transferrin, selenium), c = media plus dexamethasone (18ng/ml). d =
media plus ITS and dexamethasone. e = media plus ITS, dexamethasone and EGF (12.5f-Lg/ml),
f = media plus EGF. Each experiment represents four repeats; error bars represent 2 standard
deviations.
Conclusions
No differences were noted comparing the different culture conditions, both with
hepatocytes alone and in the presence of paracetamol. Experiments were therefore
carried out using Chee's media only.
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APPENDIX 3 CULTURE CONDITIONS FOR HEPG2 AND WRL 68 CELLS
Various culture supplements, used in a variety of studies of hepatocyte growth in the
literature were tested as shown below for WRL 68 and HepG2 cells.
Figure 3.1 (WRL 68)
Figure 3.1 (HepG2)
Addition of various culture supplements to the hepatocyte cell lines, mem or media = media
only; its = insulin-transferrin-selenium; dex = dexamethasone; egf = epidermal growth factor.
Results are repeats of three experiments, error bars represent 2 x SD. None of the differences
are significant at each time-point.
Both cell lines showed similar growth in media only, compared with a variety of
putative growth supplements. All subsequent experiments were therefore carried out in
unsupplemented media.
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APPENDIX 4 VALIDATION OF MTT AS A MEASURE OF CELL
NUMBER IN PARACETAMOL TOXICITY STUDIES
The MTT assay is a well-established method to measure cell number, based on detection
of metabolic activity of cells. However, it is theoretically possible that paracetamol may
reduce metabolic activity of cells, in addition to or instead of killing the cells, thereby
reducing the MTT result. Pilot studies were carried out on WRL 68 cells to compare
direct counting of cell number with MTT assay. Cell number was calculated by using a
haemocytometer to count cells harvested from culture dishes with EDTA. MTT was
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The figure shows cell number by cell counting (y axis) plotted against
cell number by MTT (x axis). The lower MTTs and cell numbers (left
part of graph) are paracetamol-treated samples (5mM paracetamol) and
the upper right MTTs are controls (media only).
The graph shows a linear association between cell number measured by MTT and
measured by direct counting. This suggests that MTT is a valid method to assess cell
number in toxicity studies. HepG2 cells show a similar graph (not shown).
♦«*
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APPENDIX 5 FEULGEN'S METHOD
Culture slides were fixed in glacial acetic acid / methanol / formalin as detailed in
chapter 4. Slides were immersed in 5M HC1 for 45 minutes at room temperature then
washed in tap water. Slides were then immersed in Schiff s reagent (Sigma) for 45
minutes and washed in tap water. Slides were counterstained with 0.3% light green for 1
minute and air dried. Slides were mounted in pertex and stored in the dark.
APPENDIX 6 RUNNING MEANS FOR CELL COUNTING
Running means were calculated for each morphological count in order to determine how
many cells had to be counted to identify a significant difference. Each mean count was
the total number of cells counted in p high power field (for most examples 150 - 200
cells). A cut-off of 2% around the derived mean was used (i.e. if that many cells was
counted then a difference of greater than 2% was significant) and in practice most counts
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Running mean for counting BrdU positive WRL 68
cells with (apap) and without (con) a toxic dose of
paracetamol (5mM). Other counts had similar graphs
and are not shown.
APPENDIX 7 DNA EXTRACTION FROM PARAFFIN SECTIONS
15 pm sections were cut for extraction of DNA and placed in a sterile micro fuge tube.
The sections were washed twice in xylene and twice in absolute ethanol, centrifuging at
13000rpm after each wash. After the final wash and spin the pellet was dried for 10
minutes at room temperature. 200pl of lysis buffer (50mM KC1, lOmM Tris, 2.5mM
MgCL, O.lmg/ml gelatin, 0.45% NP40, 0.45% Tween 20, distilled water; PH 8.3)
containing 200pg proteinase K was added and the sample incubated at 50°C for 2 hours,
vortexing the tube after 1 hour. The tube was placed in boiling water for 20 minutes to
inactivate the proteinase K. The sample was cooled on ice and stored at 4°C until use.
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Abstract
Paracetamol-induced hepatic necrosis is the most common form of toxic liver injury experienced
in clinical practice in the UK and USA. Recently, reports have described prevention of hepatic
necrosis, induced by other hepato-toxins, by inhibiting tumour necrosis factor alpha (TNFa). The
aim of the present study was to determine the role of TNFa in paracetamol-induced hepatic
necrosis. Six-week-old CBA/J female mice were given 300 mg/kg paracetamol by intraperitoneal
(IP) injection after an 8-h fast. Hepatic expression of TNFa was measured by enzyme-linked
immunoassay (ELISA) and reverse transcriptase-polymerase chain reaction (RT-PCR). Serum
TNFa was measured by ELISA. One hour prior to paracetamol injection, mice were also given
blocking anti-TNFra antibodies, soluble TNFa receptor, interleukin 10 (IL-10), and dexametha-
sone. Hepatic injury was measured by serum aspartate aminotransferase and histological
assessment on haematoxylin and eosin (H&E)-stained liver sections. There was a significant
increase in serum TNFa at 6h (control 0.002 + 0.002 ng/ml, n = 7; paracetamol-treated
0.022 + 0.007 ng/ml, n = 5, p <0.05), but hepatic TNFa expression did not change up to 24 h
following paracetamol injection. Histologically severe centrilobular hepatic necrosis was noted at
3 h and progressed for 24 h after paracetamol poisoning. Death rate, serum aspartate
aminotransferase, and hepatic histology were not significantly different between the groups
treated with blocking anti-TNFa antibodies, soluble TNFa receptor, IL-10, and dexamethasone,
compared with controls. In conclusion, there is no evidence to suggest that modulation of TNFa
expression affects hepatic injury following experimental paracetamol poisoning; anti-TNFa
therapies are therefore unlikely to be effective in the corresponding clinical situation. Copyright
© 2000 John Wiley & Sons, Ltd.
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Introduction
Paracetamol (acetaminophen) poisoning is the most
common cause of fulminant hepatic failure and emer¬
gency liver transplantation in the United Kingdom [1],
Despite the availability of a safe and effective antidote
(/V-acetylcysteine), patients continue to die following
paracetamol poisoning; there are around 100 deaths per
year in Scotland (population 5 million) alone.
Historically, studies of paracetamol toxicity have
concentrated on the metabolite (V-acetyl-^-benzoqui-
nomone-imine (NAPQI), which depletes glutathione
and accumulates, causing injury with resulting zone 3
hepatic necrosis [2], However, recent studies have
shown that other factors are important in determining
the severity of injury, including species and strain
studied [3], sex, non-parenchymal liver cells, and local
cytokine production. Kupffer cells have a central role
in causing hepatic injury in experimental models;
Kupffer cell blockade • can abrogate hepatic injury
Copyright (C) 2000 John Wiley & Sons, Ltd.
induced by paracetamol [4,5], galactosamine [6], and
carbon tetrachloride [7].
Tumour necrosis factor alpha (TNFa), produced by
activated Kupffer cells, is an important mediator of
liver injury and regeneration in a variety of diseases
and experimental models. TNFa can induce hepatocyte
apoptosis and necrosis after hepatotoxin exposure
[8,9]. In addition, toxic liver injury following adminis¬
tration of carbon tetrachloride [9], cadmium [10],
galactosamine/lipopolysaccharide [11], and concanava-
lin A [12] can be inhibited by pretreatments that block
hepatic TNF« expression. Evidence regarding the role
of TNFa in the pathogenesis of paracetamol-induced
liver injury, including use of transgenic technology, is
contradictory. The aim of the present study was to
determine the role of TNFa in the pathogenesis of
hepatic necrosis following paracetamol poisoning and
in particular, to ascertain whether TNFa inhibition





Six-week-old female CBA/J mice were fasted, but with
free access to water, for 8 h prior to intraperitoneal
(IP) injection of 300 mg/kg paracetamol dissolved in
normal saline. After injection, the animals were
allowed free access to laboratory chow. Rabbit anti-
murine TNFa antibodies were prepared by multiple
site immunization of New Zealand White rabbits with
recombinant murine TNFa; serum IgG was purified
using a protein A column and 0.5 ml of immune serum
injected intraperitoneally, 1 h prior to paracetamol
administration. The resultant anti-murine TNFa anti¬
bodies are specific for TNFa, with no demonstrable
cross-reactivity to intcrlcukin (IL) la, IL-l/j, 1L-6, IL-
10 or 1L-8. The anti-TNFa antibody neutralizes TNFa
in a WEHI killing assay, thus demonstrating its
effectiveness. Non-immune serum was used as a
control. Many previous studies have shown the efficacy
of this immune serum in inhibiting the in vivo effects of
both circulating and tissue-expressed TNFa when
administered by IP injection 1 h prior to treatment
with various noxious agents [13-16], An Fc antibody
linked to a soluble TNFa receptor (200 pg; a kind gift
from Immunex Corp., Seattle, WA, USA), which is
more stable and 1000-fold more effective than mono-
meric naturally occurring soluble TNFa receptor, was
administered Ih prior to paracetamol injection [17].
Mice were also injected intraperitoneally with recom¬
binant IL-10 (5 pg; purchased from R&D Systems
Inc., Minneapolis, MN, USA) and dexamethasonc
(4 pg; purchased from Sigma-Aldrich, St Louis, MO,
USA) or saline as control, 1 h prior to paracetamol
administration. Such doses and treatments have also
been shown to inhibit the in vivo effects of TNFa in
experimental animals [18-20] in this laboratory.
TNFa expression
Samples of liver were weighed and homogenized in
1 ml of phosphate-buffered saline containing 0.5%
Nonidit P40 and the supernatant was recovered
following centrifugation. Measurements of antigenic
TNFa from serum and liver homogenate were made
using a double ligand EL1SA specific for murine TNFa
as previously described [17], Liver was also 'snap-
frozen' in liquid nitrogen and homogenized in 1 ml of
4.2 m guanidine isothiocyanate, 25 ium Tris (pH 8.0),
0.5% Sarkosyl, and 0.1 m 2-mercaptoethanol. An equal
volume of IOOium Tris (pH 8.0), lOmM EDTA, and
1.0% SDS was added and total RNA prepared
following phenol-chloroform and chloroform-isoamyl
alcohol extraction. The isolated RNA was quantitated
by spectrophotomctric analysis at 260 nm and 5 pg was
reverse-transcribed into cDNA using oligo (dT) 12— 18
primers and AMV reverse transcriptase. The cDNA
was amplified using specific primers for TNFa and
cyclophylin (TNFa sense CCTGTAGCCCACGTCG-
TAGC, TNFa anti-sense TTGACCTCAGCGCTGA-
GTTG; cyclophylin sense CATCTGCACTGCCAA-
GAC, cyclophylin antisense CTGCAATCCAGCTAG-
GCATG). The amplification reaction was incubated
initially at 94°C for 5 min, followed by 35 cycles at
93°C for 45 s, 52°C for 45 s, and 72°C for 90 s. The
amplification products were visualized under UV light
following separation in a 2% agarose gel containing
0.3 mg/ml ethidium bromide [18],
Assessment of hepatic injury
Hepatic injury was measured by serum aspartate
aminotransferase activity determined using a standard
colorimetric assay (Sigma Chemical Co., St Louis,
MO, USA) and by histological assessment of FI&E-
stained sections of liver tissue. The histological assess¬
ment was conducted by two independent investigators
(KJS and DJH) without prior knowledge of what, if
any, anti-TNFa treatment the animal had received.
Hepatic necrosis was scored as follows: +, less than
30% of the total area necrotic; + +, 30-60% of the
total area necrotic; + + +, greater than 60% of the
total area necrotic.
Statistical analysis
A two-way analysis of variance was used to test for
differences in serum and hepatic TNFa concentrations
and serum aspartate aminotransferase activities. A chi-
square test was used to test for significant differences in
mortality. Both analysis of variance and chi-squarc
tests were used to test for differences in hepatic
histology. A result of p <0.05 was chosen as signifi¬
cant. All data are presented as mean ±standard error.
Results
To determine the time course of hepatic injury, we
measured the scrum concentration of the enzyme,
aspartate aminotransferase, and scored hepatic necro¬
sis on H&E-stained histological sections. Three hours
following paracetamol administration, a significant
increase in serum aspartate aminotransferase (control
22.5 + 2.6 IU/1, n = 6; paracetamol-treated 2726 + 629
IU/1, n = 6, p< 0.05) and the appearance of severe
hepatic necrosis were observed. These changes were
completely prevented by the prior injection of N-
acetylcysteine (300 mg/kg). Thus, the murine model
used in these experiments is similar to the liver damage
induced in humans.
Induction of TNFa by paracetamol in vivo was
determined by measuring serum and hepatic TNFa
protein and gene expression. Serum TNFa (Figure 1)
increased 3 h following paracetamol injection
(20.4 + 0.6 pg/ml, mean + SEM, n = 5, /? <0.05) and
remained elevated for 24 h compared with con¬
trols (2.4+ 2.4 pg/ml, n = l). Hepatic TNFa protein
concentration (Figure 2) was similar at all time
points following paracetamol administration (range
0.498 4.818 ng/g wet weight) and was not significantly
Copyright « 2000 John Wiley & Sons, Led. J Pathol 2000; 190: 489 -494.
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Figure !. Serum TNFa following paracetamol poisoning. Para¬
cetamol (300 mg/kg) was injected intraperitoneally and serum
TNFa measured by ELISA at the given time points following
administration. #= significant difference (p<0.05) compared
with saline-injected controls; n = 5 in each group except the
control group, in which n = 7
4.0 -.
3.5 -
!■■■ I , ■■■III ' ,
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Figure 2. Flepatic TNFa following paracetamol poisoning.
Paracetamol (300 mg/kg) was injected intraperitoneally and
hepatic TNFa. measured by ELISA at the given time points
following administration. No significant differences (f>< 0.05)
were noted compared with saline-injected controls; n = 5 in each
group except the control group, in which n = 7
different compared with controls (0.941 +0.114 ng/g
wet weight, n= l). Hepatic TNFa gene expression
was not induced following paracetamol (Figure 3).
Although we found a small, but significant increase in
serum TNFa protein, there was therefore no induction
of hepatic TNFa protein or gene expression following
paracetamol poisoning.
To determine further the role of TNFa in the
pathogenesis of hepatic injury induced by paracetamol,
we inhibited the biological effects of TNFa in vivo,
using anti-TNFa antibodies, soluble TNF receptors,
IL-IO, and dexamethasone. Mortality (Table 1) follow-
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Figure 3. Hepatic TNFa mRNA expression following paraceta¬
mol poisoning. Total RNA was extracted from liver tissue
after intraperitoneal paracetamol injection (300 mg/kg), cDNA
synthesized, and TNFa mRNA expression determined using PCR
amplification as described previously [17]. Cyclophylin was used
as a control. I, 3, 6, 12, and 24 correspond to the numbers of
hours post-paracetamol injection; C = saline-injected control and
N = negative PCR control. No significant difference in hepatic
TNF mRNA expression was noted following paracetamol
poisoning compared with saline-injected controls
ing paracetamol poisoning was similar in mice pre-
treated with blocking anti-TNFa antibodies (12.5%),
soluble TNF receptor (8.3%), IL-10 (12.5%) and
dexamethasone (0%) compared with controls (0%).
Serum aspartate aminotransferase (Table 1) was also
similar in all groups. Histological assessment of the
extent of hepatic necrosis (Figure 4 and Table 2),
determined 20 h post-paracetamol injection, was also
similar in controls (2.0 + 0.2, mean score+ SEM,
« = 16) and mice pretreated with blocking anti-TNFa
antibodies (2.5 + 0.3, 77 = 8), soluble TNFa receptor
(2.3+0.3, 77=10), IL-10 (2.43+0.2, 77 = 7), and dexa¬
methasone (2.1 ±0.2, 77 = 8).
Discussion
In this study, we found an increase in serum TNFa at
3 h post-paracetamol injection, but there was no
increase in hepatic TNFa protein or gene expression.
In addition, treatment with anti-TNFa antibodies,
soluble TNF receptor, IL-10, and dexamethasone did
not protect against paracetamol-induced hepatic necro¬
sis, as determined 20 h post-paracetamol poisoning.
Table I. Mortality and serum aspartate aminotransferase following paracetamol poisoning; effect of TNFa inhibition
Control Anti-TNF antibody Soluble E NF receptor IL-10 Dexamethasone
Mortality 0/18 1/8 1/12 1/8 0/10
(0) (12.5) (8.3) (12.5) (0)
Serum AST (IU/1) 661 1 ±858 9684+ 762 5770 + 772 6137 + 884 5532 + 772
Results are mean + SEM. No statistical differences were detected.
Copyright ,c; 2000 John Wiley & Sons, Ltd. J Pathol 2000; 190; 489-494.
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Figure 4. Hepatic histology following paracetamol poisoning; the effect of anti-TNFa therapies. Representative sections from
control animals (APAP) and mice preinjected with anti-TNFa antibodies (Anti-TNF), soluble TNF receptor (sTNFr), and interleukin
10 (IL-10) prior to paracetamol injection are presented. No difference in hepatic histology was observed. The data from
dexamethasone-treated animals are now shown, but no improvement in hepatic histology was observed
Table 2. Histological assessment of hepatic necrosis following paracetamol poisoning; effect of TNFa inhibition
Control Anti-TNF antibody Soluble TNF receptor IL-10 Dexamethasone
+ 4 0 1 0 1
+ + 8 2 3 4 5
+ + + 4 5 6 3 3
Results are numbers of animals with hepatic necrosis assessed as +. + + or -(- + +: hepatic necrosis as defined in methods. No statistical differences
were detected.
Although not measured in this study, the anti-TNFa
therapies used in the paracetamol model have pre¬
viously been shown to be highly effective in inhibiting
TNFa in other animal models used in our laboratory.
For example, the anti-TNFa antibodies administered
by IP injection, 1 h prior to lipopolysaccharide (LPS)
IP injection, reduce peak serum TNFa concentrations
of R0 000 pg/ml at 1.5 h to undetectable levels [15],
Similarly, the anti-TNFa antibodies used in this study
can significantly reduce circulating TNFa concentra¬
tions for at least 16 h when administered intraperito-
neally at the time of caecal ligation and puncture [15],
These antibodies also significantly reduce TNFa-
induced hepatic injury induced by endotoxin injection
[16]. The soluble TNFa receptors used in these studies
are a chimera of an Fc antibody linked to soluble
TNFa receptors. This chimera is more effective than
the naturally occurring monomeric soluble TNFa
receptor and inhibits 125 pg/ml TNFa in an L929
bioassay at concentrations of 10" -10"10 m. The
Fc-TNFa receptor chimera administered by IP
injection 1 h prior to LPS reduces circulating con¬
centrations of TNFa of approximately 1 ng/ml
to undetectable concentrations. In addition, the
Fc-TNFa receptor chimera, administered by IP injec¬
tion, inhibits TNFa-dependent tissue infiltration with
neutrophils and eosinophils for up to 24 h [17]. The
dose and mode of administration of IL-10 significantly
Copyright (('• 2000 John Wiley & Sons, Ltd. J Pathol 2000; 190: 489- 494.
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inhibit TNFa release and improves murine survival
following caecal ligation and puncture [18]. Similarly,
the dose and mode of administration of dexametha-
sone significantly reduce circulating TNFa and hepatic
expression of TNFa following endotoxin injection [20],
Therefore, the anti-TNFa therapies employed in this
paper would be more than adequate to inhibit
completely the circulating concentrations of TNFa
observed in this study following paracetamol poisoning
(maximum 30 pg/ml).
Other studies of paracetamol-induced injury have
shown no increase in serum TNFa in Swiss mice [21]
and no increase in serum or hepatic TNFa in male
C57BL/6 mice up to 8 h after injection [22], The latter
study also showed no difference in hepatic injury
between TNFa/LT double knockout mice and controls
at up to 8 h, consistent with our observations that
exogenous inhibitors of TNFa do not prevent para¬
cetamol-induced liver injury in mice. The TNFa
knockout study suggests that TNFa is not involved in
paracetamol-induced toxicity. However, compensation
of a deleted gene by altered expression of other genes is
well recognized in transgenic knockout models. This
may be particularly relevant in a complex area such as
cytokine production. TNFa is a multifunctional cyto¬
kine produced in many pathological situations and
TNFa synthesis and release are related to, and
regulated by, other cytokines, chemokines, and other
factors. TNFa production is related to that of TL-1
[23,24], which shares some of its biological effects, and
many of the cytotoxic effects of TNFa may be
accounted for by If,-18 [25], which could be up-
regulated by other pathways. Conversely, a variety of
factors may down-regulate TNFa synthesis and
release, such as IL-10 [11,26] or chemical inhibitors
[27], or neutralize 'active' TNFa (e.g. soluble TNF
receptor) and inhibit TNFa effects in vivo [28]. Our
data confirm the results of the earlier study using
TNFa knockout mice, but we have used animals that
have not had the opportunity to compensate for the
lack of TNFa.
Others have also found increases in serum TNFa,
but these workers showed that anti-TNFa antibodies
limited paracetamol-induced liver damage [24,29]. We
did not find any elevation of hepatic TNFa protein or
RNA, despite the serum elevation. Whilst we have not
identified the source of this TNFa, many cells produce
this early response cytokine following appropriate
stimulation, including circulating monocytes and sple¬
nic and enteric macrophages [30,31], The role of TNFa
in the pathogenesis of liver injury by another toxic
agent, carbon tetrachloride (CC14), has been studied
with similarly contradictory results [9,32], Elevation of
serum and hepatic TNFa has been described, with
increases in the same range as our findings in serum in
paracetamol-induced toxicity, with conflicting studies
showing inhibition of injury by soluble TNF receptors
but no prevention of injury by anti-TNFa antibodies.
In summary, the data presented in this paper do not
implicate TNFa in the pathogenesis of hepatocyte
necrosis following paracetamol poisoning. Therapies
directed against TNFa are therefore unlikely to be
clinically effective in preventing or limiting hepatic
injury.
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